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P2 EFFECTS OF THE PHOSHPHATIDYLINOSITOL 3-
KINASE FAMILY INHIBITOR WORTMANNIN ON THE
CYTOTOXIC MECHANISMS OF ETOPOSIDE IN A549 NSCLC CELLS
S. Boulton, S. Kyle and B.W. Durkacz. Cancer Research Unit, University of
Newcastle-Upon-Tyne, NE2 4HH.
DNA dependent protein kinase (DNA-PK) shares homology with the
phosphatidyl 3-kinase(PI 3-K)genefamily,whichalsoincludesataxiatelangiectasia
(AT) gene product. DNA-PK is required for DNA double strand break (DSB)
repair. DSBs contribute to the cytotoxic effects of ionising irradiation (IR).
Wortmannin (WM) is an inhibitor of DNA-PK and other enzymes of the PI 3-K
family. We have demonstrated that in CHO-K1 cells, IR-induced cytotoxicity was
potentiated by non-toxic concentrations of WM(DEF10* values of2.7 ± 0.3aM &
5.3 ± 0.9jaM for 5jM & 20pM WM, respectively) and the repair of DSB was
completely inhibited (Boulton et al (1996), Carcinogenesis 17: 2285). These data
implicate DNA-PK inhibition and the consequent inhibition of DSB repair as the
reason WM potentiates the cytotoxicity of IR. WM also inhibits the p110 PI 3-K,
an enzymewhich transducesgrowth factorresponses mediatedby tyrosine kinases.
Flow cytometry analysisdemonstratedthat WM (5OjaM) causedan accumulation of
cells in GI, but this was a transient effect, presumably reflecting the instability of
WM in culture medium, with resumption ofthe cell cycle observed after 16 hr.
A mutant cell line,xrs-6, which lacks DNA-PK activity due to the absence
ofKu 86 subunit, exhibitshypersensitivity to etoposide,atopoisomerase II inhibitor
(Jeggo et al (1989), Cancer Res. 49: 7057). We investigated the effect ofWM on
etoposide, in A549 NSCLC cells. WM (2OjM) potentiated etoposide cytotoxicity
with a DEF,o of 1.48 ± 0.12gM. A 1 hr exposure to etoposide resulted in a
concentration dependent increase in DSB levels. WM had no effect on the DSB
levels at this time. However, following a 1 hr incubation with 20jaM etoposide,
DSB repair over a 3 hr period was retarded by coincubation with WM. This delay
was more pronounced at the later repair times, e.g. 61% compared to 69% DSB
remaining at 30 min, and 25% compared to 43% at 2 hr, for etoposide and
etoposide + WM, respectively.
Topoisomerase II inhibitors have been shown to cause an early inhibition
of DNA synthesis, and this effect is abolished in AT cells (Kaufmnann et al (1991)
Mol. CellBiol. 11: 371 1). Preliminary data indicatesthat WM (5OjM) preventsthis
inhibitory effect. These data suggest that WM may also be actingto inhibit the AT
PI 3-kinase as part ofthe cytotoxic mechanism.
* DEF,o: dose enhancement factor at 10% survival.
7 3) ELUCIDATION OFTHE SIGNAL TRANSDUCTION
PATHWAY OF A TUMOUR-DERIVED LIPID-
MOBILISING FACTOR S Khan, SA Price*, MJ Tisdale,
Pharmaceutical Sciences Institute. Aston University, B'ham B47ET.
A cytosolic extract of a cachexia-inducing murine adenocarcinoma
(MAC16) was found to stimulate lipolysis in isolated murine white
adipocytes, and adenylate cyclase (AC) in adipocyte plasma membrane
preparations, in a dose dependent fashion. The effect upon AC activity
exhibited responsiveness to GTP, with low concentrations (0.1PM)
causing stimulation whilst high concentrations (10pM) proved inhibitory,
suggesting the influences of both stimulatory (Gs) and inhibitory (Gi)
guanine nucleotide-binding proteins. Stimulation of lipolysis or AC
activity by both isoprenaline and the tumour-derived lipid-mobilising
factor (LMF) was significantly enhanced in adipocytes isolated from
cachectic MAC16-bearing mice. However, there w'as no measurable
increase in the stimulation ofAC activity by forskolin, indicating that the
up-regulated response observed in the cachectic state resulted from an
alteration in either the number oractivity of receptors or G-proteins. The
induction of lipolysis by LMF was effectively inhibited by pre-treating
adipocytes with the non-selective B-receptor antagonist propranolol
(10yM). Further studies employing the selective 1B3-receptor antagonist
SR59230A, revealed that pre-treatment of either isolated adipocytes, or
plasma membrane fractions with this drug (10yM) significantly
attenuated the effects of both isoprenaline and LMF. Given the up-
regulated response observed in the cachectic state, the biphasic role of
GTP, and the inhibition produced by both propranolol and SR59230A, it
would seem probable that the effects of LMF are mediated via a B3-
adrenergic receptor. Therefore, the lipolysis observed in white adipose
tissue during tumour-induced cachexia appears to be the result of a
tumour-derived lipid-mobilising factor which acts to stimulate cyclic
AMPformation in a similar manner to natural lipolytic hormones.
P4 LACK OF PENETRATION THROUGH MULTICELL
LAYERS IS A CONTRIBUTING FACTOR TO THE
FAILURE OF E09 IN THE CLINIC. R.M.Phillips*. P.M.Loadman and B.P.Cronin.
Clinical Oncology Unit, University of Bradford. Bradford BD7 tDP.
The indoloquinone compound E09 (3-hydroxy-5-aziridinyl-1-methyl-2-lIH indole-
4,7-dionelprop-p-en-a-ol) is a bioreductive drug which is activated by the enzyme
DT-diaphorase (EC 1.6.99.2) to a DNA damaging species. E09 was selected for
clinical trial based upon its mechanism of action together with evidence of activity
against solid tumours in vitro and in vivoand its lack ofmyelosuppresion in animal
studies (Hendriks et al, Eur J Cancer, 29A: 897-906. 1993). Despite reports of 3
partial remissions in phase I trials, recent phase II trials have demonstrated that
E09 is inactive against a variety of human cancers (Dirix et al, Eur ICancer, 32A,
2019-2022, 1996). A key parameter for bioreductive drugs is that they must be able
to penetrate through several layers ofcells in order to reach their target. The aim of
this study was to determine whether or not drug penetration barriers could explain
the lack of activity of E09 in the clinic. We have developed an in vitromodel to
study drug penetration based upon the assay described by Cowan et al(Br.J.Cancer.
74 (suppl XXVII), 28-32, 1996) where cells are grown in transwell culture inserts
(Costar) forming an upper and lower chamber separated by a microporous
membrane. Drugs were added to the top chamber and the concentration of drug
appearing in the lower chamber was determined by HPLC as a function of time.
DLD-1 human colon carcinoma cells (2.5 x 105 cells) were initially seeded into the
top chamber and grown for several days with daily medium changes. The thickness
of the cell layer was determined by routine histological procedures and cell layers of
15.0 6.2 pimto 78.3 + 10.1 jim thickness were obtain6d on days 1 and 8 of the
growth curve respectively. E09 (10 FM) was added to the top chamber and the rate
at which E09 crossed the cell layer was inversely pruportional to the thickness of
the cell layer. Cell layers of 78.3 ± 10.1 gm completely blocked the passage of E09
across the membrane with no E09 detectable in the lower chamber following a 3
hour incubation at 370C. At 50.3 + 10.1 jim, E09 was only detectable (< 0.5 AM) in
the lower chamber 30 minafter drug administration. E09 has an extremely short
half life in vivo(3minin mice and 10 minin humans) and the results ofthis study
suggest that E09 is unlikely to reach the hypoxic fraction of tumours within the
pharmacokinetic lifespan ofthe drug. Poor penetration into tumours in conjunction
with rapid clearance may therefore play a major role in E09's disappointing clinical
activity. Improving drug delivery or developing
- ialogues which have the same
desirable properties as E09 (ie bioactivation by DT-diaphorase) but have better
pharmacological properties may result in drugs which are capable of exploiting
elevated DT-diaphorase levels which exist in certain tumours.
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P5 SPECIES DEPENDENT DIFFERENCES IN THE
METABOLISM OF INDOLOQUINONES BY WHOLE
BLOOD. R.M.Phillips*. P.M.Loadman and C.M.Jarrctt. Clinical Oncology Unit,
University ofBradford. Bradford BD7 IDP.
The indoloquinone compound E09 (3-hydroxy-5-aziridinyl-1-methyl-2-[ IH indole-
4.7-dioncprop-I3-en-(x-ol) has an extremely short plasma half lifc in both rodents
(TV/2 = 3 mins) and humans (TI/2 = 10 mins). The rapid clearance in conjunction
with evidence demonstrating that drug penetration barriers exist suggest that the
lack of anti-tumour activity in the clinic may be caused by pharmacological as
opposed to pharmacodynamic problems. Blood cells are known to influence the
pharmacology of drugs and the aim of this study was to determine whether or not
the rapid clcarance of E09 in vivo can be attributed to metabolism by blood cells.
The stability ofE09 in human and murine (NMRI micc) blood was determined by
HPLC at 370C. In phosphate buffered saline (pH 7.4), E09 has a half life of 8.5 h
with EO5A being the primary breakdown product. In both human and murine
plasma E09 was stable over the duration of the experiment (TV/2 > 3 h). In murine
whole blood however. E09 was rapidly removed (TI/2 = 28 mins) whereas in human
whole blood. E09 was relatively stable (T'/2 = 2 h). No EO5A could be detected in
both human and murine blood samples. In heat treated murine anid human blood
(560C for 20 min). E09 was stable (TV2 > 3 h) suggesting that E09 is metabolised
by whole blood. DT-diaphorasc activity was detected in murine blood (16.7 t 1.9
nmol/min/mg) but no activity (< 0.1 nmol/min/mg) was detected in human blood.
Cytochrome b5 reductase activity was also elevated in murine (3.05 ± 0.5
nmol/min/mg) compared with human blood (1.16 i 0.2 nmol/min/mg). Levels of
cvtochrome P450 reductase were comparable in both murine and human blood (1.1
and 0.7 nmol/min/mg respectively). Species dependent differences in enzymology
may therefore contribute to different half lives ofE09 in human and murine biod.
Several analogues of E09 were evaluated in this study and all compounds tested
were unstable in murine blood compared with human blood. E068 in particular had
an extremely short halflife in mouse blood (TV/2 < 2 mins) but was relatively stable
in human blood (TV2 > 2 h). As E068 is a good substrate for DT-diaphorase and is
selectively toxic towards DT-diaphorase rich cells (Phillips, Biochem. Pharmacol,
52, 1711-1718, 1996), thesc results have significant implications with regards to the
use of murine tumour models to evaluate potential novel analogues of E09. In
conclusion, the results ofthis study suggest that metabolism ofE09 by whole blood
may contribute to the rapid clearance of E09 in rodents but not humans. Species
dependent differences in the rates of metabolism ofE09 and its analogues suggest
that the use ofmurine tumour models may give rise to false negative results and care
needs to be taken in selecting experimental models for evaluating novel
indoloquinones.
STUDIES ON THE INTERACTIONS BETWEEN DNA AND NOVEL
p7 POLYCYCLIC ACRIDINE DERIVATIVES.
E. Gimenez-Armau*, S. Missailidis. D. J. Hagan, J. Stanslas and M. F. G. Stevens, Cancer Research
Laboratories, Department ofPharnnaceutical Sciences, University ofNoningham, Noningham NG7 2RD.
In the past few vears, acridine-based derivatives have fornmed thebasis forthedevelopment
ofagents which target DNA topoisomerases, enzymes which resolve topological constraints in
DNA and, consequently, considered valid targets indrugdesign. 1,2
We have developed a novel synthetic route tothe polycyclic frameworks oftetracyclic (1),
pentacyclic (2) and hexacyclic acridines (3) with the intention of devising molecules with
appropiate substituents (R) which can discriminate between topoisomerase II a and 3
isoforms.
Structures ofpolycyclic acridines
R~~~~~~
H H HI
(1) (2) (3)
The interaction between DNA and compounds (I)-(3) has been studied using a range of
physicochemical techniques such as spectrophotometric analysis, fluorescence quenching,
thermal denaturation, circular and linear dichroism and X-ray crystallography. Results with
compounds (2) (R=H, Cl, CH3, NH2) confirm: (i) strong DNA-binding affinity, 3-100 fold
greater than that ofm-AMSA; (ii) binding in an intercalative mode at high DNA todrug ratios;
(iii) A-T base-pair binding preference; (iv) disordered binding at low DNA to drug ratios.
Even without appropiate structural embellishments (R), the compounds show sub-micromolar
IC50 values against an extensive panel of cell lines in vitro and cytotoxicity correlates with
DNA-binding affmity and topoisomerase 11 inhibition.
I. Dcnny. W. A.: Baguley. B. C.: Cain. B. F.; Waring. M. J. Antitumor Acridines. In
Molecular Aspects ofAnticancer I)rug Action. st ed.: Neidle. S.. Waring M. J.. Eds.:
Macmillan Publishing Co.: London. 1983. pp 1-34.
2. D;Arpa. P. Liu. L. F. Topoisomerase-targeting Antitumor Drugs. Biochim. Biopkhs. Actto
1989. 989. 163-177.
P6 IN VITRO EVALUATION OF COMBRETASTATIN A4
AND ITS ANALOGUE.
K. Grosios*. A.T. McGowvn G.R. Pettit M.C. Bibbv
Cliniical Oncology Unit, University ofBradford. Bradford BD7 IDP, UK
Paterson Institute for Cancer Research, Manchester M20 9BA, UK
2Arizona State Universitv, Tempe, Arizona 85287-1604, USA
Tumour angiogenesis is an essential process in tumour development and
progression. Development ofantiangiogenic or antivascular agents could
therefore have a major impact in cancer therapy. Currently, in vitro screening for
antiangiogenic agents is very limited although endothelial cell culture svstems
provide useful models for the investigation ofsuch compounds. In vivo work with
combretastatin A4 and its phosphate analogue demonstrated that both drugs cause
extensive haemorrhagic necrosis in experimental tumours. In this study, in vitro
evaluation ofthese twoagepts was carried out using human umbilical vein
endothelial cell (HUVEC) cultures. Initial experiments using the Neutral Red
assay. showed that 0.31lcM and lower concentrations ofcombretastatin A4 and its
analogue were not cytotoxic to HUVEC (77.79% and 96.26% cell survival was
obtained respectively at 0.31 AM concentration). Both compounds caused
inhibition ofHUVEC migration through collagen, in transwell chambers as
compared to control, untreated cells. Endothelial cells grown in between type I
calf-skin collagen, form cell networks. Such networks were significally disturbed
after 4h exposure to 0.31sM ofboth agents. Disruption was observed with even
lower concentrations and wvas complete after 24h. Investigation ofthe cellular
mechanism ofaction ofthese compounds using staining ofF-actin (using
rhodamine conjugated phalloidin), revealed that at the same, non-cvtotoxic
concentration, 4h treatment with both compounds resulted in high levels ofF-actin
disorganisation and rounding up ofthe endothelial cells. These in vitro results,
strongly indicate the antiangiogenic potential ofcombretastatin A4 and its
phosphate analogue andjustify further evaluation.
This work has been supported bv War on Cancer, Bradford, UK.
IFOSFAMIDE METABOLISM AND ITS EFFECT ON
P8 DNA IN TUMOUR CELLS IN VITRO AND IN VIVO.
I.A. Willits', S.M. Yule2, A.D.J. Pearson2, L. Price2, C. Brock2, R. Wyllie2, S. Cholerton3 and A. V. Boddyt,
'Cancer Research Unit, 2DeptChild Health, 3Dept Pharmacological Sci, University ofNewcastle Upon Tyne
NE2 4HH.
The anticancer drug ifosfamide (IF) is widely used in the treatment of paediatric
malignancy. It is a prodrug requiring metabolic activation to produce 4-
hydroxyifosfamide (4-OHIF), which then spontaneously breaks down to form the
ultimate alkylating species, isophosphoramide mustard (IPM). It is believed that the
cytotoxic action ofIPM is due to its binding to DNA, forming a range oflesions which
inhibit cell replication. The effect of these metabolites on DNA damage was
investigated in vitro in the lymphoid leukaemia cell line CCRF-CEM using the single
cell gel electrophoresis (SCGE) assay. The extent of DNA damage was measured as
the tail moment (TM). Cells exposed to gamma irradiation showed a linear increase in
TM up to 10 Gy. Cell inhibition studies showed that the IC5o of CCRF-CEM cells
exposed to 4-OHIF and IPM was 20 and 250 tM respectively, whilst IF exhibited no
effect at millimolar concentrations. Cells were exposed to IPM or 4-OHIF at IC5o and
4xIC50 concentrations for lh and samples were taken at lh, 24h, 48h and 72h for
SCGE analysis. No increase in TM was detected after lh, but all samples showed
significant increases after 1 day compared to controls. Cells incubated with the IC50
concentration ofdrugs showed resolution ofTM after 72h, whilst those incubated with
4xIC50 showed continued damage. Studies on the nuclear morphology of cells using
Hoescht dye fluorescence revealed both metabolites caused extensive apoptosis which
was not directly related to TM. Ifosfamide metabolism was investigated in 11 children
receiving chemotherapy using thin-layer chromatography. Subjects received IF at 6 or
9g/m2 administered over 2 or 3 days either as a continuous infusion or as 3 hour daily
infusions. Peripheral blood lymphocytes (PBLs) were collected at regular intervals
throughout the course and after 3 weeks for analysis with SCGE. A high degree of
inter-patient variation in terms of both IF metabolism and DNA damage was seen. In
all cases DNA damage accumulated throughout the course and resolved after 3 weeks.
DNA damage peaked at 48h in 7 patients. There was no difference in mean TM values
between the different administration schedules, nor was any relationship between PBL
TM and metabolite production observed. These results verify that IF is not cytotoxic
per se but its activity is due to its metabolites. These metabolites cause DNA lesions
and trigger apoptosis in CCRF-CEM cells. When IF is introduced systemically in
patients DNA damage is measurable in PBLs, but this is not directly related to
measurable metabolites.Poster Presentations 21
P9 ASSESSMENT OF DNA DAMAGE CAUSED BY
D9 IFOSFAMIDE AND METABOLITES IN PATIENTS AND IN
MCF-7 CELLS
E.C. Johnstone*, M.J. Lind, N. Siddiqui, F. Chapman, A.V. Boddy*. Cancer Research
Unit (*) and Northern Centre for Cancer Treatment, Newcastle upon Tyne NE2 4HH.
Ifosfamide (IF) is a widely-used oxazophosphorine which has
demonstrated activity against advanced breast cancer. It is metabolically
activated to 4-hydroxyifosfamide (40H ifo), which is unstable and
subsequently breaks down to isophosphoramide mustard (IPM), an
alkylating species which causes DNA damage via crosslinks and
monofunctional adducts. The production of IPM is thought to occur
intracellularly as IPM is ionised at physiological pH and thus its cellular
uptake may be hindered. In a clinical study to determine the DNA
damaging properties of ifosfamide, patients with advanced or metastatic
breast cancer were treated with IF (5g/m2 as a 24 hour infusion) in
combination with doxorubicin (DX) (40mg/M2 bolus). DNA damage
was detected in the peripheral blood lymphocytes (PBL) and also in the
tumour cells of patients using single cell gel electrophoresis (the comet
assay). DNA damage in PBL's showed an increase 24h into treatment
compared to basal damage. A subsequent increase to maximum damage
at 48h was seen in all cases. Complete resolution of damage 3 wk after
treatment was observed in 50% of patients. In tumour cells, DNA
damage at pre treatment and 24h after the start of infusion showed a
similar distribution. However a definite shift towards increased damage
at 3wk post treatment was observed. In growth inhibition studies in
vitro, the breast cancer MCF-7 cell line was approximately 4 fold more
sensitive to 40H ifo than to IPM (IC50 1.5gM vs 6.2jiM). The time
course of DNA damage was investigated in MCF-7 cells; on exposure to
6,uM 4-hydroperoxyifosfamide (4 x ICs5), maximum damage occurred at
48h, similar to the in vivo situation with PBL. The mean of the
maximum 4-hydroxyifosfamide concentrations in vivo was determined to
be 5.4tM ± 2.0gM using a modification of the acrolein fluorescnce
assay, and this reflects the concentrations used in vitro. Investigations of
the pharmacokinetics of IF and DX have also been performed on these
patients for comparison with DNA damage in PBL and tumour.
P11 DNA ALKYLATION AND INTERSTRAND
CROSSLINKING BY TREOSULFAN. C.C.
O'Hare*l, J.Baumgart2 and J.A.Hartley1. 1CRC Drug-DNA
Interactions Research Group, Dept. Oncology UCL Medical
School, 91 Riding House Street, London WlP 8BT, 2Medac,
Fehlandstrasse 3, D-20354 Hamburg, Gennany.
The antitumour drug treosulfan (L-threitol 1,4-bismethane-
sulfonate) is used clinically primarily in the treatment of advanced
ovarian cancer. The lack of significant non-haematological toxicity
suggests treosulfan as a candidate for high dose chemotherapy
regimens with autologous stem cell reinfusion. Although
structurally related to the alkylating agent busulphan, its
mechanism ofalkylation is distinct. Itis a prodrug, converting non-
enzymatically to L-diepoxybutane via the corresponding
monoepoxide under physiological conditions. The present study
demonstrates that conversion of treosulfan to epoxide species is
required for cytotoxicity in vitro. Alkylation and interstrand
crosslinking of plasmid DNA is observed following treosulfan
treatment, again produced via the active epoxide species.
Alkylation is sequence specific occurring at guanine bases with a
preference for runs ofcontiguous guanines, as observed previously
with alkylating agents such as nitrogen mustards. In treosulfan-
treated human leukaemic K562 cells DNA crosslinks form slowly,
reaching a peak at approximately 24 hours. Incubation ofcells with
the pre-formed epoxides shows faster and more efficient
crosslinking. Using characterised paired human cell lines the
sensitivity of cells to treosulfan was not determined by levels of
either guanine-06-alkyltransferase or glutathione.
P19 CHARACTERISATION OF A POLYCLONAL
ANTIBODY RAISED TO DNA ADDUCTS OF
AMD473. C.B. Miner*, F.I. Raynatid, J. Ilolford, L.R. Kelland, A. Hardcastle, G.W.
Aheme. CRC Cenltre for Cancer Therapeutics at the Institute ofCanicer Researclh, Suttoni,
Surrey, UK.
AMD473 [amminedichloro(2-methylpyridine) platinum (11)1 will begin Phase I
clinical trial at the Royal Marsden NHS Trust in 1997. The compound has been
found to be active in cisplatin resistant models. Its development, as a novel
sterically hindered platinum (II) complex, was undertaken to reduce intracellular
deactivation by thiols, a frequent mechanism of drug resistance in tumours. It is
known to possess some unique DNA binding properties in comparison to
cisplatin. Less overall DNA binding (e.g. in the CHI human ovarian carcinoma
cell line there was 2.8 fold higher platination with cisplatin than with AMD473
following 2h exposure to 50, 100 and 200 pLM) of AMD473, in comparison to
cisplatin (CDDP). indicates that a more sensitive detection method than classical
flameless atomic absorption spectroscopy is required. The lower levels of DNA
binding in conjunction with different adducts formed has prompted the raising of
a polyclonal rabbit antibody to AMD473 adducts of DNA to develop an
immunoassay with improved. detection for clinical samples. Animals were
initially immunised with AMD473 platinated DNA complexed with methylated
BSA and then emulsified with Non-ulcerative Freund's adjuvant. Sensitivity in
the femtomolar AMD473-DNA adduct range has been reproducibly achieved
using competitive colourimetric enzyme-linked immunosorbent assay (ELISA).
using serum obtained after a single booster immunisation. A standard cunre was
produced in the competitive platinum concentration range of 12.5-125000
fmole/assay ivell and antiserum dilution of 1/2000. A 50% inhibition at
approximately 1.9 pmole AMD473-DNA adduct/assay well was obtained. No
cross reactivity was observed with parent compound, DNA. CDDP or conjugated
DNA-CDDP, without purification ofthe antiserum.
Characterisation of the types of DNA adducts formed/detected has begun, using
selected platinated polynucleotides as cross reactants in immuno-inhibition
studies. Initial results of these experiments indicate that AMD473 is detected
largely (>80% cross reaction) as the intrastrand AG adduct.
This work is supported by the Cancer Research Campaign, UK.
P12 METABOLISM OFKW-2149: A NOVEL
MITOMYCIN C ANALOGUE ACTIVATED IN
SERUM. S.R.McAdam*l, J.A.Hartley 1, R.J.Knox2 and
J.R.Masters3. 1CRC Drug-DNA Interactions Research Group, Dept.
Oncology, UCL Medical School, 91 Riding House St, London WIP
8BT, 2CRC Centre for Cancer Therapeutics, Institute of Cancer
Research, Sutton, Surrey, SM2 5NG, 3Inst. of Urology and
Nephrology, 67 Riding House St. London W1P 7PN.
7-N-{{2-{[2-(-glutamylamino)-ethyl} I mitomycin C (KW-2149) is a
novel, highly water soluble analogue of mitomycin C (MMC) which is
currently under investigation in clinical trials. KW-2149 demonstrates a
similar spectrum ofactivity in a wide range of tumours but at a 10-100
fold lower concentration than MMC, is less myelosuppresive and lacks
cross-resistance to MMC in vitro and in vivo. The cytotoxicity ofKW-
2149 in human bladder cancer cells (RT112) is dependent on a factor in
serum as differences were found in activity between species of origin
and batches of serum. The addition of serum to RPMI 1640 medium
increased the rate ofuptake into RT112 cells by 8-fold, cytotoxicity by
>150-fold and DNA binding by 32-fold which indicates that KW-2149
is metabolised in serum-containing medium to a compound which
enters cells and crosslinks DNA more rapidly than the parent drug. The
major active metabolite ofKW-2149 is thought to be the disulfide dimer
M-18, however, the data shows that M-18 also requires reduction by
thiols to efficiently crosslink naked DNA in vitro and also requires the
presence of serum to kill cells in a colony forming assay. Experiments
have been carried out to identify the factor in serum responsible for the
metabolising activity of KW-2149. Purification of serum by ion-
exchange chromatography has identified afraction which converts KW-
2149 to a toxic species. HPLC analysis, however, has shown that this
fraction does not metabolise KW-2149 to M-18. Conversely, a fraction
has also been identified which metabolises KW-2149 to M-18 in vitro
but does not produce a cytotoxic species when added to cells in the
presence ofKW-2149.22 Poster Presentations
P13 VARIABILITY OF MITOMYCIN C
ADSORPTION TO ACTIVATED CHARCOAL, I. A. Shah*', W. E.
2 1 Lindup, P. McCulloch Department of Pharmacology and Therapeutics,
University of Liverpool, PO Box 147, Liverpool, L69 3BX, UK.
2Department of Surgery, University of Liverpool, PO Box 147, Liverpool,
L69 3BX, UK.
Activated charcoal-adsorbed mitomycin C (AC-MMC) has been
recommended for intraperitoneal use as adjuvant therapy for operable T3
gastric cancer. It has been suggested that the adsorption and release
properties of the drug to this vehicle make it a safe and reliable slow-
1,2 release preparation for clinical use , but the kinetics of the adsorption-
desorption process have not been studied in detail. We tested the variability
ofMMC-AC adsorption. AC was ball milled and sieved to yield 4 fractions
ranging from 53 to 180pm in diameter. Adsorption isotherms of each
fraction were determined at 210C and 370C and expressed as Freundlich
isotherms. The specific adsorption (Q; jig MMC/mg AC) was greater at
370C than at 21°C but with up to 3-fold variation between samples analysed
under identical conditions (210C range: Q = 72C522 to 32C55t 370C range:
Q = 87C° 2 to 36C°12). Specific adsorption of MMC was found not to be
AC size dependent.
These results suggest that the adsorption characteristics of this
drug-vehicle combination are more variable than expected, giving rise to
potential concern about variations in effectiveness and toxicity. Further
detailed evaluation ofthe release profile ofthe drug-charcoal combination,
particularly in vivo, is required.
This work was supported by the Association of International
Cancer Research. We would also like to thank Professors Akeo Hagiwara
and Toshio Takahashi (Kyoto, Japan) for their help during this work.
Hagiwara. A., Takahashi, T., Lee, R., Ueda, T., Takeda, M., Itoh, T.
(1987) Anticancer Research, 7, 167-170.
2Hagiwara, A., Takahashi, T., Lee, R., Ueda, T., Takeda, M., Itoh, T.
(1987) Anticancer Research, 6, 1161-1164.
P15 LINEARITY OF PHARMACOKINETICS AND TISSUE
DISTRIBUTION OFC1311, C.R. Calabrese*, P.M.
Loadman, M.C. Bibbvl and J.A. Doublel. Clinical Oncology Unit, University of
Bradford. BD7 IDP. UK - IScreening and Pharmacology Group. EORTC.
C131 1 is a novel rationally designed anti-cancer agent which has shown promising
activity in vitro and in viv'o against both murine and human tumour xenograft
colorectal cancer models. The aim ofthis study was to evaluate the linearity of
plasma and tissue pharmacokinetics in non-tumour bearing mice prior to potential
clinical application. In pharmacokinetic studies, female NMRI mice were treated at
doses of 15. 50, 100 and 150 mgkg1 i.p (MTD). Plasma, liver, kidney and spleens
wvere removed at various time points up to 24 hours aftertreafment and analysed for
concentrations ofC13 11 using HPLC. Results for plasma and all tissues (below)
suggest dose dependent pharmacokinetics. In each individual study, large
differentials were observed betveen plasma and tissues with much higher
concentrations observed in all ofliver < kidney < spleen.
F AUC (tissue:plasma ratio) (ND = NotDetermined)
Dose Plasma Liver Kidney Spleen
(mgkg-1) (ki .h/ml) (pgh/g) (pg.h/O (gh/g)
15 1.06 (1) 8.24 (8) 47.8 (45) 331 (312)
50 7.30 (1) 194 (28) 560 (77) 4218 (578)
100 9.64 (1) 238 (25) ND ND
150 52.2 (1) 871 (17) 2421 (46) 7153 (137)
Tissue AUC's showed disproportional increases with dose for all ofliver, kidney
and spleen. The compartmentalisation ofC1311 in murine whole blood was studied
in order to assess how the blood distribution ofdrug may influence the
pharmacokinetics. particularlv in the highlv perfused organs (liver and spleen).
HPLC analysis was used to assess the percentage ofapplied drug present in plasma,
blood cells. blood cell membranes and blood cell cvtosol. Resultsshowved approx.
20% in plasma with the remaining 80% split between cell cvtosol (48%) and cell
membranes (32%). Further experiments replacing drug containing plasma with
drug-free plasma showed C1311 to re-equilibrate from the blood cell fraction
indicating available drug. Therefore, the increase in plasma AUC is dose dependant
though any haemolysis ofblood will influence plasma levels due to the >4 fold
concentration ofC131 1 in the blood cell fraction compared to plasma. Previous
wvork has also showvn C1311 to be highlv protein bound within murine plasma
(>98%). These data suggest that monitoring ofwhole blood in parallel to plasma
pharmacokinietics wvould prove to be useful in a clinical settinig.
(This vork was supported bv War On Cancer. Bradford. UK).
P14 A limited samplingstrategy schedule method for
determination ofthe AUC and the Cmax ofJM216 in the
multiple schedule administration. *F. Raynaud, W. Heybroek, I.R. Judson.
CRC Centre for CancerTherapeutics, the Institute ofCancer Research, 15
Cotswold road, Sutton, Surrey, UK. PK Plus, 35 Lower Green, Tewin, Welwyn,
Herts.
JM216 is the first orally administrable platinum complex to reach Phase III
clinical trials. In the first two phase I trials at the Royal Marsden hospital, it was
shown that due to limited absorption no MTD could be reached on single dose
administration and that a multiple dose schedule could overcome the saturability
in absorption observed in the single dose study. The pharmacokinetic profiles
showed that there was a good correlation between AUC for ultrafilterable
platinum on day and 5 and the myelosuppression grade (r=0.85). In order to
lessen the sampling burden on the patients we present a limited sampling
strategy that maintains sufficient predictability ofboth Cma,, and 24h AUCO-24h
for ultrafiltrable platinum. The method was validated against full profile
method. Standard regression analysis ofthe variability ofall predictor
timepoints in data from day 1 and day 5 showed maximum predictability for
Cmax and tmax of3hours and AUCO 24h at 3 and 12h post dose. Stepwise ananlysis
ofthe groups oftime points gave a suggested one point sampling at 4h for
AUCO 24h (93% predictability). Addition ofa sampling time at 6h post
administration increased the predictability to 95%. A three point sampling at 2,
4, and 6h postsampling give a 93%predictability for the C,ax. Mean percentage
error and mean absolute percent errors are estimated at <8±6% and <20+4%
respectively. This method should avoid the inconvenience ofintensive
pharmacokinetic sampling.
This work was supportedby the Cancer Research Campaign, UK
P16 ASSESSMENT OF MURINE METABOLISM OF THE
IMIDAZOACRIDINONE C1311, C.R. Calabrese*, P.M.
Loadman. M.C. Bibby** and J.A. Double**, Clinical OncologyUnit, University of
Bradford. Bradford. BD7 lDP. England - **Screening andPharmacologyGroup,
EORTC.
The imidazoacridinone C1311 is a novel rationallvdesigned anti-cancer agent and
has been identified as a probable candidate for clinical development by the EORTC.
Studies in this laboratory have shown promising in vivoactivity against murine
colorectal cancers and human colon cancerxenografts.
The aim ofthis studv was to assess the metabolism ofC1311 in mice in an attempt
to predict the metabolism and elimination ofC1311 in a clinical setting and to
identify any active or toxic metabolites. Forpharmacokinetic studies, female NMRI
mice were treated at 100 mgkg-' ip, with plasma and livers obtained atvarious time
points up to 24 hours post treatment. Samples were extracted and analysed for
parent compoundusing HPLC with fluorescence and diode array detection.
Gradient HPLC analysis ofthe urine from mice ( 8 h sample) showed the presence
of8 minor metabolites with one major metabolite (MI) present in high
concentrations. Subsequent studiesusing.p-glucuronidase clearly showed Ml to be a
glucuronide ofCl 311. Analvsis ofplasma and liver samples showed high levels of
MI in both plasma and liver. A further metabolite M2 was detected at high levels in
the liver but notplasma or urine. M2 was non-fluorescent at the wavelengths used
with Xmaxima of240 and 450nm (C1311 kmaxima = 250 and 420nm). AUC
values for C1311 and metabolites were calculated to be: plasma 9.14 (C1311) 58.4
(M1) and <Igg.h/ml (M2) and liver 231 (C1311), 405 (M1) and 289jsg.h/ml (M2) (using C1311 calibration values). In vitro incubations ofparent compound with a
variety ofmurine liver fractions (S9, cvtosolic and microsomal) with NADH showed
that conversion ofparent compound to M2 occurred predominately in thecytosol. Total excreteddrug (parent and metabolite) in urine was approximately 12% ofthe
applied dose with parent compound andMl comprising 5 and 95% ofthis
respectivelv. Analvsis ofthe collected faeces from the same experiment showved the
presence ofapproximately 30% ofthe applied dose (94% C1311, 6% Ml). M2
detected in liver samples has been isolated andpurified and studies into its structure
(using LC mass spectrometric analvsis) and potential cvtotoxic activity arecurrently
ongoing. The high concentrations ofgluctironide observed in plasma, liver. urine
and faeces mavbe associated with potential enterohepatic recirculation ofC131 1
and therefore mavbe clinically important.
(This work wvas supported by War On Cancer. Bradford. UK).Poster Presentations 23
P17 POTENTIATION OF DDATHF BY PREVENTION
OF HYPOXANTHINE SALVAGE
E.Marshman*, A.H.Calvert, D.R.Newell & N.J.Curtin, Cancer Research
Unit, Medical School, University ofNewcastle-upon-Tyne, NE2 4HH.
Hypoxanthine (HPX) abolishes the cytotoxicity of the antipurine 5,10-
dideaza-5,6,7,8-tetrahydrofolate (DDATHF). The nucleoside transport
inhibitor, dipyridamole (DP) has been found to potentiate methotrexate
cytotoxicity by inhibition ofthymidine and HPX uptake (T.C.K Chan & S.B.
Howell, Eur.J.Cancer, 26, 907, 1990). An earlier study from this laboratory
demonstrated that DP prevented HPX rescue from DDATHF cytotoxicity in
some cells but not others. The tissue-specificity ofthis observation has been
extended to include further human tumour cell lines. DP did not have a
synergistic effect with DDATHF, the combination producing similar IC50
values compared with DDATHF alone (ranging from 4-590 nM). In all
colon cancer (SW620, HCTl 16 and HT29) and leukaemic cell lines (CCRF-
CEM, K562, MOLT4) DP did not inhibit HPX rescue. In addition, 2 ovarian
cancer cell lines were also DP insensitive. Cell lines from other tissues
produced variable responses, in 1 out of3 breast carcinoma, 1 out of3 lung
carcinoma, and 2 out of 3 bladder carcinoma ceil lines treated with
DDATHF, DP effectively blocked HPX rescue; but the other cell lines were
insensitive to DP. Thus the sensitivity of HPX rescue to DP has limited
tissue specificity.
Sites of dose limiting toxicity of DDATHF are the bone marrow and gut
mucosa. Two assays have been developed to investigate ifthe observation
that DP does not block HPX rescue in leukaemia and colon cancer cells
could be extended to their nonnal counterparts. A method for preparing
rodent small intestine primary cultures has been established to study the
response of intestinal epithelium. A granulocyte-macrophage colony-
forming unit assay using human umbilical cord blood has been employed to
investigate the effect of the combination of DDATHF, DP and HPX on
haematopoietic progenitor cells. If these tissues are found to have DP
insensitive HPX transport the combination ofDDATHF, HPX and DP might
be selectively cytotoxic to some tumours whilst not increasing dose-limiting
toxicities.
P19 TITANOCENE DICHLORIDE: CIRCUMVENTION OFPLATINUM
RESISTANCE, FIRST EVIDENCE OF IN VITRO DNA ADDUCTION AND
POTENTIATION OF 5FU. C. Christodoulou1, A. Eliopoulos1, T. Sheehan2, L.
Hodgkins1,, L. Young1, D. Ferry1 and D. J. Kerr1. 1CRC Institute for
Cancer Studies, University of Birmingham, Birmingham, B15 2TA,
2Regional Laboratory for Toxicology, City Hospital, Birmingham, B18 7QH,
UK.
Titanocene dichloride (TD) was found to significantly overcome platinum
resistance in vitro. The ICso values for the A2780 cells treated for 2 and
48 h with TD is 5.7 (±1.3) x 10-4 and 2.8 (±0.9) x 10-4 M respectively,
whilst the 2780CP cell line is only 1.5-2-fold more resistant to TD (MTT
assays). Similar results were obtained for CH1/CH1cisR cells. Moreover
TD overcomes mutated p53-mediated platinum resistance. The ICso values
for the mutated p53-expressing A2780 cells treated for 2 h with TD is 6.7
(±1.3) x 10-4 M. The cytotoxic activity of TD could be attributed to the
formation of titanium-DNA adducts. A2780 cells were treated with 1 x
10-3 M TD for 2, 6 and 15 h. DNA was isolated from the cells and DNA-
bound titanium was determined by flameless absorption spectrophotometry.,
Binding of titanium to DNA increased in a linear fashion propotional to the
duration of exposure. We have also performed studies to determine
whether there is synergy of TD and other cytotoxics in vitro. A2780 cells
were treated for 2 h with various combinations of TD and 5FU, doxorubicin
or cisplatin. Cytotoxicity was assessed 48 h later using MTT assays.
Isobologram analysis suggests that combination of TD -and 5FU is
synergistic.
Supported by medac Hamburg, FRG.
A COMPARISON OF3-FLUOROURACIL(5-FU)PHARMACOKINETiCS P1) IN WHOLE BLOOD, PLASMA AND RED BLOODCELLS IN PATIENTS
WITH COLORECTAL CANCER. Wiboon Wattanatornl. HowardL. McLeod2, Fiona Macklon2
Muriel Reid2 Keith E. Kendley 'andJames Cassidy2. 1School ofPharmacy, The Robert Gordon
University, Schoolhill, Aberdeen ABIO IFR. 2Department ofMedicine & Therapeutics, Institute of
Medical Sciences, University ofAberdeen, Aberdeen AB25 2ZD
Jntroduction The study of therapeutic drug monitoring (TDM) is of importance for
anticancer therapy where most agents have a narrow therapeutic index. As measurement
of drug concentrations in tumour tissue is not routinely possible, the choice of another
surrogate biological matrix for analysis is necessary. Pharmacokinetic model selection is
also important for accurate description and predictive ability.
Alms To compare whole blood, plasma and red blood cells 5-FU pharmacokinetics and
to explore the feasibility ofusing intracellular concentrations of5-FU for TDM.
Methods Five patients with colorectal cancer received folinic acid 200 mg/m2 i.v. over
2 h followed by 5-FU 600 mg/m2 i.v. bolus over 30 min, then 5-FU 600 mg/im2 i.v.
infusion over 22 h, administered on both days I and 2. This 48-hour cycle was repeated
every 14 days. Blood samples (8 ml) were collected prior to the start ofeach cycle, and 5,
10, 20, 30 min, 1, 2, 16 h from the end of 5-FU bolus, then at the end of the 5-FU
infusion, 20 and 40 min later to assess the decay phase. Concentrations of 5-fluorouracil
in whole blood, plasma and red blood cells were determined by a previously described
HPLC system (Wattanatom et al, J Chromatogr, in press). ADAPT 11 was used for
pharmacokinetic computations.
Results The concentrations of 5-FU in whole blood were 106-115% of simultaneous
plasma concentrations (median = 112%), whilst packed red blood cell levels were 5-17%
of plasma concentrations (median = 11%). The concentration-time profile of 5-FU was
similar in the three matrices suggesting no benefit in monitoring intracellular
concentrations. In addition, 5-FU is reported to be unstable in whole blood and red blood
cell 5-FU concentrations were near the limit of detection (10 ng/ml), supporting the
continued use of plasma as the preferred matrix for 5-FU TDM studies. Six
pharmacokinetic models were fitted to the 5-FU individual data sets for determination of
the best fit. The optimal model for whole blood and plasma data sets was a one
compartment with both linear and non-linear elimination model; whilst a one
compartment model with non-linear elimination provided the best fit for 5-FU in red
blood cells. A two compartment model with non-linear elimination gave a similar degree
of fit for plasma 5-FU as the one compartment model with both linear and non-linear
elimination.
Concluson These pharmacokinetic results provide the basis for further investigation
into the ability to correlate 5-FU systemic exposure with clinical drug activity.
P,0 FOOD REDUCES THE RATE BUT NOT THE EXTENT OF
ABSORPTION OF THYMITAQTM FOLLOWING ORAL
ADMINISTRATION. A.N.Hughes*', M.J.Griffin', A.H.Calvert'
D.Simmons',I.Rafi , A.Johnston2, N.J.Clendeninn2, A.V.Boddyl.'Cancer Research Unit,
University ofNewcastle Upon Tyne. 2Agouron Pharmaceuticals, San Diego, USA.
THYMITAQTM is a non-classical thymidylate synthase (TS) inhibitor
which has shown activity in Phase II clinical trials against head and neck
cancer, hepatoma and pancreatic cancer. Due to its lipophilicity and lack
of a glutamate moiety it does not require a specific cellular transport
mechanism for uptake into cells and does not undergo conversion to
polyglutamate forms. Initial studies using intravenous THYMITAQTM
infusions demonstrated that continuous administration-over 5 days was
needed to maintain adequate inhibition of TS. Further bioavailability
studies on an oral preparation demonstrated that in fasted patients,
absorption ofTHYMITAQT was rapid and almost complete (89%). In
this study, we have sought to investigate the effect of food on the
absorption of orally administered THYMITAQTm. Single oral doses of
200mg/M2 (free base) were administered on 2 consecutive days. Patients
were randomised and either fasted or fed a standard meal on Day 1 prior
to drug administration. Day 2 was the opposite to Day I. On the
subsequent 5 days, patients received 200mg/mi2 THYMITAQTM every 6
hours. The order of the study days was reversed on the 2nd cycle, 3
weeks later. Data from 8 patients were available for evaluation. In the
fed state, the maximum plasma levels of THYMITAQTM were lower
(median 10.6ig/ml; range 7.6 to 15.2gg/Iml compared to 20.4igg,ml;
range 10.3 to 31.5,ug/ml) and the time to maximum later (median
150min; range 45 to 185 min compared to 45min; range 30 to 60min)
than in the fasted state. Nevertheless, the areas under the plasma
concentration / time curves (AUCs) for the 2 doses were similar (fed
3.0mg/ml.min; range 2.0 to 4.8mg/ml.min compared to 3.3mg/ml.min;
range 1.1 to 6.5mg/ml.min). The order of the study did not significantly
affect the results. Since inhibition of TS is rapidly reversible, dosing of
THYMITAQTM may be preferable following the ingestion offood, as the
slower absorption will result in a shorter duration of non-inhibitory
concentrations prior to successive doses.24 Poster Presentations
P2 1 SYNTHESIS AND ANTITUMOUR ACTIVITY OF
P21 CYCLOPENTA[g]QUINAZOLINE-BASED
ANTIFOLATES, A NOVEL CLASS OF THYMIDYLATE SYNTHASE (TS)
INHIBITORS: V. Bavetsias*1, J. H. Marriott1, C. Melin1, R. Kimbellt, F. T.
Boyle2 and A. L. Jackman1, 1CRC Centre for Cancer Therapeutics at The
Institute of Cancer Research, Sutton, Surrey, UK; 2ZENECA
Pharmaceuticals, Alderley Park, Cheshire, UK.
Over the last two decades there has been extensive interest in the
thymidylate synthase (TS) enzyme because of its critical role in DNA
synthesis. TomudexTM, a polyglutamatable inhibitor of TS has recently
completed phase IlIl clinical trials with promising activity against colorectal
cancer. In addition, other antifolates (e.g., LY231514, BW1843U89, ZD9331,
and AG337) are currently under clinical evaluation. Our present research
program is mainly focused on the synthesis of cyclopenta[g]quinazoline-
based, non-polyglutamatable inhibitors of TS, such as 1a-d, that do not utilise
the reduced-folate carrier (RFC) to enter cells. In the design of this series, the
cyclopenta[g]quinazoline moiety was chosen because the conformational
restriction introduced by the presence of the cyclopentane ring is believed to
be favourable for binding to TS (F.T. Boyle et. al., Proc. Am. Assoc. Cancer
Res. 1996, 37, Abstr. 2610).
Antifolates 1 were synthesised by coupling of 4-[N-((6RS)-2-methyl-4-oxo-
3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-
ynyl)amino]benzoic acid to the appropriate ligand via DEPC or PyBOPS
carboxyl activation, followed by the removal of the protecting groups. This
strategy required the development of synthetic routes to each individual
glutamate-derived ligand. Antifolates of this type showed potent TS and cell
growth inhibitory activities (e.g., for 1 b: Kiapp = 0.78 nM, L1210 IC5o
=0.44±0.16 gM).
P2?3
COMBINATION STUDIES WITH TOMUDEXTm AND
SN-38 (CPT-11) IN A PANEL OF HUMAN COLON
TUMOUR CELL LINES. Rosemary Kimbell* and Ann L.
Jackman. The Institute of Cancer Research, Sutton, Surrey.
ZD1694, (TomudexTM, ZENECA Pharmaceuticals), a folate-based thymidylate
synthase (TS) inhibitor, has recently been registered in several countries for first-
line therapy in advanced colorectal cancer. Advantages over 5-fluorouracil (FU),
which has been the main treatment for several decades, include significantly
decreased leucopenia and mucositis, and a convenient bolus 3-weekly
administration schedule. SN-38, a DNA topoisomerase I inhibitor, is the active
metabolite of CPT- I1(Rhone-Poulenc Rorer), which is registered in some countries
for the treatment of FU-resistant colorectal cancer. Both ZD1694 and SN-38 are
potent inhibitors of cell growth (ICsos l-5nM) in a panel of six human colon
tumour cell lines (HT29, MaWi, LoVo, HCT8, SW620 and SW480), and SN-38
retained activity in a panel of cell lines with various mechanisms of resistance to
antifolates (eg. elevated TS, defective transport or polyglutamation). Their
different mechanisms of action suggest there may be a rationale for their
combination in the clinic. In vitro combination studies have been carried out using
a range of dosage and scheduling regimens in the panel of colon tumour lines.
Dialysed serum was used to eliminate any potential protective effects of thymidine
during exposure to ZD1694. Growth inhibitory activity was determined by MTT
assay after five days. Co-incubation with equitoxic doses of both drugs for five
days, or for twenty four hours with drug-free medium for the remaining period,
showed additivity or antagonism (as measured by Chou & Chou computerised
analysis, aBIOSOFT), giving combination index (CI) values at fraction affected
(Fa) 0.5 of 1.0 to i.8. Sequential exposures, such as twenty four hours to one drug
followed by four days to the second drug, with or without removal of the first drug,
gave similar results, with slightly more antagonism if the initial exposure was to
ZD1694. Manual isobologram construction confirmed these findings. Non-
equitoxic combinations (with up to a hundred-fold dose reduction of either drug),
were also additive or antagonistic. However, ifexposure was re-duced to four hours
SN-38 followed by four hours ZD1694, at approxiinately equitoxic doses, some
synergy was obscrved, with the reverse sequence again giving additivity or
antagonism (MaWi. CI n Fa 0.5, SN-38 dosed first, 0.75. ZD1694 first, 1.25;
HCT8 0.8 and 1.0; HT29 0.8 and 0.95 respectively). The effects of combinations of
ZD1694 and SN-38 in vitro are therefore highly dose, time and sequence
dependent. and this should be taken into consideration when extending studies to
the clinical situation. Supported b.vthe CRC.
P22
IN VITRO ACTIVITY OF
THE CYCLOPENTA[gJQUINAZOLINES, A NOVEL CLASS
OF THYMIDYLATE SYNTHASE (TS) INHIBITORS. C.Melin*',
R. Kimbell', V. Bavetsias', J. H. Marriott', F.T. Boyle2 and A.L. Jackman.'
'CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton,
Surrey. 2ZENECA Pharmaceuticals, Alderley Park, Cheshire.
The identification of intrinsic resistance mechanisms to inhibitors of TS
whiclh rely on the reduced folate/methotrexate carrier (RFC) for cellular
transport and intracellular polyglutamation by folylpolyglutamate syntlhetase
(FPGS). has led to the synthesis and development of a series of compounds
with activity independent ofboth the RFC and FPGS. These compounds are
acid based dipeptide analogues of the quinazoline-based TS inhiibitor 2-
desamino-2-methyl-Nl0-propargyl-5,8-dideazafolic acid (ICI198583), with a
cyclopentane ring attached to the quinazoline moiety (see Bavetsias et al,
accompanying abstract). Two such examples are CB300638 (L-glu-y-D-glu)
and CB300907 (L-glu-y-D-glu, where the a-carboxyl group of the second
amino acid is replaced with a tetrazole ring). Both are potent inhibitors ofTS
(TS Kiapp = 0.2nM and 0.36nM) with similar in vitro cytotoxic potency in
the L1210 (IC50 1.1 ± 0.54j.M and 1.7 ± 0.54j.M) and WIL2 (IC50 0.48 ±
0.2iM and 1.3 ± 0.77WM) cell lines. At least a 25-fold decrease in cytotoxic
potency in WIL2 cells in the presence ofthymidine confirms TS as the sole
locus of action. The absence of cross-resistance in the RFC-defective
L1210:1565 cell line suggests that these compounds are not dependent on the
RFC for cellular uptake. These compounds also showed poor substrate
affinities for the RFC wlhen assayed in competition with [3Hlmethotrexate (Ki
in L1210 = > 2501±M and 106.LM respectively; methotrexate = 5AM). No
change in growth inhibitory activity was seen in the L1210:RD1694 cell line,
which shows resistance to polyglutamatable TS inhibitors such as ZD1694
(Tomudexm). Both compounds showed activity in the lhuman colon tumour
cell lines HT29 (CB300638 IC500.84M; CB300907 IC50 2.2gM), and SW480
(CB300638 IC50 0.92gM: CB300907 IC50 2.3gM). Compounds of the non-
RFC. non-FPGS class as exemplified above may show a different and/or
wvider spectrum ofantitumour activity in vivo compared to other classes ofTS
inhibitors. These compounds are currently undergoing further investigation
as potential antituinour agents.
P2)4 EFFECTSOF LEUCOVORIN (LV) AND ORAL FOLIC ACID
P2LI (FA) ON THIE TOXICITY AND ANTITUMOUR ACTIVITY
OF THE THYMIDYLATE SYNTHASE (TS) INHIBITORS, TOMUDEX.
(ZD1694) AND ZD9331. C. Rees*, R. Kimbell, M. Valenti, L. Brunton, D.
Farrugia and A.L. Jackman. The Institute ofCancer Research, Sutton, Surrey.
The toxicity ofantifolates such as methotrexate or lometrexol may be controlled by
the administration of LV or FA. ZD1694, a polyglutamatable TS inhibitor, is a
highly specific TS inhibitor now registered for the treatment ofadvanced colorectal
cancer. The antiproliferative effects of ZD1694 are prevented by co-administration
of LV (through competition for cellular uptake via the reduced-folate carrier and
polyglutamation i.e. the active tri-pentaglutamate drug species are not formed).
1843U89 is a TS inhibitor. (in Phase I study) that is polyglutamated to the
diglutamate only. The gut toxicity, but not the antitumour activity, of this
compound in mice and dogs is preventedby co-administration ofp.o. FA (Smith et
al, Cancer Res. Dec. 95). This effect is hypothesised to be due to the presence of a
low Km transporterfor FA in the gut. ZD9331 is a novel, non-polyglutamatable TS
inhibitorthat is in Phase I clinical study. We have examined a) the effect ofLV and
FA on the cytotoxic activity ofZD1694 and ZD9331 in 6 human tumour colon cell
lines, b) the effect ofi.p. LV and p.o. FA on the antitumour activity and/or toxicity
ofZD1694, c) the effect ofLV or FA on the toxicity ofZD9331. The colon tumour
cell lines (HT29, LoVo, SW480, SW620, Mawi and HCT-8) with 25nM LV as the
folate source, were co-incubated (5 days) with either ZD1694 (IC0, 3-8nM) or
ZD9331 (ICo 10-3OnM) and 5gM LV or 25gM FA. LV competes with both drugs
for initial cellular uptake, but, because it also competes with ZD1694 for
polyglutamation, increased its ICsw 200-fold compared with 3-fold for ZD9331.
25gM FA increased the IC5s ofZD1694 up to 9-fold, which is probably due to a rise
in the intracellular reduced-folate pool and competition for polyglutamation. The
same concentration of FA had little effect on ZD9331 cytotoxicity. Baib/c mice
were used as a model for drug-induced gut toxicity (weight loss). The toxicity of
ZD1694 (10mg/kg i.p. daily x 5 days) was completely prevented by co-
administration of LV (20mg/kg/twice daily i.p. x 8 days), but that of ZD9331
(100mg/kg/d x 7days s.c. infusion) was only partially prevented (100mg/kg i.p.
twice daily x 7days); 13 ± 3.1% weight loss by day 8 compared with 21 ± 2.6%
weight loss for ZD9331 alone. FA (300mg/kg daily p.o.) prevented the weight loss
induced by ZD1694 but not that by ZD9331. The L5178Y antitumour activity of
ZD1694 (DBA2 mice) is also prevented by p.o. FA (100 or 300mglkg daily).
Although, these data do not currently suggest a role for the co-administration ofFA
with either ZD1694 or ZD9331, the effect of LV on the arntitumour activity of
ZD933 1 will be examined. Fundedby the CRC andZeneca Pharmaceuticals.
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P25 ESTIMATION OF 2'-DEOXYURlDINE (dUrd) IN HUMAN
PLASMA BY HPLC WITH FLUORIMETRIC DETECTION; A
PHARMACODYNAMIC MARKER FOR THYMIDYLATE SYNTHASE (TS)
INHIBITION. F. Mitchell*, D. Farrugia, C. Rees, D. Cunningham, I. Judson, and
A.L.Jackmnan. The CRC Centre for Cancer Therapeutics, Institute of Cancer
Research and Royal Marsden Trust, Sutton, Surrey.
ZD1694 (TomudexTm) is a polyglutamatable, highly specific, folate-based TS
inhibitor used in the treatment of advanced colorectal cancer and ZD9331 is a non-
polyglutamatable TS inhibitor in Phase I study. TS inhibitors such as 5-
fluorouracil, CB3717, ZD1694 and ZD9331 cause an increase in the level of
intracellular dUMP which can be dephosphorylated to dUrd and transported out of
the cell. Studies in both mice and/or humans have demonstrated a rise in plasma
dUrd after treatment with the TS inhibitors, CB3717, AG337, and ZD1694. This
suggests that plasma dUrd may be a useful pharmacodynamic marker of TS
inhibition (in proliferating tissues). Plasma dUrd levels, together with
pharmacokinetic and clinical data, contributed towards the decision to initiate a 5-
day continuous infusion Phase I study of AG337 (Rafi et al, Clin. Cancer Res,
1996). HPLC methods used for the measurement of plasma dUrd have previously
relied on UV absorbance at 254/280nm (non-specific wavelength). The presence of
interfering peaks requires sequential chromatographic steps. This led us to develop
an improved, sensitive HPLC method for the detection of plasma dUrd. Following
solid-phase extraction of dUrd from plasma (to which 10nmoles of 5-CldUrd are
added as an internal standard), a derivitisation reaction is carried out using the
fluoresence tagging reagent, 4-bromomethyl-6,7-dimethoxycoumarin (BrMdmc).
The derivatised dUrd is separated on an isocratic reversed-plhase system with a run-
time of40min. (4.6x250mm SUPELCOSIL LC-18 5p±m column; mobile phase, 16%
acetonitrile in 0.05% v/v acetic acid), at 45°C. The high specificity of the
derivitisation reagent (only reacts with carboxylic acids, fatty acids, pyrimidine
compounds) reduces the number and size of interfering peaks, which means that
only a single HPLC step is required. dUrd is quantified with reference to a 4-point
standard curve. The limit of detection is approximately 0.05pmole on-column and
the limit of quantitation in a Iml plasma sample is -lnM. The inter- and intra-
batch coefficient of variation are 6% and 8% respectively. The dUrd levels in the
plasma of five patients receiving a standard dose of 3mg/M2 of Tomudex have been
analysed. The pre-treatment level was -0.051iM which rose 1.5 to 6-fold 24h after
treatment although this had returned to (or fallen below) pre-treatment levels 5 days
later. Rises in plasma dUrd have also beqn seen in some patients in the Phase I
clinical study of ZD933 1 (5-day continuous infusion).
P /'_7
IN VIVO PHARMACOKINETIC AND PHARMACODYNAMIC
STUDIES OF TWO SPECIFIC THYMIDYLATE SYNTHASE (TS) INHIBITORS.
A.Hardcastle, D. Dobinson, D. Farrugia, A.L. Jackman and G.W. Aheme, CRC
Centre for Cancer Therapeutics, Inst. ofCancer Research, Sutton, Surrey SM2 5NG.
TS catalyses the reductive methylation of dUMP to TMP, which is converted to TTP,
the only dNTP required exclusively for DNA synthesis. ZD1694 (TomudexTM,
raltitrexed) and ZD9331 are quinazoline antifolates which specifically inhibit this
enzyme. Both compounds are transported into the cell by the reduced folate carrier
(RFC) but unlike Tomudex, ZD9331 does not rely on polyglutamation for high
potency. We have previously shown by the measurement of TTP and dUMP pools in
vitro that TS inhibition is rapidly reversed when non-polyglutamatable compounds
are removed from the medium. In contrast TS inhibition is prolonged following
exposure of cells to ZD1694 even when drug is removed from the medium (Aheme
et at., 1996, Biochem Pharmacol. 51, 1293; Aheme et al., 1996, Annals ofOncology
7, Suppl.1, 89). These data are consistent with rapid efflux of ZD9331 from cells
compared with the intracellular retention of potent polyglutamated species after
exposure to ZD1694. The relationship between plasma and tumour drug levels and
perturbations in TTP pools has now been studied in vivo. In order to overcome the
problem of thymidine salvage from plasma in mice, the salvage incompetent L51 78Y
thymidine kinase negative (TK-/-) mouse lymphoma was used. This tumour is cured
by both ZD1694 (IxlOmg/kg ip) and ZD9331 (lxSOmg/kg ip and 3mg/kg sc 24h
infusion). L5178Y TK-/- cells (2.5 x105) were implanted sc into a hind leg of female
DBA2 mice Drugs were administered 4-7 days later (tumour size _8mm) to groups
of 3-6 mice. Plasma and tumour tissue were obtained at intervals for measurement of
drug (RIA for ZD1694 and ELISA for ZD9331) and tumour TTP pools (RIA). For
ZD9331 (50mg/kg ip) plasma drug levels at 4h (1.82±0.6pM) exceeded those in
tumour 2 fold but by 24h tumour levels were approx. 5 times higher than those in
plasma (0.02-0.04pM). Tumour TTP pools were significantly depleted compared to
control animals (56%) at 4h (p=0.01) and 6h (p=0.004) but not at 16h or 24h.-During
the ZD9331 infusion (3mg/kg sc 24h) plasma drug levels reached a plateau of 0.4-
0.8pM and tumour drug concentraticns were 1-2 fold higher. TTP pools were
significantly depleted at 4h (44% controls p=0.003) and at the end of infusion (27%
controls p=0.0001). Total ZD1694 levels in tumour were 50-60 times those in plasma
24 and 48 hours (0.02pM and 0.004pM respectively) after ip injection (10 mg/kg).
Significant depletion of TTP was observed at 4h (16% controls p=0.009) and at-24h
(68% controls p=0.002) but not at 48h (105% controls). These on-going pk/pd
studies in L5178Y TK-/- and other tumour bearing animals may provide important
information for the design of improved clinical schedules of administration.
P26
COMPONENTS OF THE URACIL MISINCORPORATION
PATHWAY; THEIR INFLUENCE ON CELLULAR RESPONSE TO THYMIDYLATE
SYNTHASE (TS) INHIBITORS.
S. D. Brown*, A. Hardcastle, R. D. Ladner', and G. W. Aheme. CRC Centre for
Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK, and 'Univ.
Med. Dent. ofNJ, Stratford, NJ08084.
TS plays a critical role in DNA replication since it provides dTTP and is involved in
balancing deoxynucleotide precursor pools during DNA synthesis. Inhibition of TS,
in addition to blocking dTTP formation, greatly expands the dUMP pool which in
turn may elevate dUTP pools. dUTP misincorporation and uracil misrepair have been
implicated as important events accompanying prolonged TS inhibition. However, the
enzymes of this uracil misincorporation pathway remain to be identified as critical
components influencing sensitivity to TS inhibition. We have addressed the
relationship between key enzymes involved in dUTP misincorporation and cellular
sensitivity to TS inhibition in 5 human cell lines (I lymphoblastoid, 3 non-small cell
and I small cell lung car6inoma). Sensitivity (5 day MTT assay) to the growth
inhibitory effects of the non polyglutamatable, quinazoline antifolate, specific TS
inhibitor ZD9331, were found to differ up to 9 fold (IC50 range: 0.046gM- 0.005pM).
This variation in sensitivity did not correlate with TS protein expression determined
using Westem immunoblot analysis. Using sensitive radioimmunoassay procedures,
we have measured dTTP and dUTP pools following a 24hr exposure to ItPM
ZD933 1. The amount of dUTP formed was inversely related to the pyrophophatase
activity of dUTPase (0.001pM-0.018pM/min/mg protein). The dUTP/TTP ratios
after this treatment ranged from 0.4-11.8 (control cells <0.15). The most sensitive
cell line CORL23 had the highest dUTP/dTTP ratio (11.8) after this treatment. This
compared to a dUTP/dTTP ratio of only 0.4 for one of the more resistant cell lines
(MOR). Despite having a high dUTP/dTTP ratio of 7.9, the A549 cell line was the
most resistant to ZD933 1. Uracil-DNA glycosylase enzyme activity in the cell lines
was measured. The A549 cell line had a significantly (p=0.0001) higher level ofthis
DNA repair enzyme activity (932pmol uracil/minlmg protein) than the other cell
lines (average activity 238 +153pmol uracil/min/mg protein). It appears that cellular
response to TS inhibition maybe effected by the balance betweeni factors influencing
the dUTP/dTTP ratio e.g dUTPase, and those enzymes involved in repairing DNA.
Further work will address the extent of DNA damage induced by specific inhibitors
of TS and the expression of proteins involved in the recognition and initiation of
events post DNA damage.
P28 The Induction ofApoptosis, Cell cycle arrests
and p53 protein accumulation in ovarian
cancer cell.lines by Camptothecin and its water soluble analogues.
AC McDonald* and R Brown. CRC Dept ofMedical Oncology, University
ofGlasgow, Beatson Laboratories, Garscube Estate, Glasgow G61 IBD
Given the activity ofcamptothecin analogues in platinum refractory ovarian
cancer we have evaluated the in vitro effects of such compounds in an
ovarian cancer cell line model system. The A2780 cell line exhibits
functional p53 dependent GI arrest following 2 Gy ionising radiation (IR).
Treatment of A2780 with Camptothecin and three water-soluble analogues,
topotecan, G1147211 and SN-38, (the active metabolite ofCPT-11), induces
cellular accumulation of p53 protein, maximal 24 hours following a 1 hour
exposure. Treatment ofA2780 with 2 x ID80 concentrations ofcamptothecin
and these analogues induces apoptosis assessed by TUNEL staining / FACS
analysis, maximal 72-96 hours post treatment. Similar exposure ofA2780 to
ID80 concentrations ofeach drug induces cell cycle change, with a 6-12 fold
accumulation ofcells in G2 phase 24 hours after drug exposure. No evidence
GI / S delay is observed.
We have previously shown mutant p53 (codon 143, val to ala) transfectants
(A2780/mp53) ofA2780 lose IR induced GI arrest, retained by vector alone
controls (A2780/v) (Mcllwrath et al Cancer Res. 1994; 54:3718-22).
A2780/mp53 and A2780/v express topoisomerase I equally, assessed by
western immunoblotting. Using clonogenic assay, A2780/mp53 acquires 2-3
fold resistance to a number of agents including cisplatin and adriamycin
(Vasey et al Molecular Pharmacology 1996, in press). These cells are not
cross resistant to camptothecin, topotecan or SN-38 but are 2.3 fold resistant
to GI14721 1. Cell cycle studies show each agent capable of inducing G2
arrest at 24 hours in both A2780/mp53 and A2780/v.
Camptothecin and its analogues induce apoptosis and cellular accumulation
of p53 in A2780. They also induce a G2 arrest, but both cell cycle
perturbation and cell survival does not appear dependent on wt p53.
Topotecan kindly provided by Smithkline Beecham, GI147211 by
GlaxoWellcome and SN-38 by Rhone-Poulenc Rorer.26 Poster Presentations
p.129CELLULAR RESPONSES TO TOPOISOMERASE P29 I (TOPO) INHIBITORS AND PATHWAYS OF
CELL DEATH. J.S. Macpherson, J. Cummings, E.
Miller and J.F. Smyth, ICRF Medical Oncology Unit, Western
General Hospital, Edinburgh, EH4 2XU.
Sensitivity of 5 unrelated human cell lines (HL60, A2780 and 2780AD,
HT-29 and NX002) to the novel topo I inhibitor (NU/ICRF 505) does
not correlate to topo I expression but rather to the presence of wild
typep53 and ahigh Bax/Bcl-2 ratio. To further define factors dictating
chemosensitivity to topo I poisons, studies have been extended to
include the classic inhibitorcamptothecin (CPT) and to follow cellular
responses afterdrug incubations at IC50 concentrations. A similar
pattern ofchemosensitivity to NU/ICRF 505 and a lack of a
correlation to topo Iprotein levels were observed with CPT. Treatment
of more sensitive wild type p53 cells (A2780) with NU/ICRF 505 (10
tM) resulted in a >10-fold elevation in p53 protein at 24 hr; a potent
induction ofp21 with peak levels at 36-48 hr and a 3-fold increase in
Bax protein after 48 hr.These responses corresponded to cells both
accumulating inG1/S and entering into apoptosis 24-48 hr after drug
treatment. A more sustained stimulation ofp53 occurred after CPT
treatment (4 x 10-9 M) with peak protein levels detected at 48 hr (7-
fold induction), as well as increased p21 at 48 hr. However, no
significant perturbation in cell cycle distribution was evident.
Treatment ofless sensitive mutant p53 cells (HT-29, 4.6-fold resistant
to NU/ICRF 505 and 3.2-fold resistant to CPT) with both compounds
failed to inducep53,p21 or Bax. NU/ICRF 505 had no effect on cell
cycle distribution whereas CPTproduced a marked G2/M
accumulation. These data are consistent with topo inhibitors killing
cellsthrough both more sensitive p53 dependent pathways and less
sensitive non-p53 dependent pathways. In addition, the two inhibitors
can differentially affect the cell cycle whilst essentially eliciting the
same cellular responses.
P31 (DArgl, DTrp5S7'9, Leu11]Substance P
coordinately and reversibly inhibits neuropeptide induced
signal transduction pathways in Swiss 3T3 cells, M.J. Secki'
and E. Rozengurt, ICRF, 44 uncoln's inn Fields, London WC2 3PX.
The development of novel therapies for small cell lung cancer
(SCLC) is urgently required. Since the growth of this tumour is
driven by multiple neuropeptides including bombesin and vasopressin,
a broad spectrum neuropeptide inhibitor might be a useful therapeutic
approach. Indeed, the substance P (SP) analogues, [DArg1, DPhe5,
DTrp7,9, Leu1 I]SP and [Arg6, DTrp7,9, MePhe8JSP (6-11) inhibit
the action of a broad range of neuropeptides including bombesin and
vasopressin in Swiss 3T3 cells and inhibit SCLC cell proliferation in
liquid culture, soft agar and as xenografts in nude mice. Despite their
intriguing biological effects and potential importance as
antiproliferative agents, the mechanism of action of SP analogues as
broad spectrum inhibitors of neuropeptide-mediated signal
transduction remains unclear.
Here we show that the novel SP analogue, [DArg1, DTrp5,7,9,
Leu111SP like (DArgl, DPhe5, DTrp7,9, Leu11]SP inhibited DNA
synthesis induced by bombesin, vasopressin and bradykinin but did not
interfere with the mitogenic response induced by other growth
promoting agents in Swiss 3T3 cells. Both SP analogues reversibly
inhibited bombesin stimulated mitogenesis but [DArg1, DTrp5,7,9,
Leu1 ]SP was more potent. The new SP analogue coordinately and
reversibly inhibited bombesin induced Ca2+ mobilization, protein
kinase C and mitogen activated protein kinase (MAPK) activation. In
addition, [DArgl, DTrp5.7,9, Leu1 1 ]SP reversibly inhibited
bombesin induced tyrosine phosphorylation. [DArg1, DTrp5,7,9,
Leu111 also reversibly and coordinately inhibited vasopressin
induced signal transduction and DNA synthesis. Surprisingly, deletion
of the terminal Leu of [DArgl, DPhe5, DTrp7,9, Leu1l SP to yield
[DArgl, DPhe5, DTrp7,9ISP1-10 resulted in a selective loss of
inhibitory activity of this analogue against bombesin- but not
vasopressin-stimulated DNA synthesis, Ca2+ mobilization and MAPK
activation. Collectively, these results suggest that SP analogues act at
the receptor level to coordinately and reversibly antagonize bombesin
or vasopressin induced signal transduction in Swiss 3T3 cells.
P30 IN VITRO CELL CYCLE EFFECTS AND GROWTH
INHIBITION OF THE HT29 HUMAN COLON CANCER CELL
LINE BY [D-ARGt,D-TRP5.7.9,LELJIl]-SUBSTANCE P. D.A. Jones*, E.P. Miller
andJ.F. Smyth. Imperial Cancer Research Fund, Medical OncologytJnit, Western
General Hospital, Edinburgh EH4 2XU.
[D-ArgI,D-Trp5.7.9,Leul 3]-Substance P belongs to a class ofcompounds termed broad
spectrum neuropeptide antagonists possessing the unusual ability of being able to
inhibit simultaneously the actionof several calcium-mobilising neuropeptides such as
bombesin, bradykinin and gastrin. These peptides have been shown to act as growth
factors in several cancer types including small cell lung andcolorectal cancer. In vitro,
the HT29 cell line is growth stimulated by foetal calf serum (FCS) which is kliown to
contain a variety of calcium-mobilising agents. This research has inivestigatted (i) the
abilityof[D-Arg ,D-Trp5.7.9,LeuI'i-substance P to inhibit the inicreases in[Cal2+]- in
response to FCS; (ii) the anti-proliferative effect of [D-ArgI,D-Trp5.'79,LeuIl
substance P on HT29 cells grown in the presence of FCS; (iii) the effect of the
antagonist on the cell cycle of the HT29 cells in order to define whether the observed
growth inhibition is due to decreased cell proliferation and/or induction of cell death.
Methodology: [Ca2+]i mobilisation was measured using Fura-2AM loaded cells and
employing a ratiometric analysis of the change in fluorescence at 510nm after
excitation at 340/380nm. Dose-response curves for [D-Arg ,D-Trp5,79,LeutI]-
substance P against HT29 cells were performed in quadruplicate in media containing
5% FCS. Cell cycle analysis and BRDIJ pulse-labelling was performed 24 hours post
antagonist addition on a Becton-Dickinson FACScan using CellFit software.
Results: (i) In control samples addition of 1% FCS caused a rise in [Ca2+]j of
31 nM (+/-48)whilst in the presence of 20iiM [D-Arg1,D-Trp5,7,9,LeullI]-Substance P
a rise ofonly 22nM (+/-6) was observed. The competitive nature of this inhibition was
confirmed by the addition of 10% FCS which was able to reverse the effect. (ii) [D-
Arg1,D-Trp57,9,LeuII]-substance P inhibited the growth of the HT29 cells in a dose-
dependent manner exhibiting an IC50 value of 20jiM. (iii) Following treatment with
20iM antagonist the proportion of cells in all phases of the cell cycle were
significantly affected (p <0.0001). BRDU pulse-labelling of the cells demonstrated that
the treated cells were progressing through the cell cycle at a rate 2.5-fold slower than
the controls. No evidence of induction ofapoptosis was observed on the FACScan.
Conclusions: The data presented indicate that (i) [D-ArgI,D-Trp-57.9,Leu7 i-
substance P acts as a competitive inhibitor of calcium-mobilising mitogens present in
FCS and for the first time (ii) at the IC50 the anti-proliferative activity of these
compounds is due to a prolongation of the cell cycle rather than apoptosis.
P32 GROWTH INHIBITORY EFFECTS OF THE SYNTHETIC
RETINOID CD437 AGAINSTOVARIAN CARCINOMA
MODELS IN VITRO AND IN VIVO
SP Langdont, GJ Rabiaszl, AA Ritchiel, UReichert2, JFSmythl and WRMillerl.
IICRFMedical Oncology Unit, Westem General Hospital, Crewe Road, Edinburgh,
2CIRDGalderma, Valbonne, France
Retinoids arebeingincreasinglyconsidered as cancertherapeutic and chemo-
prevention agents. Retinoid signal transduction is mediated by anetwork ofsix
interacting nuclearreceptors thatfall into twoclasses, the RARs(ot 43 andY) and
the RXRs(<c,P andv). CD437(6-[3-(l-adamantyl)4-hydroxyphenylJ-2-naphthalene
carboxylic acid is arelatively selective activatorforRAR-Y andhasrecentlybeen
demonstrated toregulatep21WAFI/aPl expression in breast carcinomacells in a
p53-independent manner(Shao et al Oncogene, 11,493-504, 1995).
In this study we have evaluated the activity ofCD437 against4 human ovarian
carcinomacell lines:PEOI, PE04 (a Pt-resistantin vivo derived counterpart of
PEOI), PECJCDDP (a Pt-resistant in vitro derived model ofPEOI) andPE014.
Growth inhibition againstthese4 lines was investigated after6 days exposure and
assessment was by cell number. IC50 values were 0.1, 0.14, 0.07 and 0.17 JuM for
PEOl, PE04, PEO1CDDP andPE014 respectively. These values indicate that this
retinoid iseffective atsubmicromolarconcentrations. Cisplatin-resistantcell lines
were as responsive to this retinoid as cisplatin-sensitive lines indicatingpotential
activity in resistantdisease.
CD437 was evaluatedagainst the PE04 xenograft grown in nude mice. The agent
was tested atdoses of20mg/kg/day(given on days 0-4) and 10mg/kg/day (days0-4,
7-11) and was given by eitherintraperitoneal delivery ororaladministration.
Significantgrowth inhibition (p<0.05) wasobtained for both doses and by both
routes.
These data provide further support for the view that retinoids may have value for
the treatment ofovarian cancer.Poster Presentations 27
P33 DEVELOPMENT OF AN INTERNAL STANDARD
FOR QUANTITATIVE PCR (QPCR) MEASURE-
MENT OF DNA DAMAGE AND REPAIR IN SINGLE COPY GENES.
J.P. Bingham*, J.A. Hartley, and K.A. Grimaldi. CRC Drug-DNA
Interactions Research Group. Dept. Oncology, UCL Medical School, 91
Riding House St. London WlP 8BT
QPCR has previously been shown to be a highly sensitive method of
detection of gene specific DNA damage and repair. It depends upon
blockage of taq polymerase by DNA adducts and damage can be
quantified since the amount of PCR product will be directly proportional
to the amount of undamaged template. It is critical to control the amount
of DNA in the reaction since any variation in DNA extraction from treated
cells will result in assay imprecision. U.V. determination of DNA
concentration lacks adequate precision and is laborious when applied to
many small samples. The use of a fixed number of cells for the treatment
followed by a parallel DNA extraction using a simple, single-tube
protocol is quicker and more reproducible but the results can still be
influenced by variation in the DNA extractions. To reduce this variation
we have investigated the use of an internal standard for QPCR. Human
U937 cells were treated with a DNA damaging agent and then "spiked"
with a fixed number of mouse L1210 cells. DNA was extracted from the
mix of cells and subjected to two separate QPCR's under appropriate
conditions for each primer pair. A 523 bp fragment of the human N-ras
gene was the target for the DNA damage studies and a 950 bp fragment
of the mouse HPRT gene as the internal standard. Conditions were
optimised to ensure no cross-reactivity between the two target species.
The results showed that the amount of amplified HPRT product generated
was directly proportional to the amount of starting DNA while the amount
of N-ras product depended also on the extent of damage. Thus the
mouse HPRT template acts as an undamaged internal control which can
be used as a baseline to account for any variation in DNA extraction when
measuring DNA damage in the N-ras gene.
ROLE OF DNA DAMAGE AND REPAIR IN THE
P35 SENSITIVITY OF NON-SMALL CELL LUNG
CANCER CELL LINES TO MITOMYCIN C N.Robertson* and I.J.Stratford.,
MRC Experinental Oncology Group, School ofPhanracy and Phannaceutical Sciences,
University of Manchester, Manichester M13 OPL.
Mitomycin C (MMC) is used clinically to treat a wide variety of solid
tumours, and is the single most active agent for the treatment of non-small cell
lung cancer (NSCLC). Activation of MMC leads to the formation of free radicals
and active alkylating species, thereby producing DNA strand breaks,
monoadducts and crosslinks. Cellular responses to such damage include cell
cycle arrest through activation of 'checkpoint' mechanisms and the triggering of
apoptosis. Cell cycle arrest provides the cell with opportunities for DNA repair,
affecting the long term survival ofthe cell.
Previous studies in this laboratory have shown a wide variation in the
response of NSCLC cell lines to MMC (Robertson et al, Biochem. Pharmacol.,
44, 409-412, 1992), and this cannot simply be explained by the levels of
reductase enzymes present in the cells.For this study, three NSCLC cell lines
have been chosen with similar levels of DT diaphorase (DTD) activity (Robertson
et al, Eur. J. Cancer., 30A (7) 1013-1019 1994) and cytochrorne P450
reductase (P450R) activity, but with a.73-fold range in their response to MMC.
The cell lines, A549, H647 and H460, exhibit high levels of DTD (4980, 4970
and 5020 nmol cyt. C reduced min-' mg-' protein, respectively ) and relatively
low levels of P450R (22 9.1 and 17.6 nmol cyt. C reduced min-' mg-' protein,
respectively). MMC sensitivity, as measured by the MTT assay (3 hour drug
exposure), is shown by IC50 values of0. 18 pM for H460, 3.55l±M for A549,
and 13.1 pM for H647.
The aims of this study are to determine whether differences in MMC
sensitivity among the three cell lines are related to different cell cycle effects, or
to differences in the DNA damage, namely crosslinks, formed after diug
exposure, FACS analysis of propidium iodide stained cells shows cell cycle
delays in S and G2 phases of varying duration in these cell lines post-MMC
treatment. Using alkaline elution, we are able to correlate drug dose with the
total amount of crosslinking measured for each cell line after MMC exposure.
However, we find no difference between the three cell lines in the relative
amounts of crosslinks formed after MMC exposure at the same dose, despite the
apparent large differences in cellular sensitivity. These results suggest that the
differences in MMC sensitivity evident in these cell lines may be due to the
differing abilities of the cell lines to repair DNA damage, as opposed to the total
amount of damage formed. Experiments are currently underway to investigate
this further.
P)34 SENSITlVrrYTONITROGEN MUSTARD IN
SACCHAROMYCES CEREVISIAE DEFICIENT IN
DNA REPAIR Gill, R.D.*1, Waters, R.2, Hartley, J.A.1 1CRC Drug-DNA
Interactions Research Group, Department of Oncology, UCL Medical
School, 91 Riding House Street, London WlP 8BT, 2School of Biological
Sciences, University of Wales, Singleton Park, Swansea SA2 8PP
Nitrogen mustard (HN2) is a potent chemotherapeutic drug which is a
bifunctional alkylating agent capable of forming both monoadducts and
interstrand crosslinks in DNA. In order to examine the mechanisms of
repair of damage induced by this drug, Saccharomyces cerevisiae strains
deficient in a single DNA repair enzyme have been studied. The strains
include representatives from the 3 major epistasis groups of DNA repair in
yeast, comprising mutants deficient in nucleotide excision repair, post-
replication repair, and recombination repair, as well as representatives
deficient in base excision repair. Comparison of the toxicity of HN2 over
the dose range 1-1000(M has revealed a wide range of responses. The most
sensitive strains tested to date are from the nucleotide excision repair
epistasis group, radl4 and rad2. RAD14 codes for a protein involved in
initial damage recognition while RAD2 codes for an endonuclease that
cleaves on the 3' side of a damaged site in DNA in the nucleotide repair
pathway. The sensitivity exhibited by these strains is approximately 105-
107-fold greater than the parental strain. Cleavage at the 5' site of the
damage is accomplished by an enzyme complex of RAD1 and RAD10
proteins, but the strains deficient in either of these enzymes exhibit much
lower sensitivity to HN2 treatment (10-100-fold). A rad3 strain had a low
sensitivity to HN2. The RAD 3 gene codes for an essential activity that is
part of the yeast transcription apparatus as well as nucleotide excision
repair. Each of the other DNA repair pathways have at least one mutant
strain that exhibits marked sensitivity to nitrogen mustard. A rad 9 strain,
from the post-replication/error-prone repair epistasis group, and rad54 and
rad52 strains, from the recombination repair epistasis group, are each 10-
100-fold more sensitive than the parental strain. Finally, a representative
of the base excision repair group, lacking 3-methyladenine glycosylase
activity, is 10-100-fold more sensitive than the parental strain. The
response of the yeast strains indicates that there is considerable overlap
among the DNA repair pathways for removing cytotoxic HN2-induced
DNA damage.
P36 06_METHYLGUANINE-DNA METHYLTRANSFERASE
(MGMT) IN TUMOUR BIOPSIES AND PERIPHERAL
BLOOD LYMPHOCYTES AS AN INDICATOR OF CLINICAL RESPONSE OF
MALIGNANT MELANOMA TO TEMOZOLOMIDE. M.R.Middleton",
S.R.Wedge2, G.Rustin3, M.J.Lind4, C.Morris', D.R.Newell4, N.M.Bleehen5,
N.Thatcher1, J.M.Lunn4, A.H.Calvert4 and G.P.Margison1.'Christie
Hospital, Manchester, U.K., 2Charing Cross Hospital, London, U.K.,
3Mount Vernon Hospital, Northwood, Middlesex, U.K., 4University of
Newcastle upon Tyne, U.K. and 'Addenbrookes Hospital, Cambridge,
U.K., on behalf of the Cancer Research Campaign Phase II Clinical Trials
Committee.
Resistance of mammalian cells to methylating and chloroethylating agents
in vitro and in vivo has been linked to levels of the DNA repair protein
MGMT. In a clinical trial of temozolomide in advanced malignant
melanoma, we have studied the relationship between pretreatment MGMT
levels in biopsies of cutaneous tumours and involved lymph nodes, and
clinical response to the drug. We have also examined tumour distribution
of MGMT by immunohistochemistry. In addition, we have measured
MGMT levels in peripheral blood lymphocytes (PBL) before and during
temozolomide treatment.
Among 24 patients, there were 4 complete responses (CR), 3 partial
responses (PR), 1 no change (NC) and 16 with progressive disease (PD),
for an overall response rate of 29%. The tumour MGMT levels (fmol/mg
protein) were: CR, 206±194; PR, 620±820; NC, 164; PD, 181 ±225.
Temozolomide treatment resulted in lowering of MGMT levels in PBL, but
there was no correlation between pretreatment levels in PBL and biopsies.
Thus, measurements of pretreatment levels of MGMT in melanoma did
not predict response to temozolomide. Further, PBL cannot be used as a
surrogate for tumour biopsies.28 Poster Presentations
P37 AN ALTERNATIVE METHOD FOR THE DETECTION OF
GENOMIC INSTABILITY IN COLORECTAL CARCINOMAS,
M. G. Coleman* ,A. C Gough', D. J. Bunyan2 and J. N. Primrose1. 'University Department of
Surgery (816) F level, Centre block, Southampton General Hospital, Southampton, Hants, S016
6YD. The Wessex Regional Genetics Laboratory, Salisbury District hospital, Salisbury, SP2 8BJ.
Microsatellite instability (MIN), implying a replication error phenotype
(RER+), characterises a proportion of colorectal cancers. Generally, the
polymerase chain reaction (PCR) using several microsatellite markers
may be required and debate remains as to how many positive results are
needed to infer RER positivity. Minisatellite variant repeat units (MVRs)
are long DNA sequences which show extreme levels of allelic variability,
not only in repeat copy number but also the interspersion pattern. MVR
mapping by PCR (MVR-PCR) assays the interspersion pattern of variant
repeat units along minisatellite alleles. We have designed novel sets of
primers specific to two MVR-PCR loci (MS31A and MS32) and simplified
their detection to non-radioactive PCR. Analysis of thirty-two colorectal
tumour-normal mucosa pairs using MVR-PCR were compared to those
using 10 microsatellite markers. Four patients (12.5%) showed MIN with 3
or more of the microsatellite markers suggesting a RER+ phenotype. All
three were positive by MVR-PCR. Three cases showed an RER+
phenotype by MVR-PCR which was not observed with any of the
microsatellite markers and in two of these we have identified mutations in
a DNA mismatch repair gene (hMLH1). These results suggest that MVR-
PCR may be an alternative, simpler method of detecting RER+
phenotype.
P39 DNA-DEPENDENT PROTEIN KINASE AND
POLY(ADP-RIBOSE). POLYMERASE INHIBITORS:
EFFECTS ON IONISING RADIATION INDUCED CYTOTOXICITY AND
DNA DOUBLE AND SINGLE STRAND BREAK REPAIR
Sallyanne Boulton, SuzanneKyle & Barbara W. Durkacz CancerResearchUnit,
University of Newcastle upon Tyne, NE2 4HH.
Poly(ADP-ribose) polymerase (PADPRP) and DNA-dependent protein
kinase (DNA-PK) constitute an unusual family of enzymes that are activated by
DNA strand breaks and mediate DNA repair. We investigated the effects of
inhibitors of these two enzymes on the cellular responses to DNA damage.
NU1025 (8-hydroxy-2-methylquinazolin-4(3H)-one)is a PADPRP inhibitorwhich
potentiatescytotoxicity and inhibits DNA single strandbreak(SSB) repairinduced
by temozolomide (Boulton et al (1995) Br. J. Cancer72: 849). Wortmannin is an
inhibitor of DNA-PK, which belongs to the phosphatidylinositol 3-kinase family
ofenzymes. It enhancesthe cytotoxicity ofionising radiation (IR) and inhibits the
repair of IR-induced DNA double strand breaks (DSBs) (Boulton et al (1996)
Carcinogenesis 17: 2285).
Possible interactions between the two enzymes were investigated. Both
are recruited to DNA ends, and could modify each other, and hence affect DNA
repair. The interactive effects ofNU1025 and wortmannin on the responses to IR-
and temozolomide-induced DNA damage in Chinese hamster ovary-Kl cells was
studied. Both drugs were non-toxic and did not cause DNA strand breakage.
NU1025 (I 00uM) potentiat9d the cytotoxicity of IR (DEFin < 1.5), and retarded
both SSB and DSB repair in a dose-dependent manner. Wortmannin (20M) also
potentiated the cytotoxicity of IR (DEF,1 5) and inhibited DSB repair, but had
no effect on SSB repair. When NU1025 and wortmannin were combined, their
potentiatingeffects on IR cytotoxicitywere additive. Both wortmannin orNU1025
alone potentiated the cytotoxicity of temozolomide, and again the potentiating
effects of the combined drugs were additive. The combinatorial effects of the
drugs on DSB and SSB levels in IR-treated cells are currently under investigation.
Temozolomide DSBs were not detectable within the sensitivity of the neutral
elution assay, but the ability of wortmannin to potentiate temozolomide
cytotoxicityimplicatesDSB formation asacomponentofitscytotoxicmechanism.
Although NU1025 modulatedDSB repair, indicatingthatPADPRP wascompeting
with DNA-PK for the same break sites on the DNA, the additive effects of the
two inhibitors on potentiation of cytotoxicity suggested that the two enzymes
functioned by independent pathways to mediate DNA repair.
DEFIO: Dose enhancement factor at 10% survival.
P38
DELETION OF THE TRANSFORMING GROWTH FACTOR p RECEPTOR
TYPE 11 AND REPLICATION ERROR POSITIVE COLORECTAL
CANCER D Braham*, M Coleman, H Chave, D Eccles, AC Gough, K Palmer and JN Primrose University
Surgical Unit and Department ofGenetics, Souttiampton General Hospital, Soutilampton, SO16 6YD.
Introduction:- Loss of a functional transforming growth factor beta receptor type II
(TGF,B RII) renders colorectal cells insensitive to the negative regulatory effects of
TGFI. It has been hypothesised that this allows escape from nornal growth control
mechanisms and hence contributes to malignant transformation in the colon. By virtue
of two regions of repeated DNA sequences within its gene it is suggested that the
TGFO RII may be lost in tumours with DNA mismatch repair deficiency (Replication
error (RER+) tumours) hence contributing to the malignant phenotype in these
tumours. To investigate this possibility we have studied the expression of the TGFI
RII gene in 24 samples of colorectal cancer and normal mucosa by semi-quantitative
reverse transcriptase polymerase chain reaction and polyacrylamide gel
electrophosesis. The RER status of the tumours was also determined using 9
commonly used microsatellite markers. Mutational analysis of TGFP RII was
performed by restriction digest (Bsl-J).
Results:- Two of 2 (100%) RER+ tumours and 6 of 22 (27%) RER- tumours
exhibited loss ofTGF,B RII relative to normal mucosa. No mutations were identified
in the amplified segment ofthe TGFI RII gene.
Conclusion:- The loss of TGF3 RII is common in colorectal cancer and although it
may be associated with RER+ tumours it is not confined to them.
P40 RADIATION INDUCED CELL-CYCLE DELAYS IN
ASYNCHRONOUS POPULATIONS OF NORMAL FIBROBLASTS. C.J.Orton*',
J.Berryf, 'Dept. of Experimental Radiation Oncology, 2Dept. of Physics and
Instrumentation. Christie CRC Research Centre, Manchester M20 4BX.
Introduction: Radiation damage delays the progression of cells through the cell cycle.
Lethally damaged and surviving cells cease to enter mitosis, whilst cells in mitosis
continue their progression. After a period oftime, that depends on both the cell-type and
the radiation dose, cells begin to reenter mitosis. This mitotic delay appears to be largely
due to a block in cell-cycle progression in G2 phase, whilst cells in Gl and S phase are
also delayed to a lesser extent. Most studies have examined irradiation induced cell-cycle
delays in synchronous populations. It is possible to study asynchronous populations with
continuous bromodeoxyuridine labelling and Hoechst 33358-Ethidium Bromide bivariate
flow cytometry, which separates the first and subsequent cell cycles, due to the
quenching of Hoechst fluorescence by bromodeoxyuridine. Materials: Twelve fibroblast
cell strains were studied , comprising two radiosensitive and one radioresistant human
strains and rune strains established from vaginal biopsies from pre-therapy patients with
carcinomas of the cervix. Methods:Cells were grown to confluence, irradiated at doses
of0, 2 and 4 Gy, and then plated out at low cell density for 72 hrs. Cell-cycle analysis
was then performed and compared with the control population at 0 hrs. Results:There is
emptying of the original GC compartment which is inhibited by irradiation, in the most
radioresistant cell strains maximum inhibition occurs at 2 Gy whereas in the
radiosensitive strains inhibition doess not occur at 4 Gy. The proportion of cells which
cycle (i.e. those that are labelled by bromodeoxyuridine) following irradiation correlates
with the cell surviving fractions at 2 Gy, SF2, (range 0.027-0.32), r-0.86, p=0.026, at 2
Gy, and r-0.83, p=0.04, at 4 Gy, and the level of residual DNA damage at 24 hrs
following a dose of 180 Gy as measured by gel electrophoresis, r=0.87, p=0.02 after 2 Gy,
and r=0.89, p=0.01 after 4 Gy. In the most radioresistant cell strains the accumulation of
cells in G, in the first cycle following irradiation, is greater than that in the more sensitive
cell strains and at 4 Gy this relationship reaches significance when correlated with SF.,
r=0.81, p=Q.05.The percentage ofcells entering the G, compartment in the first cycle is
the same irrespective ofwhether the cells are irradiated or not. G&/M delay measured by
the ratio ofthe percentage ofcells in G2 in the first cycle, to the percentage ofcells in G,
in the second cycle, correlates with SF,, r=-0.89, p=0.03 at 2 and 4 Gy. Conclusions:
Irradiation induced cell-cycle delays correlate with radiosensitivity. Other differences in
the distribution of cells throughout the cell-cycle were observed in the various cell
strains and probably indicate differences at the molecular level.Poster Presentations 29
P41 HEPATIC DNA DAMAGE, DETERMINED BY
32P-POSTLABELLING, OF GEOMETRIC ISOMERS OF
TAMOXIFEN & ANALOGUES. K. Brown*, J.E. Brown, E.A. Martin', I.N.H. White'.
Pharmaceutical Chemistry, University of Bradford, Bradford BD7 lDP and 'MRC
Toxicology Unit, University ofLeicester, Leicester LEI 9HN.
The antioestrogen tamoxifen is currently undergoing evaluation as a chemoprotective agent
in healthy women at an increased risk ofdeveloping breast cancer. Recently tamoxifen has
been shown to induce DNA adduct formation and liver tumours in rats, whilst in patients it
is associated with an increased incidence ofendometrial carcinoma. To determine the risk
oftamoxifen treatment it is vital to know the mechanisms involved in tamoxifen activation
leading to tumour formation. Tamoxifen (trans isomer) exhibits complex pharmacological
properties, with both oestrogen antagonistic and agonistic actions depending on the species
and target organ, whereas the cis isomer is a pure oestrogen agonist.
In this study, geometric isomers of tamoxifen and related compounds were assessed for
their ability to cause DNA damage using 32P-postlabelling (Martin, E.A. et al.
Carcinogenesis, 16, 1651-1654, 1995), the aim being to determine the contribution ofeach
individual isomer to DNA adduct formation. The compounds tested were tamoxifen itself,
a-hydroxytamoxifen, a metabolite postulated to be an intermediate in tamoxifen activation
(Osbome, M.R. et al. Cancer Res., 56, 66-71, 1996) and C-desmethylene tamoxifen, an
analogue in which the ethyl group has been replaced by a methyl. Female Fischer rats
received 40mg/kg i.p. daily for 4 days, the liver DNA was then extracted and subjected to
32P-postlabelling.
Table 1. 32P-Postlabelled DNA adducts, in rat liver.
Compound
Trans tamoxifen
Cis Tamoxifen
Trans C-desmethylene tamoxifen
Cis C-desmethylene tamoxifen
Trans a-hydroxytamoxifen
Cis a-hydroxytamoxifen
No of
determinations
6
6
5
S
6
6
Total adducts/I08Nucleotides
Mean + SD
103.4+ 19.3
18.0 + 3.5
95.5 + 22.8
1.9 + 0.5
4947.1+ 1675.6
52.7 + 14.5
These results show that treatment with the trans isomer resulted in a 5 to 90 fold higher
level of adduct formation than with the corresponding cis isomer. Differences in adduct
formation may be attributed to both differences in the metabolism and detoxification ofthe
isomers.
p43 RAI. ATiON RFSPONSE IN TONTGUT ARCINOMA CELL
LINES, N.A.Andrews'A.S.Jones' anid A.R.Kisnseila', Dept of Surgeryl, Dept of
Otorhinoiarvngoiogy Unisersity ofLiverpool PGBo.-x 147 Liverpool L69 3Bi.3
In this study we examined the effect of y irradiation induced cell cycle delay,
and radiosensitivity in three tongue carcinoma cell lines with respect to p53 expression.
The cell lines used were HN5, B2A4 (subclone ofHN5), and GBi2A (invasive population
from HN5). Inununohistochemical analysis using the p53 antibody Ab6 detected
overexpression of the p53 protein in both the HN5 and the GBi2A cell lines, but no
expression of the protein was detected in the B2A4 cell line. Twenty four hour cell cycle
data was obtained after 4 grays ofradiation using FACS analysis. The parental cell line
FIN5 exhibited maximal G2 arrest at 14hrs post irradiation with normal cell cycle
response retuniing after 22hrs. Themorphological features ofapoptosis were assessed by
Acndine Orange using cells floating in the medium after 24 hours. No evidence of
apoptosis was seen in this cell line even after 48hours. The invasive derivative GBi2A
showed evidence ofG2 arrest at 14 hours post irradiation with G2 arrest persisting past
the twenty fourhoturperiod. No apoptosis was noted after 24 hours. The subclone B2A4
exhibited G2 arrest only 4 hours post irradiation with maximal G2 arrest at 8 hours post
irradiation. Normal cell cycling was regained after 12 hours. There was evidence of
ap)ptosis after 24 hours. The survival fraction data between the cell lines after 4grays
varied from 0.38 in the HN5 cell line to 0.54 in the invasive cell line GBi2A, with the
B2A4 SF being0.29.
Taken together these data indicate thatoverexpression ofp53 is indicative of an
absiormality, in p53 function, and is not only involved in G2 arrest but also the length of
the G2 arrest. It is also evident thatoverexpression results inthe concomitant impairment
of the apoptotic finction in the parental cell line HN5 and the invasive.subclone GBi2A.
It would appear that the B2A4 stibclone has nomial p53 by virtue of its lack of
overexpression aIid theability to apoptose.
P42 PROGENITOR GROWTH FACTORS INCREASE
THE DNA DAMAGING EFFECTS OF ETOPOSIDE
IN CULTURED PERIPHERAL BLOOD MONONUCLEAR CELLS.
Wai M. Liu*, Clare L. Bamford, Simon P. Joel, ICRF Department of.
Medical Oncology, St. Bartholomew's Hospital, London.
Prior to work on the influence of dose and schedule of the topoisomerase II
inhibiting drug etoposide (VP-16) in bone marrow cells, the DNA damaging
effects of three haemopoietic growth factors necessary for short term bone-
marrow cultures (stem cell factor (SCF), interleukin 3 (IL-3) and
granulocyte/macrophage colony stimulating factor (GM-CSF)), in
combination with VP-16, were investigated. Sister chromatid exchange
(SCE) frequencies in the peripheral blood mononuclear cells (MNC) of
clinically normal volunteers were used as an indicator ofthe level ofdamage
to DNA. MNC's were separated on Ficoll, mitogenically stimulated with
phytohaemagglutinin-M, and cultured with one ofthe three cytokines (0-100
ng/ml), or with etoposide (0-2 tM) for 2 days. The effect of each growth
factor and VP-16 in combination were assessed at concentrations of40 ng/ml
for each cytokine and 0.4 pM VP-16. The number ofSCE per metaphase was
scored by Hoechst/Giemsa staining. SCF alone did not cause significant
changes in SCE numbers (5.0 ± 0.6 at 100 ng/ml vs 5.0 ± 0.6 in control
cultures). However, GM-CSF and IL-3 induced small, but significant, dose
dependent increases in the frequency of SCE's at concentrations of 50 and
100 ng/ml (100 ng/ml GM-CSF 6.4 ± 0.8, p<0.0001 vs control, 100 ng/ml IL-
3 6.9 ± 0.8, p<0.0001 vs control). With VP-16 alone there was a dose
dependent increase in SCE frequency which reached a plateau at around 0.4
tM (20.6 ± 1.9 at 0.4 ptM VP16 vs 5.0 ± 0.4 in controls). When growth factor
and etoposide were used in combination there was an approximate 50%
increase in SCE number, with any of the growth factors used, compared to
VP-16 alone (20.6 ± 1.7 vs 29.8 ± 2.3 with SCF, 30.2 ± 2.0 with GM-CSF
and 30.2 ± 1.8 with IL-3, p<0.0001 in each case). These data suggest a
sensitivity of MNC's, in this model system, to SCE induction by growth
factors either used alone or in combination with VP-16. Investigators should
be aware that the necessary use of growth factors in bone marrow cultures
may influence the activity ofDNA damaging agents.
Over expressed p53 in Germ Cell cancers as a
P44 possible factor in their high chemosensitivety.
Nouri AME, Dabare AANPM, Oliver RTD.Medical Onlcology,
Lonldon Flospital. UK.
It has lonig beet kinown that seminioma is more radiosenisitive thanl
noni-seminoma, though both area considerable order of niaginitude
more radiotherapeutically anid chemotherapeutically curable than
any other adult solid cancer.
In recent year high frequiency of p53 mutation has beeni reported in
various humaii nialignancies. Testis tumour is an exceptioni in that
the over expressed p53 is in a non-mutated form anid this could be an
importanit determiniant of response to chemotherapy.
Immunocytochemical staininig was set up to study of 40 germ cell
cancers, 31 bladder cancers anid 27 squamous head and neck cancers
usinig monoclonal antibodies (Mab) specific for p53, Bcl-2 and
HSP70.
Results showed that 89% of germ cell cancer compared to 7% of
bladder and 2% of squamous head and neck canicers were positive
for p53 using 240 Mab while only 60% of germ cell canicers but 100%
of bladder and head and neck were positive for Bc12. The
observation of higher p53 positivity for seminorima (82%,n=17)
compared to non seminoma (33%, n=6) and the inverse for Bc12-2
(53% vs. 83%) provides possible additional support for the inicreasing
literature suggesting a role for p53 in geriii cell cancer
chemosensitivity giveni the differenitial chemosensitivity of these two
subtype.
- -
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CLONING OF A YEAST SEQUENCE THAT
P45 CONFERS CISPLATIN RESISTANCE TO TESTIS
TUMOUR CELLS. Majid Hafezparast*. Xianghong Wang and John RW
Masters. Institute ofUrology and Nephrology, Universitv College London. 3rd
Floor 67 Riding House Strect. London W1P7PN
In contrast to most metastatic cancers, testicular germ cell
tumours are highly sensitive to DNA damaging agents. We have
therefore used testis tumour cells to determine the genetic basis of
curability oftesticular germ cell tumours. However, these cells are
difficult to grow ini vitro and have low transfection frequencies,
making conventional cloning strategies impractical. For this reason
we have generated an EBNA-1 (Epstein-Barr Nuclear Antigen 1)
expressing cell line of testis, SuSa-E46, that has a transfection
efficiency of 0.15%. The EBNA-1 gene promotes episomal
replication of EBV-based vectors and hence increases the stable
transfection frequency ofcells, in this case 75 fold higher than the
parent line SuSa. We have used S. cerevisiae yeast genomic and
human cDNA libraries, in EBV-based vectors, to transfect SuSa-
E46 cells and have isolated cisplatin resistant clones. Hirt
extraction of plasmids from the resistant clones resulted in
isolation of several plasmids containing different-sized inserts. So
far, one yeast insert has been taken through secondary and tertiary
transfections. This insert confers cisplatin resistance and
morphological changes to SuSa-E46 cells and is being sequenced.
Plasmids rescued from a human cDNA transfectant that is resistant
to cisplatin will be used to generate secondary transfectants and
hence identify the cDNA insert that confers this resistance.
p47 ROLE OF BAK AND BCL-xL IN CISPLATIN
RESISTANCE IN OVARIAN CARCINOMA CELL
LINES. P.J. Beale', S.Y. Sharp and L.R Kelland. CRC Centre for Cancer
Therapeutics, Institute of Cancer Research, Sutton, Surrey.
Cisplatin resistance in ovarian carcinoma is known to be multifactorial. The
role ofthe BCL-2 family of proteins in this process is not well defined. High
levels of BCL-2 measured immunohistochemically is known to confer a better
prognosis but other data suggest that high levels may be associated with drug
resistance in vitro. BAK and BCL-xL are two proteins of the Bcl-2 family;
BAK is a pro-apoptotic protein and BCL-xL is anti-apoptotic. Levels of BAK
protein as measured by densitometry after western blotting ranged from 10.to
172 (arbitrary levels) in our panel of 17 human ovarian carcinoma cell lines.
Levels ofBCL-xL ranged from 0.6 to 28. There was no correlation with levels
of BAK or BCL-XL and the 96 hour IC50 to cisplatin, as Ineasured by SRB
assay (r2 = 0.003 and 0.06 respectively). In sensitive and acquired cisplatin
resistant lines, BAK levels were lower in the resistant line (A2780cisR and
41McisR) but equal in the CHl pair. BCL-xL levels were lower in the resistant
line (A2780cisR and 4IMcisR) and there was a small rise in the level in the
CHlcisR line. Following a 2 hour exposure to cisplatin (5 x 2 hour IC50)
levels of BAK and BCL-xL were measured up to 24 hours after removal of
drug. In the A2780 line transfected with Bcl-2 and the neo-transfected pair the
pattern of change in protein levels varied. In the neo-transfected line, by 24
hours the level ofBAK was only 0.41-fold ofthat at time zero; levels ofBCL-
xL rose 1.5-fold and there was no BCL-2 detected. BAX, p53 and p21 levels
increased at 24 hours. In the Bcl-2 transfected line, however, BAK rose to 3.3-
fold that oftime zero at 12 hours and BCL-xL levels altered only slightly (1.1-
fold at 24 hours). BCL-2, BAX, p53 and p21 levels increased at 24 hours.
Levels in other lines have been measured after exposure to cisplatin and
similar results have been seen. These data support the lack of importance of
these proteins in cisplatin resistance in these cell systems.
Tlhis work is supported by the Cancer Research Campaign.
P46
BAX EXPRESSION IN PRIMARY EPITHELIAL
OVARIAN CARCINOMA: ASSOCIATION WITH WILD-TYPE P53. A. Al-
1. 1 ~ ~ ~ ~ ~~2 2 3 3 Azra7i, C. Challen, D. McKenna, B. Angus, M George3, D. Sinha3,
A. H. Calvert' and J. Lunec 'Cancer Research Unit, and 2Department of
Pathology, Medical School, University of Newcastle upon Tyne, Newcastle
NE2 4HH; 3Department of Gynaecological Oncology, Queen Elizabeth
Hospital, Gateshead.
Carboplatin is one of the main treatments for epithelial ovarian
carcinoma. In vitro studies have shown a role for wild-type p53 function
in mediating the apoptotic effect of platinum-based drugs. We have
previously reported a significant correlation between absence of pS3
mutation and initial clinical response to carboplatin, between Bcl-2
positive staining and good response ofthe same cases and between Wafl
positive staining and survival in wt-p53 cases. Bax is an apoptosis
inducing factor which interacts with and counteracts the effect of Bcl-2.
It is a 21 kd protein and transcription of the gene is positively regulated
by wild type p53. The bax coding sequence is preceded by four copies of
the p53 recognition motif. This study aimed to investigate the status of
Bax expression in 38 ovarian carcinoma cases prior to surgical debulking
and treatment with single-agent carbolpatin. Bax polyclonal antibody
(Pharmingen) was used at a dilution of 1/2000 for immunoperoxidase
staining of formalin-fixed 5 ptm sections with microwave antigen
retrieval. Irradiated skin sections were used as positive controls. In this
study, Bax positive immunostaining was significantly associated with
the lack of p53 mutation (p=0.014, n=38; Fisher's test). Bax positive
staining was not associated with initial response of patients to treatment
(p=0.59, n=3 1); however, in those cases which were positive for Bax and
Bcl-2, the association with good response is marginally significant
(p=0.06, n=24). Our results confirm an association in vivo between
wild-type p53 function and Bax expression. However, Bax expression
alone failed to show a relationship to treatment or survival.
DETECTION OF AMPLIFIED AND DELETED GENES IN SENSITIVE
P48 AND CISPLATIN-RESISTANT HUMAN OVARIAN CELL LINES BY
COMPARATIVE GENOMIC HYBRIDIZATION (CGH) AND FLUORESCENCE IN SITU
HYBRIDIZATION (FISH) 'S.Y. Shar*, 2LR. HIor. an 'LR. Kebnd. 'CRC Centre for Cancer
Therapeutics & 2Acdenslc Dept. of Haenstology, The Instiute ofCancerResearch, Sutton, Surrey.
Acquired resistance to cisplatin has been generated in vitro in the 41M human
ovarian carcinoma cell line, established from a previously untreated patient. Three
cisplatin resistant variants were selected at approximately 2, 4 and 6-fold resistance
(4lMcisR2, 41McisR4 and 4IMcisR6, respectively). Previous biochemical studies
have shown that reduced drug uptake is the major determinant ofacquired cisplatin
resistance in the 41McisR2 (2.0 ± 0.6), 41McisR4 (3.6 ± 1.0) and 4lMcisR6 (4.8 ±
0.6) cells, when compared with the sensitive 41M cells (Loh etal., 1992). To gain a
better understanding of the genetic changes which may be involved in the reduced
transport mechanism(s) in these cell lines, two complementary molecular cytogenetic
techniques were used. CGH produces a genome-wide screening of DNA sequence
copy number abberations, where differentially labelled sensitive and resistant cell
lines are hybridized simultaneously to normal metaphase spreads. Regions ofgain or
loss ofDNA sequences (ie. amplifications or deletions) can then be visualized. The
CGH results showed that amplifications were observed in the 41McisR6 cells for
regions ofchromosomes 4q, 5q, 6q, 10, and 17p, and deletions for regions of3q, 5p,
9p and 12p. A number ofcandidate genes are located in these positions. In order to
confirm the CGH findings and identify the genes involved, FISHwith specific probes
was performed. Among the genes located on chromosome 10 are genes for
mitochondrial ATPase and potassium channels. Probing with a whole chromosome
10 paint showed the parental 41M cell line had only one complete copy of
chromosome 10 and a portion translocated to another chromosome. As cisplatin
resistance increases in the 2-, 4- and 6-fold resistant cell lines, increasing numbers of
fragments derived from chromosome 10 were observed. The Tel-i gene (a
transcription factor commonly expressed in acute lymphoid leukaemia) was found not
to be involved in the deleted region of chromosome 12 in the 41McisR6 variant.
However, it was a useful marker to show progressive rearrangement and deletion of
the short arm of chromosome 12 with increasing cisplatin resistance. We are
currently probing with a whole chromosome 5 paint (which has a gene for Na/K/Cl.
transporter) and p53 (located on chromosome 17p).
Ref: Lohetal.,BrJ Cancer, 66, 1109-1115S 1992.
This work wassupported byCancerResearch Campaign.Poster Presentations 31
p49 CHARACTFRISATION OF P53 STlATlUS IN HUMAN
OVARIAN CANCER CELL LINES SENSITIVE TO CISPLATIN.
KE Pestell*, CJ Medlow, J Titley, LR Kelland, M1 Walton. CRC Centre for Cancer
tIherapeuttics, ICR, 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, IJK.
We have studied the p53 status in a panel of human ovarian cancer cell
lines relatively sensitive to cisplatin to determine whether this gene may be
important in governing cisplatin sensitivity. The cell lines investigated were LK1.
LK2. PAI, OVIP, CHI and the known wild type p53 expressing cell line A2780.
Functional p53 status was determined by measuring p53 induction 4 hours
following 5 Gy using immunoblotting techniques. G,/S checkpoint integrity was
determined by measuring bromodeoxyuridine incorporation 16 hours following 5
Gy (4 hour pulse) and subsequent FACS analysis. Single-strand conformation
polymorphism (SSCP) and direct PCR sequencing of exons 5, 6, 7 and 8 of p53
were carried out using standard techniques. Chemosensitivity to cisplatin was
determined by 96 hour SRB growth delay assay. Constitutive p53 protein levels
were barely detectable in A2780. CHl, LKI, LK2 and PAl, however following
irradiation levels were induced greater than 4-fold, suggesting wild type p53
function. In OVIP constitutive p53 protein was readily detectable and levels were
only induced 2-fold following irradiation. There was marked G,/S arrest in
A2780 (75.0 + 13.9, % mean ± SD, n = 4) following irradiation but a range of
partial arrests in LK2, OVIP, PAl, CHI and LKI, with 60.5 ± 9.8, 55.9 + 1.5.
55.5 + 12.0, 47.4 + 5.1 and 28.8 + 15.8 % arrests respectively, suggesting wild
type p53 protein induction cannot be directly correlated with G,/S arrest capacity.
No mutations were found in A2780, CHl, LKI, LK2 and PAl but a heterozygous
point mutation in OVIP was found in exon 5: an A to G conversion at codon 126,
resulting in a switch from tyrosine to cysteine. The wild type p53 expressing lines
A2780, LKI, CH1, PAl and LK2 were relatively sensitive to cisplatin with IC50'
values of 0.33 + 0.11, 0.16 ± 0.07, 0.11 ± 0.02, 0.10 ± 0.05, 0.09 + 0.02 FM
(mean + SD, n = 3) compared to 4.2 + 1.5 for the heterozygous p53 mutant OVIP.
This work suggests that wild type p53 expression may have a role in governing
cisplatin sensitivity in these ovarian cancer lines.
P51 THE DEVELOPMENT OF AN RT-PCR BASED ASSAY
FOR THE ANALYSIS OF'DIHYDROPYRIMIDINE
DEHYDROGENASE EXPRESSION IN TISSUES. SJ Johnston*, SA Ridge, J Sludden,
and HL McLeod. Department ofMedicine and Therapeutics, Institute ofMedical Sciences,
University ofAberdeen, Foresterhill, Aberdeen, UK.
Dihydropyrimidine dehydrogenase (DPD) is the rate limiting enzyme of5-fluorouracil (5FU)
reduction. 5FU is rapidly degraded by DPD and its antitumour efficacy may be influenced by
patient DPD activity. DPD activity is highly variable in populations and has been correlated
linearly with DPD protein expression. However, the ex vivo methods currently used to assess
DPD activity may not accurately reflect activity in vivo and so may be an unreliable indicator
ofpatient metabolic capacity.
We have developed a highly sensitive -everse transcriptase PCR (RT-PCR) based assay for
the analysis ofDPD mRNA expression in all types oftissue including colon tumours. This
assay will allow us to study the relationship between DPD mRNA levels and enzyme activity.
A competitor template molecule has been synthesized which competes with the wild type
cDNA for primer binding. The two PCR products are ofdifferent sizes; the wild type being
465bp and the competitor 400bp. By titrating known amounts of the competitor against
standard amounts ofthe wild type cDNA the levels of DPD cDNA within a sample can be
measured using densitometric analysis ofethidium bromide stained agarose gels.
DPD activity is highest in liver tissue and lower in other tissues such as lymphocytes, spleen,
and gastro-intestinal tract. RNA from human liver and spleen was used to determine the
reproducibility ofthe RT-PCR assay yielding coefficients of variation of 12.3% and 11.9%
respectively. This assay also showed expression in the liver to be 1.7 fold greater than in
the spleen. This was less than the 3.5 fold difference in catalytic activity seen between the
tissues ( liver - 211.7 versus spleen - 61.0 pmol min-' mg-' protein ). RNA has been extracted
from, and activity measured in human, rat, and mouse livers, human lymphocytes, gastro-
intestinal mucosa, and colon tumours for the comparison of DPD expression and enzyme
activity.
This assay provides a useful tool for the study of DPD riRNA in vivo and will allow
assessment of the clinical utility of DPD expression as a factor in optimising 5FU based
chemotherapy.
This work was supported by a University of Aberdeen Research Committee grant and a
Faculty ofMedicine studentship.
ps ) Identification of a p53-derived peptide which confers
increased cisplatin sensitivity to drug resistant cells.
M. Caimey, W. Gallagher. and R. Brown. CRC Department Medical Oncology, CRC
Beatson Laboratories, Switchback Road, Glasgow, G61I BD
Loss ofp53 function is associated with the acquisition ofcisplatin resistance
in the human ovarian adenocarcinoma A2780 cell line. Selection for cisplatin
resistance ofA2780 cells was used to isolate genetic suppressor elements (GSEs) from
a retroviral library expressing random fragments ofhuman or murine TP53 cDNA. Six
GSEs were identified, encoding either dominant negative mutant peptides or antisense
RNA molecules which corresponded to various regions within the TP53 gene
(Gallagher, et al (1996) Oncogene, in press). Expression of antisense GSEs led to
decreased intracellular levels ofp53 protein. A 17 amino acid synthetic peptide (PEP-
IF), representing the predicted amino acid sequence of a sense GSE, inhibited the
sequence specific DNA binding activity ofbaculovirus expressed p53 protein in vitro.
We have previously shown that a dominant negative mutant ofTP53 when introduced
into the cisplatin resistant A2780/cp7O line gives increased sensitivity to cisplatin. We
now show that introduction of the peptide PEP-IF into A2780/cp7O cells confers
increased sensitivity to cisplatin. The p53-derived PEP-IF peptide or the control
reverse peptide were introduced into A2780/cp7O cell by lipofection. The synthetic
peptides (I0pM final concentration) were transfected into A2780 cells using the
cationic lipid DOTAP. Cells were treated with a range ofconcentrations ofcisplatin
24h after application ofthe peptide. Cell viability was measured 3 days after cisplatin
treatment using the MTT cell viability assay.
Cisplatin Cell viability (1) Significance
concentration (2)
PEP-IF PEP-IR
zero I.08 1.11 >0.1
20pM 0.28 0.35 0.02
4pM 0.5 0.77 0.004
0.16zr 0.87 1.09 0.001
zero 1.01 1.09 >0.1I
.. .... . . . _ .. ^ . . P (I)Cell viability is measured using the MTi assay either anerapplication ofthe test
p53-derived PEP-IF peptide or the control reverse peptide PEP-1R. Results
represent the average ofeight independent assays.
(2) Statistical analysis was using a one-tailed t-test.
Thus, the p53-derived PEP-IF peptide significantly sensitises A2780/cp7O to the
growth inhibition effects ofcisplatin compared to the control reverse peptide.
p5,2 ALTERED EXPRESSION OF FOLYLPOLYGLUTAMATE P52 SYNTHETASE (FPGS) GENE IN HUMAN LEUKAEMIA
CELLS WITH DEFECTIVE POLYGLUTAMATION OF RALTITREXED (ZD1694),
YuzuruTakemura*1, Hiroyuki Kobayashi1, Hayato Miyachi2 and Ken-ichi Furihata3,
1Dept. Lab. Med., Natl. Defense Med. Coll., Tokorozawa, Saitaina 359, 2Dept. Clin.
Pathol., Tokai Univ. Sch. Med., Isehara, Kanagawa 259-11 and 3Dept. Lab. Med.,
Shinshu Umnv. Sch. Med., Matsumoto, Nagano 390,Japan.
A human acute lymphoblastic leukemia cell line, MOLT-3, has been cultured in
RPMI-1640 medium supplemented with 10% fetal bovine serum in the continuous
presence of raltitrexed (ZD1694) for the establishment and subsequent characterization
of the resistance to this novel thymsdylate synthase (TS) inhibitor. A 1600-fold
resistant subline has been selected after 6-months exposure to the drug up to 1 mM and
designated as MOLT-3/ZD1694C. The raltitrexed-resistant subline showed a cross-
resistance to methotrexate (120-fold) only under short-term drug-exposure coiiditions
and a significant collateral sensitivity to trimetrexate (0.033-fold) which is a non-
polyglutamatable dihydrofolate reductase inhibitor. The cells demonstrated extremely
low accumulation and poor retention of [3H] ZD1694, with no change of initial drug
uptake and a minimal increase of TS activity. HPLC analysis displayed a virtual
absence of ZD1694-polyglutamates in the resistant cells (Y. Takemura, et al., Int. J.
Cancer 66: 29-36, 1996). However, folylpolyglutamate synthetase (FPGS) mRNA
was only moderately decreased in spite of completely defective polyglutamation of the
drug. The growth of the resistant cells was only minimally affected either in drug-free
or in drug-containing culture medium, suggesting that physiological folates essential
for cell survival and proliferation could be effectively polyglutamated. Molecular
search of FPGS gene by direct-sequencing of FPGS mRNA extracted from the
sensitive and raltitrexed-resistant MOILT-3 cells demonstrated an altemative splicing
skipping exon 12 of the gene sequence reported. Furthermore, a deletion of guanine at
nuclcotide 1252 in exon 13 was identified in a single allele of the FPGS gene in the
resistant cells, resulting in a frame slift of amino acid codons and an appearance of
premature stop codon (TGA, nucleotides 1274-1276 in exon 13). This genetic change
may result in the production of altered FPGS with decrease affinity only for the drug or
class ofdrugs used for the selection of the resistance, but not for physiological folates.
These results also indicate variable expressions of the different splice forms of FPGS
mRNA in ditferent cells.
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MOLECULAR CHARACTERIZATION OF HUMAN ACUTE
P53 LEUKAEMIA CELLS RESISTANT TO ZD9331, A NON-
POLYGLUTAMATABLE THYMIDYLATE SYNTHASE (TS) INHIBITOR,
Hiroyuki Kobayashi* , Yuzuru Takemural, Havato Miyachi2 and Kenichi Furihata-5,
IDept. Lab. Med., Natl. Def'ense Med. Coll., Tokorozawa, Saitama 359, 2Dept. Clin.
Pathol., Tokai lJniv. Sch. Mcd., Isehara, Kanagawa 259-11 and 3Dcpt. Lab. Mcd.,
Shinshu Univ. Sch. Med., Matsumoto, Nagano 390, Japan.
ZD9331 is a non-polyglutamatable, potent quinazoline antifolate inhibitor of' TS,
which exploits the reduced folate carrier (RFC) for ccll entry. Since resistance to
chemotherapeutic agents remains one of the major obstacles in the treatment ol'
malignancies, the mechanism of resistance to a newly developed anticancer drug should
be thoroughly investigated. There are three major mechanisms of' resistance to the
selective TS inhibitors; (1) overexpression of the target enzyme, TS, (2) impaired
RFC-mediated membrane drug transport, and (3) diminished polyglutamation. In an
effort to clarify the mechanism of the resistance to this novel TS inhibitor, human
acute lymphoblastic leukaemia cell line, MOLT-3, has been cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum in the continuous presence of'
ZD9331 for the establishment of' the drug-resistant subline. A 300-l'old resistant
subline has been selected after 6-months exposure to the drug up to 7 pM and
designated as MOLT-3/ZD9331. The ZD9331-resistant subline showed a cross-
resistance to CB3717 (5-fold), ZD1694 (63-fold) and methotrexate (MTX) (120-fold),
but retained sensitivity to trimetrexate (0.88-fold), a dihydrofolate reductase inhibitor
that does not use RFC for cell entry. The MOLT-3/ZD9331 cells demonstrated
impaired initial uptake and loss accurmulation of' [3H] MTX in concord with the
decreasedexpressionofRFCJ, suggesting the down-regulation of RFC made the cells
cross-resistant to antifolates using RFC-mediated transport. In addition, Northern
analysis revealed the elesation in TS mRNA level in MOLT-3/ZD933I cells compared
with the parent MOLT-3 cells. Although no major rearrangements of the TS gene
were noted by Southern analysis, there was a significant amplification of the TS gene
in ZD9331-resistant cells. These results demonstrate that continuous exposure of
human leukaemia cells to ZD933 1 Ieads not only to the decreased expression of RFCI
and subsequent impaired RFC function but also to TS gene amplification and
overexpression which is responsible for the cross-resistance to other TS inhibitors.
Since ZD9331 is not a substrate for folylpolyglutamate synthetase, the expression of
this enzyme did not alter as expected. These observations suggest that the
development of a particular resistance phenotype, such as ampli'ication of the target
enzyme and impaired drug transport, is likely regulated at genetic and transcriptional
level tocircumvent the cvtotoxic effect of the drug.
P55
CELLULAR RESISTANCE TO MITOMYCIN C IS ASSOCIATED WITHOVEREXPRESSION OF
MDR-3 IN A UROTHELIAL CANCER CELLLINE,(MGHU-I). MC Hayes*, A J Cooper, K-JPalner, A
CGough. UniversityDept ofSurgery, Southampton GeneralHospita, S016 6YD.
Mitomycin C (MMC), an antitumourantibiotic, is used in the intravesical context in
the treatment ofsuperficial bladder cancer. Itremainsuncertainwhetherthis agent
falls withinthe classicalmultidrug resistance (MDR) family, mediatedprimarilyby
the expression ofP-glycoproteins A andB, and encodedby genes MDR-I and MDR-
3 respectively. We have induced resistance to MMC in aurothelial cancercell line
(MGHU-1) andcompared MDR-1 and 3 expression andMMC cytotoxicity against
drug sensitive controls.
MMC resistance was inducedby exposure ofwildtype MGHU-1 cells to increasing
concentrations(from 20 to 400 nM) ofMMC inDMEM/10%FCS/glutamine over six
months in culture. Cytotoxicity ofMMC andepirubicin wasthen compared for
MGHU-1, MGHU-MMC (MMCresistant) andMGHU-1R(establishedMDR,
adriamycin-induced)byMTTbiomass assay afteronehourexposure in culture to
varying concentrations (0.6-80pg/ml) ofMMC orepirubicin. Expression ofMDR-1
and 3 wasinvestigated foreach lineby RT-PCRusing cDNA specific primers after
titration, and compared to DNA andnegative controls.
MDR-1 and 3 were both significantlyoverexpressed in MGHU-1R andwere
associated witha dramatic increase inthe IC50 (p<0.001 paired ttest)for MMC and
epirubicin. In MGHU-MMC, overexpression ofMDR-3 wasmore markedthan for
MDR-I but was associated with a near-identical cytotoxiciyprofile for both agents.
Trace amounts ofMDR-3, but notMDR-1, were identified in MGHU-1wildtype.
We conclude thaturothelial cancercell resistance tomitomycin C is associated
primarilywith theoverexpression ofMDR-3 in the MGHU-1line andtherefore
suggest thatmitomycin C must fall withinthe MDRcategory.
P54 IMPAIRED POLYGLUTAMATION AS A
MECHANISM OF TOMUDEX RESISTANCE IN A
CCRF-CEM CELL LINE M.J.Barnes', E.J.Estlin2, G.A.Taylor', J.A.Calvete',
D.R.Newell', J.Lunec', A.GHall A.D.J.Pearson W.Aherne A.Hardcastle Cancer
Research Unit and 2Department of Child Health, University of Newcastle.UK. 3The
Institute of Cancer Research, Sutton, Surrey.UK.
A CCRF-CEM cell line that is insensitive to Tomudex, a classical
antifolate thymidylate synthase (TS) inhibitor has been identified. After
a 96 hr continuous exposure to Tomudex the resistant cell line (CCRF-
RTomudex CEM:R ) was > 400 fold less sensitive (IC55 560ng/ml) when
compared to the CCRF-CEM cell line (IC50 1.7ng/ml). The Tomudex
resistant cell line was cloned and a subline (CCRF-CEM:RC2Tomudex
Tomudex was isolated. CCRF-CEM:RC2 cells were >1000 fold resistant to
Tomudex (IC50 1777ng/ml for a 96 hr continuous exposure) but were
fully sensitive to the non-classical TS inhibitor, AG337 (IC50 360ng/ml
for CCRF-CEM and 281ng/ml for CCRF-CEM:RC2Tomudex 96 hr
continuous exposure). There were no differences in isolated TS activity
or 3H-MTX uptake between the cloned resistant and sensitive cells.
However, after a 24 hr exposure to IpM 3H-MTX, CCRF-CEM cells
accumulated significant levels of MTX polyglutamate metabolites
(2152 pmoles/109 cells) upto the pentaglutamate form. In direct
contrast, CCRF-CEM:RC2 Tmudex cells contained only parent drug (697
pmoles/l 9 cells) and produced no detectable polyglutamate
metabolites. On exposure to 10pM 3H-MTX for 24 hrs, the cloned
resistant cells did produce MTX diglutamate, but again lacked longer
chain polyglutamates. Following a 24 hr exposure to 0.1 tM Tomudex,
CCRF-CEM:RC2Tomudex cells accumulated >50 fold less total
intracellular Tomudex (6.53 pmoles/mg protein) than CCRF-CEM cells
(345 pmoles/mg protein). Consistent with.these findings was the FPGS
activity in cell extracts with MTX as the substrate. The CCRF-
CEM:RC2Tmudex cell line was shown to have <11% the activity of
CCRF-CEM cells, but Northern blot analysis revealed similar FPGS
mRNA levels in both cell lines. These data suggest either FPGS gene
mutation or defective translation as the basis of Tomudex resistance
due to impaired polyglutamation.
EMERGENCE OF P-GLYCOPROTEIN EXPRESSION IN P56 HUMANSARCOMA CELLS AFTER 72 HOUR SELECTION
IN DOXORUBICIN, H.C.L. Traunecker*t, M.C.G. Stevens2, D.J. Kerrt, and D.R. Ferryl,
1 CRC Institute forCancer Studies, University ofBirmingham, Birmingham B15 2TJ, 2 Dept.
ofPaediatric Oncology, The Birmingham Children's Hospital, Birmingham B16 8ET.
In vitro investigation of drug resistance mechanisms relies heavily on the
use of resistant clones derived from their parental tumour cell line by continuous
multi-step selection with a cytotoxic agent.
We investigated the emergence of doxorubicin resistant clones after a
single-step, 72 hourexposure ofthe human uterine sarcoma cell line MES-SA to 450
or 500 nM doxorubicin after allowing the cells to grow for 15 generations by using
the Luria-Delbruck fluctuation analysis. Growing cell populations, derived from a
small number of cells, in parallel cultures allowed us to describe the emergence of
resistant clones, calculate mutation rates and investigate P-glycoprotein expression
in the resistant clones.
Three fluctuation analysis experiments were performed by exposing non-
resistant, non-P-glycoprotein expressing MES-SA cells to 450 nM (n=2) or 500 nM
(n=l) doxorubicin for 72 hours. The calculated mutation rates were 3.5 x 10-8
1.0 x 10-7 and 3.0 x 10-6 clones/generation (Catcheside, The Genetics of Micro-
organsisms, London, 1951, p 158). In the two experiments with low mutation rates
17/19 clones were analyzed. Only 2 clones were 22-fold resistant to doxorubicin
compared to MES-SA cells and neitherexpressed P-glycoprotein.
The experiment with a high mutation rate yielded 359 clones of which 17
were analyzed. 8 clones were 22-fold resistant to doxorubicin compared to MES-
SA cells. All 8 clones expressed P-glycoprotein asjudged by Western blotting and
had detectable [3H]-vinblastine binding of 2 I pmol/mg protein (Ferry et al,
Biochem and Biophys Research Commun, 188:440, 1992). There was a strong
correlation between [3H]-vinblastine binding and resistance to doxorubicin (n = 19,
r= 0.8, p< 0.001).
These experiments show that a short, single-step exposure ofMES-SA cells
to doxorubicin led to selection of clones which expressed P-glycoprotein. Other
mechanisms of resistance appear to be rarely operative. The reason why non-
resistant clones were selected could be due to inducible mechanisms ofresistance or
statistical survival of non-resistant cells. If similar biological processess occur in
human tumours, even if they are initially P-glycoprotein negative, treatment may
select resistant clones at a frequency not detectable by current immunohistochemical
methods.Poster Presentations 33
P57 THE DEVELOPMENT OFMDR] AND MRPRIBOZYMES
AS A NEW STRATEGY TO STUDY MULTIDRUG RESISTANCE IN
TUMOUR CELLS. E.L. Lewis* and I Gibson. University ofEast Anglia,
School ofBiological Sciences, Norwich NR4 7TJ.
Multidrug resistance (MDR) in tumour cells is often associated with over-expression of
the htunan mdrl and mrp genes encoding the 170 kDa phospho- glycoprotein (P-gp) and
190 kDamultidrug resistance associated protein (MRP), respectively, and numerous
studies suggest they are involved in the efflux ofmany structurally unrelated anticancer
drugs from cultured MDR tumour cells (Gottesman &Pastan, 1993, Ann. Rev. Biochem,
62, 385). The high incidence ofmdrl and/ ormrpoverexpression inpatients who are
relapsed orresistant tochemotherapeutic drugs underlies the clinical importance of
controlling P-gp and MRP and we areusingribozymes(catalytic antisenseRNAs;
reviewed by Eckstein etal, 1996, Nuc. Acids. Mol. Biol., 10, RNA catalysts, Springer
Verlag, Heidelberg) to targetthese genes.
We have designed and developed a novel and flexible strategy forthe exogenous and
endogenous synthesis oftrans- actingasymmetric hammerhead ribozymes (StemIll 100-
300 mer, StemI, 3 mer) addressing their effectiveness aspotential therapeutic agents
(Lewis & Gibson, 1996, Proc. ofInt. Congress; Therapeutic Oligonucleotides, Rome,
Abstract no. PR6, 108). Possiblecleavage sites on the mdrl andmrp genes were selected
in conserved sequences and/or regions wherein the mRNAs werepredicted Lo have a low
folding potential (Sczakiel etal, 1993, Antisense Res. Dev.,3, 453). Appropriate mdrl
andmrp target sequences were amplified by RT-PCR using total cellular RNAtemplates
extracted from parental (NIH H69/P; COR-L23/P) andresistantderivatives(H69/LX4;
CORL23/R) ofhuman small andlarge cell lung carcinoma cells, respectively. Using the
Xbal andEagl sites incorporated on the PCRprimers, the mdrl andmrp cDNA
sequences were converted into aribozyme constructby directional cloning into the
pFORTH DNA cassette (Tabler & Tsagris, 1991, Gene, 108, 175). Ribozymes and
substrate RNAs for in vitro analyses weretranscribed from the vector-encoded T7 or T3
promoter, respectively, usingAmpliscribe (Cambio). Cleavageproducts were assessed by
electro-separation through denaturing gels(Separide, Life Technologies) or PAGE
analysis. Ribozymes showing catalytic activity in vitro were subcloned into the
mammalian expression vector, pHBAprl-neo (Gunning etal, 1987, PNAS, 84, 4831), for
constitutive expression ofthe ribozyme underthe B-actin promoter.
Cell lines were transfected with theribozyme constructs (complexed withcationic lipids
orpolyamines) to assess their effect ontheMDRphenotype exvivo. Expression ofthe
ribozymes in stably(500Ug/ml G418 selection) andtransiently transfected cell lines were
studied usingNorthern blotting, RT-PCR andtoxicity assays.
This work is funded by Mrs. P. Salter.
P59 DIPYRIDAMOLE REVERSES VP16 RESISTANCE IN
MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN
(MRP)-OVEREXPRESSING CELLS. N.J. Curtin* and D. Tumer.
Cancer Research Unit University of Newcastle upon Tyne, UK
Multidrug resistance may be mediated by either P-glycoprotein (P-gp),
the first identified plasma membrane drug efflux pump, or the more
recently discovered, MRP. The nucleoside transport inhibitor,
dipyndamole (DP), can reverse 'multidrug resistance in P-gp
overexpressing cells (Shalinsky et a/ Cancer Res. 50 7537: 1990).
However, DP potentiated the cytotoxicity of VP16 in both wild-type
and P-gp overexpressing cells to the same extent, suggesting this
was not via P-gp (Tumer and Curtin Br.J.Cancer 73 856: 1996). This
observation was explored using COR L23/P lung cancer cells and the
MRP overexpressing drug-resistant variant, COR L23/R (Versantvoort
et a/Br.J.Cancer72 82: 1995)
In growth inhibition assays coincubation with 10gM DP potentiated
VP16 and adriamycin 8- and 7.5-fold respectively but there was only a
2-fold potentiation of either drug in the parental cells. The resistant
cells accumulated about 50% less VP16 and DP caused a modest
time-dependent increase (1.5-2x) in both cell lines. Efflux of VP16
was initially very rapid, and faster in the resistant cells, but by 20
minutes only 20-30% of the original cellular concentration remained in
both cell lines. DP slightly inhibited the rapid phase of VP16 efflux in
the resistant but not the parental cells, but after 5 minutes the effect
was similar in both cell lines.
Drug transport, and cytotoxicity, is regulated by cellular glutathione
(GSH) in MRP-overexpressing cells, depletion of GSH by BSO
potentiates vincristine and daunorubicin in COR L23/R cells3. DP
lowered the GSH concentration significantly (24%) after 1 hour in the
resistant cell line but only after 24 hours in the parental cells. The
potentiation of VP16 and adramycin cytotoxicity by DP may be
mediated by GSH depletion
This work was supported by the NECRC (UK)
P58 REVERSAL OF MULTIDRUG RESISTANCE IN V7TRO
BY XR9051, A POTENT INHIBITOR OF P-GLYCOPROTEIN
W. Tuffley, K. Martin, 1. Dale, M. Luscombe, P. Bevan, H. Ryder and P. Mistry.
Xenova Ltd, Slough, SLI 4EF.
Expression ofP-glycoprotein (P-gp) can confer multidrug resistance (MDR) on
cancer cells and limit the effectiveness ofmany clinically important drugs. XR905I
is a potent inhibitor ofP-gp, which restores drug sensitivity in a broad panel oa'
murine and human P-gp overexpressing cell lines including examples where the
resistance was intrinsic (e.g. MC26 murine colon carcinoma) or acquired following
exposure to increasing concentrations ofcytotoxic drug (e.g. EMT6 ARI 0 murine
mammary carcinoma and H69/LX4 human lung carcinoma). Full reversal of
resistance to several cytotoxic drugs, including doxorubicin, vincristine and taxol,
was observed following 4-t days coexposure to XR9051 (0.1-0.5 iM). In the drug
resistant 1847AD human ovarian cancer cell line, P-gp expression results in reduced
calcein-AM accumulation relative to the parental drug sensitive cell line. XR9051
reversed this accumulation deficit with an EC5o of0.07AM. Furthermore in
experiments designed to examine the duration ofmodulator action, a prolonged
biological activity was observed following removal ofXR905 from the incubation
medium. These studies in a number ofcell lines demonstrated that P-gp dependent
rhodamine-123 efflux was inhibited for several hours and that reversal ofthe [3H]
daunorubicin accumulation deficit was maintained for 22 h. These results suggest
that XR905I may not be transported by P-gp since two resistance modulators known
to be P-gp substrates, cyclosporin A and verapamil, lost their inhibitory activity
within I h ofremoval from the medium. Further studies on the mechanism of
XR9051 action using [3H]-azidopine, a photoaffinity label, demonstrated that
XR9051 interacts with P-gp causing a concentration dependent inhibition of[3H]-
azidopine binding. These mechanistic studies suggest that XR905 reverses drug
resistance through a direct inhibition of P-gp function, but may not itselfbe a
substrate.
In summary, XR9051 is a potent modulator ofP-gp mediated MDR and may be
beneficial in the treatment ofMDR cancers. XR9051 has also been evaluated in
several in vivo cancer models and Phase I studies in healthy volunteers are currently
in progress.
N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phenyl)-3-((3Z,6Z)-6-benzylidine-
I-methyl-2,5-dioxo-3-piperazinylidene)methylbenzamide.
LOW LEVELMULTIDRUG RESISTANCE EXPRESSION
TO C131 1, A POTENTIAL CLINICAL CANDIDATE.
J.R.Warr*l, D.M. Quinnl. J.A. Double2;3 & M.C. Bibby2I3,Dept. of Biology,
University of York, York, YOI 5YW, 2Clinical Oncology Unit, Universitv of
Bradford, Bradford BD7 IDP, 3Screening and Pharmacology Group, EORTC.
C1311 is a novel, water soluble, imidazoacridinone with potent in
vitro activity against several colorectal and breast cancer cell lines and
is also active in vivo at well tolerated doses against the corresponding
solid tumours and is a candidate for clinical development. We have
used a series of P-glycoprotein expressing KB multidrug resistant
(MDR) cell lines to examine the extent to which the expression ofthe
P-glycoprotein confers resistance to Cl1311. We have also examined
the resistance ofthese cell lines to the structurally related compound,
DUP-941, which is currently undergoing clinical trials. The low level
MDR cell line, KB-8.5 (which is 3 fold resistant to doxorubicin, only
expressed very slight resistance to C1311 (1.2 fold), but was 7 fold
resistant to DUP-941. Two more highly resistant KB cell lines, KB-
Al and KB-C1, (which are 97 and 160 fold resistant to doxorubicin
respectively), were 2.2 fold and 4 fold resistant to C1311 respectively.
These two cell lines were 100 fold and over 100 fold resistant to
DUP-941. Resistance to both drugs was reversible by verapamil. We
have also made preliminary studies on the levels ofresistance to these
drugs shown by the MRP expressing MDR lung adenocarcinoma cell
line, COR-L23/R, which indicated that this cell line is 4.7 fold
resistant to C1311 and 10 fold resistant to DUP-941 respectively.
Whilst the ultimate potential of C1311 can only be determined by
clinical trials, these data add to the growing body of evidence that
suggests it may have a significant advantage over the standard and
investigational agents currently in use against breast and colorectal
cancer.34 Poster Presentations
P6. QUANTITATION OF RADIOLABELLED ANTIBODY
DISTRIBtJ I ION IN TUMOUR BEARING NUDE MICE USING RADIOLUMINOGRAPHY.
A. A. Flynn, A. J Green, G. Boxer, J Casey, R.B.Pedley,RH.J Begent Department ofClinical
Oncology, Royal Free Hospital School ofMedicine, London, NW3 2PF.
Conventional dose estimates, based on the Medical Internal Radiation Dose (MIRD) formulation,
assume uniform distribution ofradionuclide within tissue. Thisassumption has beentested, in the case
ofradiolabelled antibodies directed againstCEA, byusing astatistical model topredict thepixel value
distribution obtained from the digitised radioluminographs ofaknown radioactive source. The model
is based on the statistical nature ofthe detection ofradiation where any uniform source distribution
can be expected to have adetected distribution that isNormal orGaussian. We describe the novel use
ofsuch a test to assess the degree of uniformity ofradionuclide distribution in tissue.
Radiolabelled anti CEA antibodies were administered to nude micebearing LS174T colorectal cancer
xenograft, and then sacrificed at 3, 24, 48 and 72 hoyrs after injection. Theuniformity ofantibody
distribution in tumour and normal tissues was measured using theradioluminographs offormalin fixed
paraffin sections.
A normal distribution has aspecific shape and issymmetric. Two statistical techniques have been used
to test the shape and symmetry of the histogram of pixel values produced from the antibody
distribution in a tissue section. Kurtosis and skew are measures ofshape and symmetry and have
statistically defined critical values for anornal distribution. The test statistic forkurtosis and skew
was calculated for each tissue and compared with critical values from statistical tables (as shown in
table below).
The radiolabelled antibody was found to be distributed uniformly in liver, spleen, muscle, lung and
colon (insignificant kurtosis and skew values) and therefore allows conventional use ofthe MIRD
formulation. The results showed that for kidney and tumour the kurtosis and skew values were
significant and for bone the skew values alone.
Kurtosis Skew
Bone 0.7908 (p>0.2) 0.508 (p<0.01)
Colon 0.7936(p>0.2) 0.073 (p> )
Kidney 0.8956 (p<0.02) -0.23 (p<0.01Y
Liver 6 (p>0.2) - (p>0.1)
Lung .906(p>0.2) 0.1155 (p>0.1)
Muscle 0.7916 (p>0-2) 0.0856(p>0.1)
Spleen 0.8012 (p>0.2) (p>0.1)
Tumour 07549 (p<0.02) 1.309 (p<0.01)
P62 PRODUCTION OF A CHIMERIC ANTI-NCAM Fab'
FOR USE IN TARGETING OF SMALL CELL LUNG CANCER K.F., EagletK.A., Chester, G.M.Boxer, R.B., Pedley, R.H.J., Begent. Department of Clinical Oncology, Royal FreeHospital Schoolof Medicine, London, NW3 2PF.
Small celllung cancer (SCLC) is a common disease accounting for 25% of all
lung cancer. It is characterised by its innate chemo- and radiosensitivity
but despite this, the 2 year survival is <5% due to the emergence of
subsequent drug resistant disease. SCLC expresses a number of cellular
antigens including the neural cell adhesion molecule (NCAM) which is
expressed by all SCLC and therefore is a suitable target for antibody
therapy. An intact murine IgGl antibody - NY.3D11 which recognises
NCAM has previously shown specific uptake in nude mice bearing SCLC
xenograft tumours. A recombinant chimeric Fab' (CFC) with Fvs derived
from the monoclonal NY.3D11 and human CH1 and C kappa has been
cloned. CFC was produced in E. coli culture supernatant and isolated by
affinity chromatography and size fractionation. The purified CFC was
tested for NCAMbinding using ELISA and westem blotting, demonstrating
specific binding compared to a negative control which was a recombinant
Fab' molecule (THFC) containing the NY.3D11 V kappa chain. FACS
analysis showed specific binding of CFC only at a concentration of50i.g/ml
but immunohistochemistry using both H69 cell lines and xenografts was
negative. A biodistribution study in H69 xenografts showed no specific
localisation with tumour:blood ratios of 1.2 and % injected dose of 0.3 at 24
hours. We conclude that, although a chimeric anti-NCAM Fab' was
successfully engineered, there was no specific localisation in vivo This
may be due to a reduction in avidity by using a univalent Fab' or
alterations in the murine framework regions in Vkappa which were made
to allow forced cloning.
This study demonstrates that tormacroscopicabsorbeddosecalculations, kidney cortexandmedulla
should be considered separately, as should bone marrow andhard bone. Antibody heterogeneity in the
tumour requires the incorporation ofa microdosimetric tumour model for the accurate absorbed dose
calculations.
A further potential application ofthis method is to evaluate the relative uniformity ofradiolabelled
antibody distribution within tumours, for intact antibodies andtheirfiagments, to assist in theselection
ofantibody forradioimmunotherapy and other tumourtargeting strategies.
P63 RADIOIMMUNOGUIDED SURGERY (RIGS) WITH ANTI-CEA
SINGLE CHAIN FV ANTIBODY IN COLORECTAL CANCER
A. Maycr', K. Chester', G.Boxerl, D. O'Malley', B. Davidson2, M.A.M. Winslet2, A.J.W.
Hilson3, R.H.J. Begent'. ('CRC Targeting and Imaging Group, Dep. of Clin. Onc., 2Dep. of
Surgery, 3Dep. ofMed. Physics, Royal Free Hospital MS, LondonNW3 2PF)
RIGS is based on the preoperative injection ofa radiolabelled antitumour antibody
and the intraoperative detection of radioactivity by a hand-held gamma detecting probe
(Neoprobe). The slow blood clearance ofwhole IgG, which results in intervals ofup to
three weeks before tumour:blood ratios are high enough to permit accurate distinction of
tumour tissue during surgery, has been disadvantagous. Single chain Fv antibody
fragments (scFvs) consist ofa variable heavy and avariable light chain regionjoined by a
flexible linker and are the smallest antibody fragments to retain full binding capacity. The
low molecular weight (27 kD) gives better tumour penetration and more rapid blood
clearance than whole IgG resulting in high tumour:blood ratios at early time points.
MFE-23-his is an scFv with high affinity and specificity for CEA derived from
bacteriophage technology. It was secreted as a bacterial supematant using an E.coli
expression system and was purified by immobilised metal ion affinity chromatography
and gel filtration.
40 patients undergoing surgery because of primary or recurrent colorectal or any
other CEA-expressing abdominal cancer will receive lmg MFE-23-his iabelled with
25Iodine to a specific activity of 185 MBq/mg 24, 48 or 72 hours prior to operation.
After traditional exploration the abdomen is scanned with the hand-held probe. Results
obtained by the probe are correlated with histology and counts obtained by a gamma
well counter. Phosphorimaging is performed to determine the microdistribution of the
antibody. Preliminary results showed selective tumour localisation in a patient
undergoing resection of2 liver metastases. This was confirmed by gamma well counting
(tumour:normal liver - 3.3:1) and histology. RIGS-positive tissue was also recorded in
the region of the celiac axis, the hepatoduodenal ligament and suprapancreatic aorta.
Rapid excretion ofthe radiolabelled scFv was confirmed by a tumour to blood ratio of
4.4:1. A further two patients undergoing resection ofprimary colorectal cancer showed
localisation of the antibody within their primary tumour. The results show that scFv
antibodies can be prepared and used successfully for RIGS.
P64 99mTc LABELLING OF MFE-23 (AN ANTI-CEA SINGLE--
CHAIN ANTIBODY) D.A.Read*, M.S.Cooper2, R.Boden,
J.A.Boden, K.A.Chester & R.H.J.Begent. CRC Labs., Dept. Clin. Oncology &
Dept. Pharmacy2, Royal Free Hospital Shool of Medicine, London NW3 2PF.
The single-chain Fv antibody, MFE-23, radiolabelled with 1231, has been
demonstrated to be an effective diagnostic imaging agent in patients with
CEA expressing tumours (Begent etal. 1996, Nature Medicine 2, 979). For
routine use, the labelling of MFE-23 with99mTc rather than 1231 may have
several advantages; Technetium is inexpensive, readily available for use in
general hospital practice and is imaged efficiently by gamma cameras. In
addition, direct labelling with `eiTc to a residue away from the binding site
is likely to be less damaging to antigen binding than the indescriminate
iodination of tyrosine residues, some of which are sited in the CDRs.
A gly-ala-ser-(gly)4-cys Tc chelating peptide (George et al. 1995,
Proc.Natl.Acad.Sci.USA 92, 8358) was fused to the carboxyl terminus of MFE-
23. The scFv was expressed by E.coli and purified from culture supernatant by
CEA affinity chromatography, before reduction by mercaptoethanol,
aliquoting and storage in PBS at -70'C.
50lg thawed scFv was adjusted to pH 9.8 then labelled with 10MBq 99mTc
"Gluheptoscint"(DuPont), a glucoheptonate based Tc labelling kit.
TLC/phosphor imaging systems were used to assess % activity associated
with colloid (3.0 %), glucoheptonate (68.6 %), free pertechnetate (8.6 %) and
scFv (19.8 %). The in vivo distribution properties of the Tc labelled MFE-23
product were assessed in nude mice bearing LS174T (CEA producing)
xenografts. 400kBq labelled product was injected iv/mouse.
The mean % injected activity per gram tumour at 24 hours was 0.67 with a
tumour toblood ratif of5.88. Normal tissue to blood ratios ranged from 0.31 to
2.03 (liver) with the exception of the kidney which displayed a tissue to
blood ratio of 31.4.
Both circulating scFv and pertechnetate/glucoheptonate clear via the
kidneys (reflected in high %inj. activities) whereas uptake in the liver is
related to levels of colloidal Tc in the labelling product. Recent
improvements in the methodology have reduced this colloidal Tc to <0.3%.
This simple "one-pot" labelling method fulfills the requirement for the
clinically- friendly production of a Tc labelled single chain antibody.
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P65 TUMOUR ANTIGEN GENE EXPRESSION
IN DIFFERENT TUMOUR TYPES. S. Rodgersl, K. A.
Mulcahy1, K. E. Platts1, C. A. McIntyre1, R. C. Rees2 and A. K. Murray *.
lInstitute for Cancer Studies, University of Sheffield Medical School, S10 2RX,
2Department ofLife Science, Nottingham Trent University, NG1 1 8NF
It is well established that tumours can express antigens which distinguish
theM from surrounding normal tissue. The MAGE, GAGE and BAGE gene families
are silent in normal tissue except for the testes but expressed in tumours of different
histological types. These antigens therefore represent potential targets for tumour
directed therapy. To determine which patient groups would be potential candidates,
the expression of MAGE, GAGE and BAGE genes in a variety of tumour types has
beendeternined. These included head and neck squamous cell carcinoma, cutaneous
malignant melanoma, lung carcinoma, prostate carcinoma and seminoma.
MAGE gene expression was assessed by reverse transcription followed by
polymerase chain reaction amplification and ethidium bromide staining. Products
were verified by Southem blots with digoxigenin-labelled oligonucleotide probes
specific for each MAGE gene (Mulcahy K. A. et al., (1996)Int. J. Cancer 66:738).
The results show that 6/39 head and neck tumours, 6/23 melanomas, 0/2 lung
tumours, 12/37 prostate cancer and 2/5 seminomas express MAGE-1 MAGE-2 was
expressed by 4/39 head and neck tumours, 7/23 melanomas, 0/2 lung tumours, 2/37
prostate cancers and 1/5 seminomas. MAGE-3 was expressed by 7/39 head and neck
tumours, 7/23 melanomas, 1/2 lung tumours, 1/37 prostate cancers and 0/5
seminomas. MAGE-4 was expressed in 7/39 head and neck tumours, 1/23
melanomas, 1/2 lung tumours and 1/37 prostate cancers. GAGE and BAGE gene
expression is currently being investigated using a similar technique.
Phase I clinical trials ofMAGE peptides are currently underway in Sheffield
in collaboration with the Ludwig Institute for Cancer Research (Brussels Branch).
These data show that the MAGE gene family of tumour antigens are expressedin-a
variety of tumour types, some of which have not yet been reported in the literature,
and so widens the patient groups for which targeted therapy may be appropriate as
and when it become available in the future.
This work was supported by the YCRC
P67
Gene Transfer Therapies for Colorectal Cancer. H. Chong, 'RM. Diaz, G.
Hutchinson ',I. Hart ',N. Hardwicke, S. Castledon andRG. Vile. ICRF Laboratory
of Cancer Gene Therapy, Hammersmith Hospital, 'ICRF/Richard Dimbleby
Departrnent, St Thomas' Hospital, London.
To develop protocols for the molecularimmunotherapy of colorectal cancer we have
used the poorly immunogenic CMT93 colorectal tumour line to compare the efficacy
ofdifferent genes to treat primary tumours and/or to stimulate anti-tumour immunity.
Simultaneously, we have developed efficient and rapid gene delivery systems.
Eradication ofprimary tumorigenicity was most effective with the HSVtk/Ganciclovir
system. Even large tumours (-0.7 cm3) could be cured with GCV treatment,
consistent with the strong local bystander killing effects in this line. Primary
tumorigenicity was also greatly reduced by expression of IL-12, B7. 1, B7.2 or IL-2,
all ofwhich required T cells for the anti tumour effects. Expression of GM-CSF, or
the cytosine deaminase genes were largely ineffective.
Killing CMT93 cells in vivo with HSVtk/GCV afforded some protection against
parental cells. IL-2, GM-CSF or B7.2 were more potent but not completely effective.
Therefore, we used combinations of genes to improve on these effects. Tumour cells
expressing IL-12 and B7.1 or GM-CSF and B7.1 were optimal for generating
systemic protection although the combination of GM-CSF and HSVtk'also conferred
some protection. Other cytokines are currently being tested.
To complement these studies, we have continued to develop protocols for the rapid
tranduction ofprimary tumour cells ex vivo. Previously, we described the use of1st
generation recombinant adenoviral vectors to obtain IL-2 gene expression in freshly
resected colorectal cells at levels equivalent to those which are effective in our animal
experimentsin stimulatingtumour cell rejection (-70ngIL-2/106 cells/48hrs) aslittle
as seven days following surgery. We have now shown that the adenoviral system is
consistently superior in terms of titre and speed of transduction to retroviral-based
delivery systems (MFG-lacZ) in both primary colorectal and melanoma cells. In
addition, experiments are underway using 2nd generation adenoviral vectors free of
replicating virus expressing other cytokines (HSVtk, GM-CSF, IL-12, B7), alone or
in combination, to demonstrate the feasibility of such approaches for clinical trials.
P66 MUCI MUCIN AS A TARGET FOR ANTIBODY
MEDIATED ANTI-TUMOUR REACTIONS, E. Petrakou', G. Denton', A.
Murray', R.A. Robins" and M.R. Price', 'Cancer Research Lab., Dept.
Pharm. Sci., 2Dept. Immunology, Univ. of Nottingham, Nottingham
The MUC1 mucin is a high molecular mass transmembrane
glycoprotein (>400kD) with lubricant and anti-infective properties in
normal epithelia. In malignant cells, MUC1 expression is up-regulated,
the molecules are incompletely/aberrantly glycosylated and normal
cellular architecture is lost. There is increasing evidence that MUC1
exprested by tumour cells may provoke an anti-tumour immune
response in the autochthonous host. We have therefore undertaken
firstly to characterise the expression of MUC1 molecules on a panel
of human breast tumour cell lines, and then determine whether the
MUCI mucin mav function as a target for complement dependent
cytotoxicity as an example of an anti-tumour immune reaction.
MUC1 antigen expression on human tumour cells was assessed
using both adherent cells and cells in suspension harvested by
trypsinisation. Good concordance was obtained using these cell
preparations in an evaluation of antigen expression by ELISA, FACS
analysis and immunofluorescence. The cell lines T47D and MCF7-wt
showed highest MUC1 expression, followed by MCF7-adr and
MDA231.
The 4 cell lines were examined for their susceptibility to
complement dependent antibody-mediated lysis using both murine IgG
and IgM anti-MUC1 monoclonal antibodies which recognise
determinants within the MUC1 mucin protein core. OnlyT47D showed
any indication of complement dependent lysis using rabbit serum as
source of complement. Antibody binding to MUC1 could be enhanced
by treatment of cells with neuraminidase to remove sialic acid and
render the protein core more accessible to antibody. However, this did
not result in any marked increase in cytotoxicity.
It is possible that the inability of MUC1 mucin to function as an
effective target for complement dependent cytotoxicity, despite high
levels of antibody binding, is attributable to the extended rod-like
conformation of the antigen. Antibody is bound, but is not in
sufficiently close proximity to the lipid bilayer to initiate effective lysis.
BIODISTRIBUTION OF A5B7-F(ab')2-CPG2 CATALYTIC ACllVITY IN
P68 XENOGRAFTEDNUDEMICEFORADEPr. S.K.Sharma*,R.B.Pedley,
J.A.Boden, R.W.Boden & R.H.J.Begent. CRC Labs., Dept. of Clinical Oncology,
Royal Free Hosp. Sch. of Med., Rowland Hill St., London NW3 2PF.
The ADEPT approach of targeting enzymes to tumours, where they
can convert a non-toxic prodrug to a cytotoxic molecule at the tumour
sites, has shown feasibility as a treatment for cancer.
The bacterial enzyme carboxypeptidase G2 (CPG2), conjugated to an
anti-CEA antibody fragment A5B7-F(ab')2, has been used
extensively in our ADEPT pre-clinical and clinical studies.
Biodistribution studies of radiolabelled conjugate have shown
preferential localisation in the tumour, but the radioactivity does not
indicate whether the localised CPG2 is active. Although an established
spectrophotometric assay can measure enzyme activity in plasma
using methotrexate as a substrate, it is not suitable for measurement of
enzyme activity in tissues. A more sensitive HPLC assay for enzyme
activity has therefore been developed in order to assess both the
therapeutic potential and normal tissue toxicity of the conjugate. Nude
mice bearing LS174T xenografts were injected with A5B7-F(ab')2-
CPG2 (36units per mouse) and CPG2 activity measured in tumour
and normal tissues at time points ranging fromlhr to 72hrs after
conjugate injection. The % injected enzyme activity per gram of
tumour at 24 and 72hrs was 8.9 and 1.4 respectively. The tumour to
plasma ratio was 1.6 at 24hrs and 6 at 72hrs. The tumour to other
normal tissue ratios ranged between 1.6-8 at 24 hrs and 2.4-11 at
72hrs after the conjugate injection. This shows the level of enzyme
necessary for anti-tumour activity in mouse models and defines levels
needed for therapy in man. Further experiments to investigate the
effect of dose escalation of conjugate on CPG2 activity in both normal
tissues and the tumour are in progress.36 Poster Presentations
P69 ZD2767, an improved system for ADEPT -
investigation ofdifferent dosing regimes for the
prodrug, ZD2767P. S.J. East*, B.J. Curry, R.I. Dowell, D.H. Davies and
D.C. Blakey. Cancer, Metabolism and Endocrine Research Dept., ZENECA
Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.
ZD2767 is being developed as an improved system for antibody-
directed enzyme prodrug therapy (ADEPT). It consists of a conjugate
(ZD2767C) of the F(ab')2 A5B7 antibody fragment and carboxypeptidase
G2 (CPG2) and a bis-iodo phenol mustard prodrug (ZD2767P). Previously
(Blakey D.C. et al, Cancer Research 56, 3287, 1996) we have described
studies in which administration of ZD2767 to nude mice bearing human
LoVo colorectal tumour xenografts resulted in major tumour regressions
and prolonged growth delays. These studies have now been extended to
investigate different dosing regimes for ZD2767P.
Mice bearing established LoVo tumour xenografts (approx. 6 x 6
mm) were administered with a single i.v. dose of ZD2767C (500 U/kg)
followed 72 hr later by ZD2767P. Three different ZD2767P dosing regimes
(single bolus injection, three doses at hourly intervals, 24 hr infusion using a
mini-pump) were investigated. The dose of ZD2767P was chosen to give
similar toxicity, asjudged by body weight loss, and anti-tumour activity was
assessed by measuring the size ofthe tumours and calculating growth delays
compared to control groups. The results are summarised below:
ZD2767P GD (days) BWL (%) No of
schedule studies
Single bolus 24 6 5
3 doses in 2 hr 31 6 5
24 hr infusion 20 7 2
(GD - Growth Delay, BWL - Body weight loss)
The best anti-tumour activity with ZD2767P was achieved when the
prodrug was administered as 3 doses at hourly intervals. This regimen has
been selected for initial clinical trials with ZD2767 in CEA positive cancer
patients.
P71 THE
NOVEL ADEPT AGENT ZD2767: THE ROLE OF
CELLULAR GLUTATHIONE. N.R.Monks*', D.R.Newell',
J.A.Calvete .S.J.East D.C.Blakey2. Cancer Research Unit, University ofNewcastle, Newcastle upon
Tyne, 4HH. 2Dept Cancer, Metabolism and Endocrine Research. Zeneca Pharmaceuticals.
Alderley SKIO
ZD2767P is a novel phenol mustard glutamate prodrug which has
been developed for use in ADEPT, (Blakey et al. Cancer Research.
56:3287 (1996). ZD2767P (4-[N,N-bis(2-iodoethyl)amino]phenoxy
carbonyl-L-glutamic acid) is cleaved to the active bifuntional
alkylating agent (4-[N,N-bis(2-iodoethyl)amino] phenol, ZD2767D)
by the action of the bacterial enzyme carboxypeptidase G2. The aims
of these investigations were to determine the sensitivity of a panel of
six colorectal cell lines (HT29, LoVo, LS174T, HCT15, SW620 and
HCT116) to ZD2767D and P using the sulphorhodamine B staining
growth inhibition assay, and the role of glutathione (GSH) as a
determinant of cellular sensitivity. The IC50 values for ZD2767D and
P, ranged from 0.06-1.4ptM and 8-200sM respectively. In all cell
lines ZD2767D was 100-200 times more potent than ZD2767P.
Chlorambucil demonstrated a similar range of sensitivities (IC50 26-
200 M) with the cell lines that were at the extremes being the same as
for ZD2767D and P (most sensitive LS174T, least sensitive HT29).
Intracellular GSH concentrations, determined by HPLC varied
between 1.3-12.5 nmoles/106 cells, but did not correlate with cellular
sensitivity to ZD2767D, P or chlorambucil. Depletion of GSH using a
non-toxic concentration of butathionine sulfoximine (1 OiM), resulted
in an 80% reduction in intracellular GSH, although this was found to
only increase cell sensitivity by a maximum of 2.3-fold. These studies
have demonstrated that GSH is not a major determinant of inherent
chemosensitivity to ZD2767 in six colorectal cell lines.
PTO MUTANT HUMAN RIBONUCLEASE FOR USE
IN ANTIBODY-DIRECTED ENZYME PRODRUG
THERAPY (ADEPT), D. C. Blakey*', F. IBoyle, D. H. Davies,
R. I. Dowell', D. W. Heaton', M. S. Rose1, A. M. Slater', H. J.
2 -Fio~~2 2 2 Eggelte2, A. Tarragona-Fiol, C. J. Taylorson and B. R. Rabin
,
IZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire,
SK1O 4TG, 2University College London, London, WC1E 6BT.
ADEPT is a two step antibody based targeting strategy for the
treatment ofcancer. We have initially focused on developing ADEPT
systems incorporating the bacterial enzyme carboxypeptidase G2 (D.
C. Blakey et al, Cancer Research, 56, 3287, 1996). These systems
utilise an enzyme comnponent which is immunogenic and this will
limit the courses of therapy that can be given in the clinic. In an
attempt to overcome this limitation we have been developing an
ADEPT system incorporating a mutated version of human
ribonuclease in which the substrate binding pocket has been altered to
change substrate specificity. This involved mutating a positively
charged lysine residue at position 66 in human ribonuclease to a
negatively charged glutamic acid residue. A positively charged uracil
based prodrug was synthesised which releases, by the action of
mutant ribonuclease, the potent dichlorophenol mustard drug. This
prodrag was shown to be a substrate for Lys66Glu mutant human
ribonuclease (kent/Km = 3.6 mM'1 s- ). Native human ribonuclease
cleaved the prodrug approximately 20 fold slower (kca/Km = 0.2
mM'1 s-'). The uracil based prodrug was approximately 30 fold less
cytotoxic than the corresponding dichlorophenol mustard drug (IC50
approximately 1 FiM) when incubated with LoVo colorectal tumour
cells. These studies demonstrate the potential to reverse the polarity
ofhuman ribonuclease for use in ADEPT.
P72 CHARACTERISATION OF THE MYCN AMPLICON IN
NEUROBLASTOMA
*RM Kenyon, RE George, AG McGuckin, ADJ Pearson, 2p Kogner, 3H Christiansen,
J Lunec. Cancer Research Unit, Univ. of Newcastle upon Tyne, Newcastle upon
Tyne, NE2 4HH, UK, 2Childhood Cancer Research Unit, Karolinska Institute,
Stockholm, Sweden, 3Univ. Kinderklink, Giessen, Germany.
Neuroblastoma is a paediatric solid tumour with a varied clinical course. One genetic
feature used as a poor prognosis marker for patients is the amplification ofthe MYCN
gene, which is found in 25% of primary tumours. However, patients whose tumours
exhibit this feature are not all seen to have a poor survival. We therefore investigated
the co-amplified DNA surrounding the MYCN gene which potentially includes other
genes, that may influence the biology ofthese tumours.
Two sequence tagged sites (STSs) were isolated from a yeast artificial chromosome
(YAC) clone containing the MYCNgene. These lay 70Kb 5' and 3' ofthe MYCNgene
and were used as DNA probes in a Southern blot analysis to asses the co-
amplification patterns of outlying sequences in neuroblastoma primary tumour and
cell line samples. A panel of 35 MYCN amplified primary tumour samples were
studied. The STS probes identified a subset of primary tumours that showed
amplification of the 3' STS, but not the 5' STS, with the MYCN gene, while the
majority of samples were seen to amplify both the 3' and 5' STSs. When tested by
Log-rank survival analysis, this subset of patients was seen to have a significantly
longer progression-free interval than those patients that were seen to amplify both
STSs in their tumours (p= 0.036). This association was independent of the stage of
the tumours and the number ofcopies ofthe MYCN gene. The STSs also identified a
difference in the region amplified between cell lines and primary tumour samples
with cell lines amplifying the 5' STS, but not the 3' STS; a pattern not seen in primary
tumours. This suggests a selection pressure for the amplification of the region 5' of
MYCN in cell culture, which could be provided by another co-amplified expressed
gene.
The amplification status of three genes known to map to the same chromosomal
region as MYCN was analysed. The number of copies of the genes for Adenylate
cyclase 3 and thyroid peroxidase was indistinguishable from the normal diploid
complement in these tumours. The N-cym gene, which occurs on the antisense strand
opposite the MYCN gene was found co-amplified in 16/17 tumours. One tumour was
identified that did not amplify exon three of the N-cym gene, placing the start of the
amplified region within 0.5Kb of the start of exon I of the MYCN gene. This
redefines the "core region" (the smallest region commonly amplified in all
neuroblastoma MYCN amplified tumours) reported by Reiter et al, 1996, Genomics,
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P73 ALTERATIONS OF P53 AND MDM2 IN TRANSITIONAL
CELL CARCINOMA (TCC) OF THE BLADDER, R. Abdel-Fattah*', I. Sigalas',
L.Griffiths2, D. Neal2, J. Lunec', 'Cancer Research Unit, 2Dept. ofSurgery, University of
Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH.
Genetic alterations in the p53 gene have been reported as frequent events
in bladder cancer and are associated with disease progression. The mdm2
gPne is a target for transcriptional activation by p53 and the MDM2
protein binds to p53 , acting as an autoregulatory feedback inhibitor ofp53
transcriptional function. The aims of this study were to: i) determine and
relate mdm2 and p53 abnormalities in bladder tumours and ii) examine the
clinical relevance of altered patterns of expression in bladder cancer. 74
cases ofTCC were assessed by immunohistochemistry (IHC) forp53 using
D07 antibody. Exons 4 to 9 ofp53 were sequenced in 32 frozen tumours.
Expression of the mdm2 gene was studied by IHC (NCL-MDM2 Clone
IB1O, Novocastra Laboratories) and RT-PCR. Focal (>20%) and
heterogeneous (<75%) MDM2 staining was detected in 47% of tumours
and was associated with Ta disease. No association was found with grade
and p53 staining. Diffuse (>75%) MDM2 staining was detected in 12% of
tumours, none of which had p53 mutation. MDM2 overexpression in
tumours that did not show p53 muta.ion suggested that binding by mdm2
might be an alternative way in which p53 function is abrogated in these
tumours. At short-term follow-up, five TI tumours progressed. Diffuse
MDM2 and diffuse p53 staining was detected in all five tumours (Pd0.03,
Fisher's). Our studies revealed different pattems ofmultiple-sized RT-PCR
products in 11/39 (28%) tumour samples when amplified for the complete
coding region of mdm2. There was a higher incidence of alternatively.
spliced forms in 8/15 (53%) late stage (T2-T4) compared with 3/24
(12.5%) early stage (Ta-TI) tumours, suggesting an association with
tumour progression. Studies are in progress to investigate the prognostic
and functional significance ofthese forms ofmdm2.
THE MAPPING OF INTRON-EXON BOUNDARIES IN THE HUMAN
P75 MDM2 ONCOGENE AND IDENTIFICATION OF A POSSIBLE P53
PROMOTER REGION IN THE INTRON UPSTREAM TO EXON 3, H. Liang,I. Sigalas, C.
Challen, J. Lunec, Cancer Research Unit, University of Newcastle upon Tyne, NE2 4HH,
U.K
We hypothesised thatthe five alternatively sized transcripts ofthe human mdm2
oncogene (mdm2 a-e) with deletion ofinternal sequences in human tumour samples
(Nature Medicine 1996 2, 912-917) resulted from an alternative splicing mechanism
and that thejunctions ofthe deleted region corresponded to the boundaries between
introns and exons. To test this hypothesis, sequence analysis of long range PCR
products of human genomic DNA across these putative splice junctions has been
carried out.
Exon no. Sequence ofboundary Exon no Intron size (kb)
GCA-gtgctgg- ccttgtagQCAA 3* -1.2
307 308
3* CCTQgttagtat----------tcttatag&TTA 4* -6
392 393
4* AGA-.gtaagctg---------gatttcatQTTC 5* -5
467 468
9* TCCWgtaatgtt---------- tgttttag-QATC 10* -8
977 978
11* AGClgtagtata---------cattgaagQACT 12* -5
1211 1212
The figures underneath the underlined nucleotides denote theircDNA sequence number.
*: The exon numbers are denoted by homology with the corresponding exons ofmouse mdm2, since the
full human intron-exon map has not been produced. Our data indicates that the equivalent ofexon 3 of
the murine gene should be designated exon 2 in human mdm2.
The result shown in the table has confirmed that three transcripts (mdm2 a-c)
with missing nucleotide 393 to 977, 393 to 1211 and 468 io 977 are generated by
multiple exon skipping. However, the remaining two transcript variants (mdm2 d
and e) missing nucleotide 400 to 1476 and 536 to 1759 have neither intron nor
consensus splicing sequences at the deletion junctions, suggesting that these two
transcripts result from either very unusual splicing or partial gene deletion.
Interestingly, the 3' end ofthe intron upstream to exon 3* has a TATA box and
several motifs which show a good match to consenstis p53 binding sequence. We
are investigating whether there is a p53-dependent promoter in this intron.
P74 DNA BINDING BY-THE HUMAN MDM2 ONCOPROTEIN.
C.Challen , 1. Mitroul, J.J.Anderson2 and J.Lunecl. Cancer
Research Unit, University. ofNewcastle upon Tyne Medical School, England, NE2
4HH. 2Dept ofPathology, RVI, Newcastle Upon Tyne, England, NE2 4HH.
The MDM2 oncogene encodes a 90 kilodalton nuclear
phosphoprotein that binds and inactivates the p53 tumour
suppressor gene.We have previously characterised alternatively
spliced MDM2 transcripts which retain transforming ability despite
the loss of sequences from the 5' end of the gene that encode the
p53 binding domain (Sigalas I, et al, Nature Medicine 1996 2:912-
917). Although the C-terminal region ofMDM2 includes an acidic
domain together with.zinc and Ring-Finger regions, suggesting a
DNA binding and transcription factor function, these properties
have yet to be shown. We have examined the DNA binding
properties of both full length and C-terminal fragments of the
MDM2 protein. Gel retardation analysis confirmed the ability of
full length and C-terminal regions of MDM2 to bind DNA from a
pool of random sequences. Furthermore, sub-pools of DNA could
be selected from this random mixture for which the C-terminal
region of MDM2 had increased binding ability, shown by gel
retardation assays, indicating some degree of selective binding.
Characterisation of the DNA binding by MDM2 showed that
increased concentrations of EDTA (100mM), DTT (lmM-lOmM)
or P-mercaptoethanol (2mM-l0mM) decreased the efficiency with
which MDM2 bound DNA. Heat denaturation completely
abolished the binding. Current studies are aimed at the cloning of
DNA sequences for which MDM2 shows enhanced binding and
establishing whether there is a consensus binding sequence for
MDM2.
P76 THE INFLUENCE OF MICROSOMAL EPOXIDE HYDROLASE GENETIC
POLYMORPHISMS IN COLORECTAL CANCER SUSCEPTIBILITY.
K-J. Palmer A.C. Gough, C.A.D.Smith and J.N. Primrose. University Department ofSurgery, Southampton
General Hospital, Tremona Road, Southampton, Hampshire, S016 6YD.
Human cancer risk has been associated with exposure to pro-carcinogens. The
Epoxide Hydrolases are a family of at least four enzymes which play an important
role in the detoxification of mutagens, carcinogens and other xenobiotics. One of
these, microsomal epoxide hydrolase (mEH). has been shown to be polymorphic.
Two specific sites within the gene have been associated with alterations in activity.
An increase in activity has been associated with a mutation in exon 4 and a
decrease in activity associated with a mutation in exon 3. (C.Hassett et al, Human
Molecular Genetics, 1994, vol 3(3):421-428) As epidemiological studies have
suggested that colorectal cancer is linked with exposure to dietary and
environmental carcinogens, it is the aim of this study to ascertain the influence of
polymorphisms within the mEH gene on colorectal cancer susceptibility.
Genomic DNA was extracted from colorectal cancer mucosae (n=58) and random
unaffected individuals (n=72). Polymerase Chain Reaction (PCR) was performed
using specific oligonucleotide primer sequences designed to detect the genetic
polymorphism in exon 4 of the mEH gene, which results in an amino acid
substitution at position 139 (His/Arg). PCR products were analysed by restriction
digestion with the restriction endonuclease RsaI, polyacrylamide gel electrophoresis
and visualised by ethidium bromide staining under ultraviolet transillumination.
Of the 58 colorectal cancer samples genotyped at position 139. 1.7% were
homozygous Arg'39/Arg'39. 25.9% heterozygous Arg' 39/His'39 and 72.4%
homozygous His'39/His'39 whereas the random population frequencies were 5.6%,
40.2% and 54.2% respectively. gtatistical analysis showed that there was a
significant difference between the two populations.(X2 Yates correction
0.05>P>0.O 1).
In conclusion, these preliminarv results suggest that the exon 4 polymorphism in
mEH may influence colorectal cancer susceptibility. The exon 3 mutation at
position 113 has been suggested to lower the activitv ofmEH by the replacement of
a tyrosine with a histidine. The genetic analysis of this site in conjunction with the
exon 4 site is in progress.38 Poster Presentations
P77 CYTOGENETIC AND MULTIPLE CHROMOSOME
PAINTING STUDIES OF HUMAN LYMiPHOMA CELL LINES,
Mohammed Alqahtanil*, David W.Hammondl and Malcolm H.
Goyns2. IDepartment of Clinical Oncology, Y.C.R.C. Institute for
Cancer Studies, Sheffield University Medical School, Beech Hill Road,
Sheffield, SIO 2RX; 2School of Health Sciences, University of
Sunderland,Wharncliffe Street, Sunderland, SR2 3SD, U.K.
The use of cell lines can be of considerable importance in
studying the genetics of cancer. However, the detection of
chromosome abnormalities in malignant cell lines by conventional
cytogenetics is particularly problematic because of the difficulty in
routinely preparing metaphase spreads of sufficient quality or quantity
and because of the complex nature of many of the chromosomal
changes. Fluorescence in-situ hybridization (FISH) is a powerful tool
for improving the analysis of malignant cell chromosomes (Hammond
et al., Ann. Oncol., 1994, 5 suppl.l, 51-54) and we have therefore
adopted this approach in our studies of lymphoma cells. In this study,
we have analysed five human lymphoma cell lines (Daudi, HS 602,
Raji, MC116 and Namalwa). Some of these were partially analysed
cytogenetically in the early 1970s using conventional staining
techniques, but no chromosome analysis had been previously
attempted on the Raji and HS 602 cell lines. Initially we completed the
cytogenetic analysis of each of these cell lines using the G-banding
technique. We then refined these preliminary findings by applying
multicolour FISH analysis with whole chromosome paint probes for all
twenty three human chromosome types using direct and indirect
combinatorial labelling with two fluorochromes (FITC and Texas
Red). In this way we were able to simultaneously visualise multiple
target chromosomes in the same cell. These studies are still in
progress, but they have already enabled complex rearrangements such
as an ins(lp), ins(3p) and dup(lp)to be characterised and made the
identification of marker chromosomes e.g. as a t(6q;7q) possible.
M. A. acknowledges a Government of Saudi Arabia studentship. This
work was supported in part by the Yorkshire Cancer Research
Campaign.
p79 INVESTIGATION OF GENES WHICH EXHIBIT
DIFFERENTIAL EXPRESSION DURING AGEING, AND
THEIR RELEVANCE TO THE IMMORTALISATION OF TUMOUR CELLS.
M.A. Charltonl,2*, M. Salehi1,2, B.J. Merry3 and M.H. Goyns1, IMolecular
Gerontology Unit, School of Health Sciences, Univetsity of Sunderland, Whamcliffe
Street, Sunderland, SR2 3SD, 2lnstitute for Cancer Studies, University of Sheffield
Medical School, Beech Hill Road, Sheffield, SIO 2RX and 31nstitute for Human
Ageing, University ofLiverpool, P.O. Box 147, Liverpool, L69 3BX.
Malignant transformation of cells produces a number of differences in phenotype
compared to their non-malignant counterparts. One such change, which is poorly
understood, is the suggestion that tumour cells may undergo immortalisation so that
they no longer exhibit signs ofsenescence. To study which genes might be important
in this process, we have studied changes in gene expression that occur during ageing
ofadult mammalian tissues as a means ofidentifying putative immortalising genes.
In this study we have used the PCR-based technique ofdifferential display (Liang
& Pardee, Science, 1992, 257, 967-971) to analyse changes in gene expression during
ageing ofthe brains and livers from CFY rats. This colony ofanimals has a maximum
life span of 35 months when fed ad libitum, but few animals reach this age, and the
LD50 ofthe colony has been 23 months for the past 20 years. In this study we have
compared three sexually-mature young adults (6 months) with three old adults (22
months). RNA preparations were initially prepared from homogenised brains and
subjected to RT-PCR using 40 different combinations ofprimer pairs. The comparison
of three young to three old animals ensured that we reduced the risk of scoring
artefacts on the differential display gels. Over 2,000 PCR products were identified
from brain mRNA, ofwhich 40 appeared to represent genes that exhibited differential
expression during ageing (Salehi et al., Experientia, 1996, 52, 888-891). Since this
preliminary study, we have greatly improved both the resolution and reproducibility of
the differential display gels. As a result, a combination of30 primer pairs now enables
up to 9,000 PCR products to be revealed for each tissue, ofwhich some 200 appear to
represent genes which are differentially expressed. This approach has now been
applied to a study of the liver and rat hepatoma cell lines. We are currently
characterising these PCR products, but have already observed that the fos proto-
oncogene, which has previously been implicated in the immortalisation of cells, is
down-regulated during the ageing ofall tissues so far studied.
MAC acknowledges a Yorkshire Cancer Research Campaign studentship. MS
acknowledges a Govemment ofIran studentship.
P78 ALU-PCRFINGERPRINTING ANALYSIS IN PROSTATE
CANCER. H. Y. Leung, R. Brown, A. B. McKie, N. R. Lemoine, C. N.
Robson and D. E. Neal., Dept. ofSurgery, Newcastle uponTyne NE2 4HH
Genetic events related to the development of human prostate cancer are
under intense investigations using conventional methods including loss of
heterozygosity, snicrosatellite instability and linkage analysis. We describe
the use ofAlu-repeat based PCR DNA fingerprinting to scan genomic DNA
from prostate cancer for identifying novel prostate cancer related genes. Alu-
specific primers have been designed for PCR analysis on paired genomic
DNA (tumour and blood) from ten patients with locally advanced prostate
cancer. Control samples from a normal prostate (organ donor) and a normal
testes were included. Two sub-clones from SV40 transformed prostatic
epithelial cell lines (PNTI) were also examined. Five Alu-specific primers
were assessed. Genomic DNA were subjected to restriction digest prior to
PCR analysis to reduce the number ofband products and four endonucleases
were assessed.
The condition for Alu-PCR was optimised. Two restriction digests were
found to be most useful. Similarly, threeAlu-specific primers were particular
informative. Differences were seen between the two sub-clones ofthe PNT1
cells. In prostate cancer, different band profiles were noted between tumour
and normal DNA and four bands of interest (three from tumour tracks and
one form blood track) were identified and cloned for further characterisation.
Alu-based PCR DNA fingerprinting have been successfully applied in
prostate cancer and may facilitate further study to identify novel prostate
cancer related gene.
P80 ACTIVATION OF TELOMERASE DURING
HEPATOCELLULAR CARCINOGENESIS,
.M. Miura*'. K. Higashi K. Ikemura' and S. Gotoh2,'Deps.
of Oral -Surgery, Dept. of Biochem.,Univ. Occupational and
Environmental Health. Kitakyushu City 807, JAPAN
Telomerase is required for the maintenance of
telomere length during chtomosome replication.
Activation of telomerase has been associated with
human cancers and immortal cells.
To study the telomerase activity we first,
improved the original TRAP assay ( Kim et al., 1994,
Science, 266, 2011 ), by modifying the labelling
method and the designs of the primers. With these
modifications, the assay is more sensitive and more
quantitative.
With our improved TRAP assay. we wanted to study
oni the dynamic process of upregulation of the
telomeras'P activity during in vivo carcinogenesis.
Rats were administered with a potent hepatocellular
carcinogen, 3Y-Me-DAB for 8 weeks. Every week after
the first day of the administration, rats were
sacrificed and the telomerase activity in liver
homogenates was assayed . The augmented telomerase
activity was detected a couple of weeks after the
initiation of 3'-Me-DAB administration , before the
appearance of hyperplastic nodules. On the contrary,
the specimens of normal control liver showed weak
telomerase activity.
These results suggest that activation of
telomerase is an early event in hepatocellular
carcinogenesis and may be a characteristic feature of
precancerous hepatocellular lesions.Poster Presentations 39
P81 pl6INK4A POINT MUTATIONS LEAD TO LOSS
OF CDK4 INHIBITORY ACTIVITY, L. Betts*,
R.M. Haigh+, N. Redemann and J.C.A. van Meel, Oncology
Research, Boehringer Ingelheim Pharma Germany, 88397 Biberach,
FRG, +present address: Ferring Research Ltd, Southapton S016 7NP,
UK
In many tumours, the INK4 gene is homozygously or
heterozygously deleted leading to a loss ofp16 which contributes to the
tumourigenic process and has led to p16 being recognized as an
important tumour suppressor. Recently, a number of point mutations in
p16 have been detected in pancreas carcinomas. We constructed two of
these mutatations, G23N (first ankiryn repeat) and H83Y (third ankiryn
repeat), by site-directed in vitro mutagenesis in order to examine their
functional effects on CDK4 kinase activity in comparison to wild type
p16. Using retinoblastoma protein as substrate, results'showed that 1 sg
of p16 protein was able to inhibit fully cyclin D1/CDK4 activity
whereas the same amount of both mutants had no effect The inhibition
by wild type p16 was concentration-dependent with a mean IC50 of0.17
+ 0.07 ttg/ml (SEM of 3 experiments). For mutant G23N there was a
400-fold increase in the IC50 and for H83Y over a 500-fold increase
indicating that both are significantly less able to inhibit cyclin'D1/CDK4
activity. Since p16 must first bind to the CDK4 complex to inhibit its
activity, we further investigated whether the mutants could bind to
CDK4. Wild type p16 or mutants attached to glutathione-Sepharose
beads through a GST tag were incubated with cyclin D1/CDK4 and
specifically bound complex was assayed by immunoblotting. Wild type
p16 clearly formed stable complexes with cyclin D1/CDK4 whereas in
contrast using the two mutants binding above non-specific background
was not detected. It is concluded that pl6INK4A point muatations can
lead to a loss of inhibitory activity which may contribute to
tumourigenesis in pancreatic adenocarcinoma.
p2,3 EXPRESSION AND PRODUCTION OF TGF-1 IN
EPITHELIAL -CULTURES DERIVED FROM
NORMAL BREAST AND BREAST TUMOURS, A.R. Green* and V. Speirs,
Department ofMedicine, University ofHull, Hull HU6 7RX.
A role for TGF-p as a mediator of cell proliferation and differentiation in both
normal breast and breast cancer has been proposed. However, most previous
reports have not classified between the three human isoforms of TGF-p. and the
expressionlproduction of these have not been fully investigated. Using a series of
primary epithelial cultures derived from normal breast (n=6) and breast tumours
(n=9), we have studied the expression and production ofTGF-p1 and 12 and the
expressioi, of TGF-p3. Epithelial cells were isolated from collagenase dispersed
tissue by differential centrifugation followed by culture in selective media. Total
RNA was extracted from cell cultures and analysed forTGF-f 1, 02 and 03 mRNA
transcripts by RT-PCR. Furthermore, CM was collected from the same cultures
prior to RNA extraction and analysed for TGF-11 and 12 protein by ELISA.
Constitutive expression ofTGF-p1 mRNA was observed in all cultures irrespective
oforigin whereas TGF-12 and 03 were less commonly expressed with one culture
from each population failing to express either isoform. Production ofTGF-1 1 and
P2 by these cultures is summarised below:
Table 1 Production ofTGF-p1 and 02 by primary epithelial cultures derived from
normal breast andbreast tumours (pg/ml/g RNA)
TGF-111 TGF-2
Normal 4.9 - 66.3 (mean = 26.9) 0.7- 15.1 (mean =6.1)
Tumour 6.6 - 41.7 (mean = 20.9) 2.1 - 7.0 (mean = 3.1)
Production ofTGF-1 1 corresponded with mRNA expression in all cases, however
TGF-12 mRNA and prxtein did not always agree. There were no significant
differences in expression of TGF-1 mRNA or protein between the epithelial
cultures derived from normals or tumours. However secretion of TGF-12 was on
average 4-7 fold lower compared with TGF-P1 in both sets ofcultures. This study
confirms that all three human isoforms ofTGF-P are expressed by epithelial cells
ofneoplastic origin together with those derived from normal breast and it is likely
that differential expression and regulation between these three isoforms may occur.
Supportedby Yorkshire Cancer Research Campaign
P82 CDK4 AND QDC2 EXPRESSION ARE
DIFFERENT IN YUMAN FIBROBLASTS AYD
§ERATINOCYTES, S. Moumtzi* and H.M. Warenius ,
Department of Medicine, University Clinical Dept
Daulby Street, Liverpool, L69 3GA.
In vitro cell culture systems provide the
opportunity to analyse the growth requirements
and behaviour or normal cells, to compare the
properties of normal cells and cancer cells and
to develop quantitative and reproducible assays
for neoplastic cellular transformation.
The ultimate purpose of this work is to compare
and identify the differences in the expression
of proliferation related genes between trans-
formed and norm4l keratinocytes and fibroblasts.
We have examined four primary keratinocytes
cultures in low calcium and four primary fibro-
blasts cultures from human skin of 8 different
individuals. The fibroblasts grew rapidly
(doubling time 2.86 days) in DMEM + FCS 10%.
Whereas, the keratinocytes grew slowly (doubling
time 4.75 days) in MCDB 153 + EGF medium.
Initial studies involving Western immunoblotting
for the two cyclin dependent kinases cdc2 and
cdk4 showed a strong relationship between these
proteins in fibroblasts (r=0.96, p=0.04) but not
in keratinocytes (r=-0.66, p=0.34). Previously
in our laboratory we have shown that in a wide
range of human cancer cells there was a strong
relationship between cdc2/cdk4 as observed in
the normal fibroblasts reported here. Many of
these cancer cell lines were of epithelial
origin, however, suggesting cdk4/cdc2 relation-
ships might be changed by malignant transform-
ation. We are now undertaking transfection
studies of normal keratinocytes to investigate
this possibility.
P84 THE EFFECT OF 12-LIPOXYGENASE OVER-
EXPRESSION iN THE HUMAN BREAST
CANCER CELL LINE MCF-7 ON CELL GROWTH, APOPTOSIS,
AND THE BCL-2 PROTEIN. Jeanne M. Connolly* and David P.
Rose, Amnerican Health Foundation, Valhalla, NY 10595, USA.
The human breast cancer cell line MCF-7 grows slowly
both in vitro and as solid tumors in nude mice in vivo. We have
previously reported the successful transfection of 12-lipoxy-
genase (12LOX) into this estrogen receptor-positive cell line,
which results in high secretion of 12-hydroxyeicosatetraenoic
acid (12-HETE) and enhanced cell growth both in vitro and in
vivo (Liu etal., Cancer Letters, inpress, 1996). One mechanism
which can result in enhanced cell accumulation is reduced
apoptosis. Our current investigations show that soluble nuclear
matrix protein (NMP) levels, released by dead and dying cells
and detected by ELISA in conditioned medium of MCF-7/12LOX
cell cultures, are significantly lower than those in identically
treated MCF-7 cultures (59.7+12.9 vs 100+6.7% of MCF-7 NMP
U/mI, p<0.001), which suggests a reduced rate of programmed
cell death in the 12LOX transfectants. In addition, levels of the
bcl-2 proto-oncogene protein, an inhibitor of apoptosis, are
elevated in the 12LOX transfected cell line compared to the
MCF-7 parent as detected by Western blot. These data suggest
that endogenous overexp5ression of 12LOX results in reduced
apoptosis in these human breast cancer cells, and may
contribute to enhanced cell growth and tumor development.40 Poster Presentations
NAVELBINE (NVB) & FRACTIONATED DOSE DOXORUBICIN (DX)
P85 IMPROVES IST LINE ADVANCED BREAST CANCER (ABC). AN
OVERVIEW OF 3 PHASE 11 TRIALS. J. Carmichael I, R. Hegg2, D. Firat3, M. Pawlicki4,
F. Le Bras5, F. M.Delgado5, P. Dane)5 and S.A.N. Johnson6 INottingham City Hosp UK; 2ELAN
Brazil; 3Ankara, Turkey;4 Krakow-Poland; 51.R.P.F., France; 6Taunton & Somerset Hosp, UK
Anthracycline combinations represent the most powerful chemotherapeutic
approach in the treatment of ABC inducing objective response in 40%-70% of
patients (pts) and halting progression in the majority of the others. The limiting
toxicities ofanthracyclines are neutropenia and cardiac impairment. NVB as a single
agent has demonstrated a high activity in the treatment of ABC, the overall response
rate (RR) ranging from 40% to 60% with good tolerance by pts. Impressive results
have previously been obtained with NVB 25mg/m2 on days I & 8 + DX 50 mg/m2
on day 1, every 21 days. Of 89 pts, 74% responded to the therapy (21% CRs),. and
high RRs were observed in visceral metastatic sites: liver 50% (13% CRs), lung
68% (21% CRs) (Spielmann JCO 1994). A significant survival advantage was
observed in pts with liver metastases treated NVB + DX compared to CAF
(Blajman, ESMO 1996). Conceming DX there is evidence that dividing the dose
and administering it at weekly intervals may reduce the cardiac toxicity without
substantially impairing the efficacy (Chlebowki R, CTR 1980). Based on this
rationale 3 Phase II studies were conducted in order to check the efficacy, improve
the tolerance of NVB+DX in combination and to make out patient administration
easier. Ii.) Chemotherapy naive ABC pts were treated with NVB and DX, both at
25 mg/ma IV on days I & 8 every 21 days, for a maximum of 8 cycles. Pts
characteristics were: age from 30-73y; PS 0-1: 85%; visceral involvement: 52%;
adjuvant chemotherapy: 18%. 668 cycles were administered; at least one episode of
WHO grade (G) 3-4 neutropenia was observed in 24% of pts; the incidence of
infection episodes was very low (G 3: 6/120 pts); G 3-4 nausea/vomiting was seen
in 17 pts; only 1.5% of patients experienced G 3-4 constipation; G I peripheral
neuropathy was observed in 13% pts. 53.5% of pts developed grade 3 alopecia. No
life threatening (G 3-4) cardiac impairment was observed. The overall RR ranges
from 70% to 76% showing the high and reproducible efficacy, furthermore, 18-35%
of pts achieved a CR. On visceral sites, RR ranges from 56% to 86%. These results
confirmed that NVB. + fractionated doses of DX has major and reliable antitumour
activity as front line therapy. Given its very favourable tolerance profile, low
morbidity and absence of life threatening cardiac toxicity, out patient administration
of NVB + DX (both 25 mg/m2 on days I & 8) could be recommended as first line
treatment for ABC.
ROLE OF TRK-A EXPRESSION IN PPNET CELL
P87 LINES*D.Li, S.Buckley, P.Berry, I.Lewis and S.A.Burchill,
Cancer Research Unit, St James University Hospital, Leeds LS9 7TF.
Peripheral primitive neuroectodermal tumours (pPNETs) and neuroblastoma are
paediatric malignancies derived from neural crest cells. We have previously shown
nerve growth factor (NGF) induces differentiation in neuroblastoma cells'. This effect
occurs following phosphorylation of Trk-A (the high affinity NGF receptor) which
is expressed by neuroblastomas. In this study we have examined the effect of NGF
and Trk-A expression in pPNET cell lines.
Two pPNET cell lines were used, RDES and TC-32. A neuroblastoma cell line, SK-
N-SH, was used as a positive control. The effect of NGF (10-80ng/ml) on cell growth
and differentiation was measured over 3 days. Cells were analysed by reverse
transcriptase polymerase chain reaction (RT-PCR) for expression of the high affinity
NGF receptor, Trk-A. TC-32 and RDES cells were transfected by lpofection with
Trk-A DNA in the PLNCX vector (a kind gift from Dr D Kaplan, NCI). Transfected
cells were selected with G418. Expression of Trk-A was confirmed at the RNA level
by RT-PCR and at the protein level by Westem blot analysis using a rabbit polyclonal
Trk-A antibody. The effect of Trk-A expression on cell growth and proliferation was
examined by incorporation of bromodeoxyuridine incorporation and cell number using
a haemocytometer. Cell phenotype was examined by Westem blot analysis and
morphology. The effect ofNGF in transfected and nontransfected cells was examined.
NGF did not induce proliferation or differentiation in the pPNET cells. In SK-N-SH
cells, NGF enhanced thenev;onal phenotype demonstrated by increased neurofilament
expression and neurite extension. Trk-A mRNA was detected by RT-PCR in the SK-
N-SH cells, but not in the pPNET cells. Following transfection of RDES and TC-32
cell lines with Trk-A, a neuronal phenotype and neurite extension was induced under
normal growth conditions. Transfection of cells with Trk-A had no effect on cell
proliferation and cell number. Treatnent of tran'sfecte'd cells with NGF increased
proliferation and cell number, but did not further increase neurite extension.
In summary, NGF did not induce differentiation of pPNET cell lines. This lack of
effect may be due to absence of a functional NGF receptor. Transfection of pPNET
cell lines with Trk-A induced a neuronal phenotype, which was associated with an
increase in cell proliferation following treatment with NGF. These observations
suggest absence of Trk-A receptors in pPNETs may contribute to their
undifferentiated phenotype and may provide a mechanism for the modulation of
pPNET cell behaviour.
1 Burchill SA, Berry PA and Lewis IJ.(1995). J. Neurol. Sci., 133:3-10.
P86 IDIENTIFICATION AND CLIARACTERISATION OF TWO P GENEIS ASSOCIATED WITH ANDROGENREIJLATION
IN'I HE HIJMAN PROsTATE. (.P.(Collett*., A.M. Betts, ).E. Neal, and C.N.
Robson, Department of Sturgery, Newcastle IJniversity, Newcastle, NE2 4HH
Androgens are intimately associated with the growth and progression of prostate
cancer. In ani attempt to understand the mechanisms by wlich these tumour cells
undergo the transitionl from an androgen dependent to an androgen independent
state we have used the mRNA differential display technique to isolate anidrogen
regulated genes from the prostatic epithelial cell line LNCaP and from prinsary
cultured stromal cells obtained from patients undergoing transurethral resection of
the prostate for bladder outflow obstruction. Northern analysis was used to confirlm
that these genes were truely anidrogen regulated. DNA sequence analysis of two
cDNA clones revealed greater than 95 per cent homology to Peroxisomne proliferator
activated receptor-alpha (PPARa), a member of the steroid receptorsuLperfamily of
nuclear transcription factors and to Talius, a genie involved in cell imiotility and
adhesion.
Both PPARa and Talin showed between 2-3 fold down-regulation in mRNA levels
followiisg chronic exposure to the syritlhetic androgen, Miboleroise (48-96 hours).
Exposure of cells to the anti-androgen, Casodex prevented Mibolerone-induced
down-regulation of these genes implying regulation is through the Androgen
Receptor. Treatment of cells with the protein synthesis inhibitor cycloheximide
prior to Mibolerone exposure blocked the down-regulation in mRNA suggesting
that these genes are indirectly regulated by androgens.
Using RNA in situ hybridisation we have localised the PPARa and Taluis transcripts
within the prostate gland. Further data will be presented o0i the association betxveen
the expression of these genies and the stage or grade of prostate cancer.
P88 THE REGULATORY ACTION OF
CYTOKINES ON TUMOUR PROLIFERATION
J. Lawry*, A. Andalib, M.O.Smith, J.A.Roydsi, Institute for Cancer
Studies andDepartment ofPathologyt, University Medical School,
Beech HillRoad, Sheffield. S10 2RX(J.Lawry@sheffield.ac.uk)
Whilst the growth stimulatory or inhibitory actions ofcytokines
have been reported formany celltypes, the analysis oftheir mode of
action is lesswell known. We have previouslyreported on the role of
TGFf1 in controllingproliferation in colon cancer cell lines, through
the actions ofthe cyclin dependent kinaseinhibitors (CDKIs)
p15(K4B), p2l(cipl/WAFI) and p27(Kipl). As colontumoursprogress, cells
become unresponsiveto TGF31 which hasbeen linked with
recurrence and metastases. In-vitroproliferation studies were
undertakenusing flow cytometry and identified TGFI31 asbeing
growth inhibitoryfor HT29 cells, inducingp27, reducingp15 &
p21expression;but growth stimulatoryfor SW742 cells (low level
p27, inducedp15 & p21), in serumfree conditions. Asthis maybe
tissue biased, we have extendthis studyto analyse the modulation of
cyclin expression by TGF2,IL-6, TNFa & IFNa, on two melanoma
cell lines derived fromprimary (WM793) and metastatic (WM1205)
lesions ofthe samepatient (M. Herlyn, WistarInstitute, USA).
WM793/1205 were both growth inhibitedbyTNFct; stimulated by
IFNa; unresponsive to IL-6; whilstTGF02 stimulated growth ofthe
metastatic line (43% increase in cyclin D expression), yet inhibited
growth oftheprimary line (cyclin D reduced by 36%, cyclin B by
44%). Mnimalchangeswere seen in cyclin A and E with any cell line
or cytokine. In the parental line (WM793), TGF,2 induced inhibition
was also associated with a 200%increase in the expression ofCDKI
p15, 30% increase in p21, and a 30% decrease in p27 over controls,
representing opposite resultsto those seen in the colon cell lines.
Funding was fromthe Yorkshire Cancer Research Campaign.Poster Presentations 41
P89 PRODUCTION OF THE ANGIOGENIC FACTORS VEGF AND
bFGF AT TUMOUR SITES MAY ALSO CONFER AN ACUTE
HAEMODYNAMIC ADVANTAGE TO THE TUMOUR. J.O. Curwen and D. Ogilvie,
CME department, Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire
SK1O 4TG.
A wide range ofhuman tumours express the growth factor VEGF. It has been postulated
that both this growth factor and bFGF may play an important role in tumour progression by
aiding angiogenesis within tumours. Recent literature reports have demonstrated that both
VEGF and bFGF have haemodynamic effects when given systemically to rats and rabbits
(Cuevas et. al., Science 1991 254, 1208-1210 and Yang et. al., J. Cardiovasc Pharmacol
1996 27, 838-844 ). In both cases the growth factors have been shown to induce significant
hypotension without direct cardiac inhibition. In addition, VEGF has been shown to cause
dilation ofdog coronary arteries (Ku et. al., Am J Physiol 1993 X, H586-H592). In the
experiments described below we examined the simple haemodynamic effects ofboth human
VEGF and human bFGF in an anaesthetised rat preparation.
Rats were anaesthetised and the carotid artery and thejugular vein were canulated to enable
blood pressure and heart rate measurement and i.v. growth factor administration
respectively. The preparation was allowed to equilibrate until a steady baseline blood
pressure was obtained. Growth factors were then administered via thejugular vein cannula
and their effect on blood pressure and heart rate recorded.
VEGF induced blood pressure falls of up to 82 mmHg at a maximal dose of8 ig. bFGF
induced smaller decreases in blood pressure with maximal falls of36 mmHg at a maximal
dose of20 ig. A rapid desensitisation (tachyphylaxis) was observed following both VEGF
and bFGF adminis:ration. It was found that, following a submaxima! dose ofVEGF a second
identical dose ofVEGF was ineffective but a submaximal dose ofbFGF induced an
additional blood pressure fall. Conversely, following a submaximal dose ofbFGF, a second
identical bFGF dose was ineffective but a submaximal dose ofVEGF induced an additional
blood pressure fall. This indicated that bFGF and VEGF induced blood pressure changes via
different pathways. Given that VEGF and bFGF have their own receptors it seemed likely
that the hypotensive effect was mediated by the individual growth factor receptor.
In conclusion, VEGF and bFGF both induced hypotension associated with a reflex
tacchycardia by independent pathways. Local dilatation ofthe blood supply near a tumour
induced by either VEGF or bFGF could result in an increased blood supply to the tumour by
the process of "vascular steal". Thus bFGF and VEGF may act to promote tumour
progression by acute haemodynamic mechanisms in addition to their angiogenic properties.
P91 ANTIVASCULAR EFFECTS OF CHEMOTHERAPEUTIC
AGENTS
GG Dark*, SA Hill, DJ Chaplin. Tumour Microcirculation Group, Gray Laboratory, Northwood, Middlesex,
HA6 2JR, UK.
Anticancer agents damage both malignant and non-malignant tissues and a
major pharmacological goal remains the development of highly selective. non-toxic
therapies for the treatment of malignancies. Many antineoplastic agents act on rapidly
proliferating cells, without regard for the malignant phenotype. Damage to the
endothelium may be responsible for unwanted toxicity manifested by non-malignant
tissues, however, tumour associated endothelium represents a key target for the
development of new approaches to cancer therapy.
Using a tumour microenvironment model system we have examined the
cytotoxic effects of a number ofchemotherapeutic agents. Many agents do not have an
effect on endothelial cells, but the tubulin polymerisation and depolymerisation
inhibitors show a preferential action against endothelium, compared to cancer cells.
Podophyllotoxin, although a weak tubulin-binding agent, is more toxic to tumour cells
than endothelium. The derivative Etoposide shares this property, without any tubulin-
binding action. Colchicine, Dolastatin, Taxotere, Vinblastine, Vincristine and
Combretastatin all have increased toxicity towards endothelium, with enhancement of
this action under hypoxic (1% 02) conditions. Tumour cells show a reverse relationship
with increased resistance to these agents under hypoxia. The presence of tumour cells
in coculture with the endothelium causes further enhancement of the cytotoxicity. This
is particularly true for Taxotere and Vincristine, at 1% 02, and there is a small
enhancement with Combretastatin A-4 and its more soluble prodrug. The tubulin-
binding agents appear to have most of their effect on proliferating endothelium, and
this may explain the enhancement seen with endothelial:tumour coculture. The breast
cancer cell lines studied, produce VEGF in significant quantities, and cause a higher
endothelial proliferation rate. In contrast, quiescent endothelium is more resistant to
these agents, particularly combretastatin A-4 prodrug, which appears to have no
detectable toxicity.
In view of these selective actions against tumour associated endothelium,
vascular studies were performed in experimental and human breast cancer models in
vivo. Histology of a variety of human xenografts and murine transplants indicated
extensive haemorrhagic necrosis with the tubulin binding agents Colchicine,
Vinblastine and Vincristine, although only when administered at the maximum
tolerated dose (MTD). Taxotere does not share this effect. Combretastatin A-4 prodrug
is most promising as it causes selective vascular shutdown in tumour vasculature at
doses <10% MTD and without evidence of morbidity or action to non-tumour tissues.
Thus the antivascular effects of these agents could be used for therapeutic gain.
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Effects of Enhanced Platelet Derived-Endothelial Cell Growth
Factor/ Thymidine Phosphorylase Activity on Tumour Growth
and Metastasis
Leigh Grifliths*, Roy Bicknell' and Ian J. Stratford*
* Experiinental Oncology, Department of Pharmacy, Manchester
University, Oxford Road, Manchester, Ml3 9PL.
+ Molecular Angiogenesis Group, ICRF, histitute of Molecular
Medicine, University of Oxford, John Radcliffe Hospital, Oxford,
OX3 9DU
The vascularisatioii of tumours is relatively poor and disordered
compared with that of normal tissue, leading to insufficient
oxygenation and delivery of nutrients to some tumour cells.
Platelet derived-endothelial cell growth factor (PD-ECGF)(also
known as thymidine phosphorylase) is a 55kDa polypeptide existing
in vivo as a IlOkDa homodimer. PD-ECGF, which was originally
isolated fromplatelets as an endothelial mitogen and has
chemotactic activity in vitro and angiogenic activity in vivo. It
has been shown that thymidine phosphorylase activity is
critical for the angiogenic activity of PD-ECGF. Overexpression
of PD-ECGF/TP in MCF-7 breast carcinoma cells has produced
markedly enhanced tumour growth. Thus the preseiice of PD-
ECGF/TP may atfect tumour oxygenation v hich has
implications for both radiotherapy of tumours and use of
bioreductive drugs. Expression of PD-ECGF/TP protein has been
investigated as a prognostic indicator in breast, ovarian,
bladder and colorectal tumours, and in some instances has been
associated with invasiveness and malignancy of tumours.
We are investigating the effects of modest overexpression of TP on
tumour growth, vascular density, hypoxic fraction and metastasis.
Results indicate that tumours grown from the human breast cancer
cell line MDA 23.1 (with a physiologically significant expression 6
fold higher than basal levels) develop significantly quicker than
their wild type counterparts. However these cells do not grow
more rapidly in vitro. Tumours with enhanced TP also show'
diflerences in their vasculature and hypoxic fraction. Currently we
are studying the metastatic characten'stics of these cells.
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Analysis of integrin expression m six melanocytic cell lines derived from
C57/Bl mice. D.R.Rutherford, D.Davies, I.R.Hart and J.F.Marshall
Richard Dimbleby/ICRF Department of Cancer Research, St. Thomas
Hospital, London SE1 7EH, UK.
As a prelude to investigating their in vivo behaviour we have examined the
integrin repertoire of 2 melanoma lines (B16 Fl and B16 F10), 2 melanocyte
strains (Melan-a and Mel-ab) and two H-Ras-transformed melanocyte lines
(Ltr Ras2 and Ltr Ras3) all of which are syngeneic for C57/Bl mice. Using
monoclonal antibodies specific for the mouse integrin subunits al, a2, a4, a5,
a6, av, 11 and 133, flowcytometry revealed that the most abundant subunits
were cxv, 31 and ax6 whereas a4 was expressed only by the B16 lines.
Immunoprecipitation showed that the a4 subunit exists both as the 180 kDa
form and as a doublet of approximately 85/70 kDa. In contrast, the 150kDa
and 80/7OkDa forms, but not the 180kDa form, were detected in human
melanoma cell lines. Immunoprecipitation with mAb C8F12 (anti-av)
revealed a 150 kDa av subunit associated with 3 subunits of 120, 95 and 90
kDa. Co-migration of the 120 kDa band with the j31 subunit suggested this
band was 11. Immunoprecipitation of J33 integrins with mAb 2C9.suggested
the 90' kDa band associated with av probably was 133. Thus all 6 lines
appeared to express at least three different av integrins: av1l, avf3 and
avP9okDo. (possibly avI35). Since C57/Bl-derived melanocytic lines express
many of the same integrins as those expressed by human melanoma cell lines,
this syngeneic model may be useful for studying the role of integrins in
metastatic melanoma.42 Poster Presentations
P93 IN VITRO EFFECTS OF TWO NOVEL
CYTOCHALASINS ON TUMOUR AND ENDOTHELIAL
CELLS
l.G.Popa*, K.Grosios1, M.J.Thompson2, D.J.Maitland, M.C.Bibby1,
J.A.Double1
Chemistr and Chemical Technology, Clinical Oncology Unit1, Biomedical
Sciences,, University of Bradford, Bradford, UK.
Cytochalasins are a class of more than 50 structurally related secondary
fungal metabolites, which have been shown to have marked effects on the
morphology and motility of cells and have cytostatic, as well as cytotoxic
activity. The reported effects and properties of these compounds on cells
and tissues in culture vary vastly within the class. Their ability to inhibit cell
motility could have important implications, considering that tumour and
endothelial cell migration is a major aspect of tumour development and
progression. The present study investigated the potential of these natural
products as anti-cancer agents.
Two novel cytochalasins SHyp and THYP were isolated from the fungus
Hypoxylon terricola and their respective structures determined using various
spectroscopic techniques. They have been tested for their cytotoxic activity
on four cell lines and have been found to have differential effects after
continuous 96 h exposures, varying from 0.02 mM (IC5o value for SHyp on
MT1, a breast cancer cell line) to 3 mM (IC50 value for THyp on MAC15A, an
adenocarcinoma of the colon cell line). These cytotoxic effects are much
lower than the cytotoxicities of other members of the class previously tested
in our laboratory.
The importance of endothelial cells in tumour angiogenesis and tumour
development is widely recognised. and therefore our finding that primary
human umbilical vein endothelial cells (HUVEC) are mor6 sensitive to these
agents than tumour cell lines, promoted their further investigation.
Staining for F-actin, using rhodamine conjugated phalloidin, revealed that
exposure of HUVEC and HMEC-1 (a human microvascular endothelial cell
line) to non-cytotoxic concentrations of both cytochalasins caused. extensive
F-actin disorganisation. Additionally, this effect was much stronger than that
exhibited by other members of the class.
The above results indicate that these natural products have potential
antiangiogenic activity and therefore further evaluation is worthwhile.
This work has been supported by War on Cancer, Bradford, UK.
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 (PAI-I) OVER-
P95 EXPRESSION IN HUIMAN FIBROSARCOMA CELLS FACILITATES
EXPERIMENTAL METASTASES IN ATHYMIC MICE, V.A. Carroll1, P. Hufnagl', E.
Matsuda2 and B.R. Binderl,IDept. ofVasc. Biol. and Thromb. Res., Vienna Univ.,
Austria and 2Dept. ofOrthopaedic Surgery, Kanazawa Univ., Japan.
Plasminogen activator inhibitor type I (PAI-1) has been implicated in the
metastatic process in a number ofhuman cancers including breast, skin, colon, lung
and brain. In an experimental metastasis model in athymic mice we have shown
that the ability of HT1080 human fibrosarcoma cells to colonise the lung after
intravenous injection into the lateral tail vein increased after consecutive in vivo
passages and that this increased metastatic potential correlated positively with their
PAI-I and tissue factor (TF) expression, (Tsuchiya H., et al. Fibrinolysis 1992;
6(2):60). Additionally, two cell lines were established from the parent HT1080 with
either a low endogenous expression of PAI-1 and TF (1-3C) that exhibited a low
metastatic potential, and a second cell line with a high endogenous expression of
PAI-I and TF (26-6) that exhibited a high colonisation potential (Matsuda E., et al.
Thromb. Haemost. 1993;69(6):548). Furthermore, the number of pulmonary
metastases formed after injection with 26-6 cells were significantly decreased after
pretreatment ofmice with either heparin to inhibit TF activity or with an inhibitory
antibody against PAI-I (Matsuda E., et al. Fibrinolysis 1994;8(1):7).
In order to furtherelucidate the role ofPAI-I and TF in this model, the low
metastatic cell line (1-3C) was transfected with human PAI-I cDNA containing the
entire coding region (1430bp) inserted into a plasmid (BCMGSNeo). A stable
transfected clone was isolated (3F52) that exhibited a twenty fold increase in PAI-I
antigen concentration (28.908.45tg/106cells/24hours) as compared to mock
transfected (1-3CM) cells (1.2± .51sg/1O6cells/24hours). TF activity between these
two cell lines remained virtually unchanged.
When the ability ofthese cells to form metastatic colonies in the lung was
evaluated, it was observed that 3F52 exhibited a significantly increased metastatic
potential as determined by the mean number±SD of colonies on the lung surface,
276±251; range (120-650) as comparcd to the control (1-3CM), 0.5±0.6; range (0-
1); p<0.05.
We therefore provide evidence that PAI-I antigen overexpression facilitates
pulmonary metastasis formation in this mouse model. Lack of dissolution of fibrin
due to local inhibition of the fibrinolytic system may favour the formation and/or
growth ofmetastases in this system.
ELEVATED EXPRESSION OF VASCULAR
P94 ENDOTHELIAL GROWTH FACTOR IN METASTATIC
HUMAN COLORECTAL CARCINOMA CELL LINES AND IN SERA
FROM PATIENTS WITH ADVANCED COLORECTAL CANCER.
D.F.Baban1, N.R.J. Cruickshank2, A. Fabra3, B. Liu I D.J. Kerrl and L.W. Seymour1.
ICRC Institute for Cancer Studies, University of Birmingham, Birmingham B 15 2TJ, U.K.,
2Dept. of Surgery, Queen Elizabeth Hospital, B 15 2TH,, U.K. & 3Department of Metastasis,
Hospital Duran y Reynals, Barcelona 08907, Spain.
Vascular endothelial growth factor (VEGF) plays an important role in
tumour growth and differentiation. VEGF is expressed by numerous human tumour
cells in vitro and in vivo In contrast VEGF expression in normal tissues is limited
and found only in activated macrophages and keratinocytes during wound healing,
ovarian corpus luteum formation and endometrium regeneration during the female
menstrual cycle, renal glomerular visceral epithelium and mesangialcells. VEGF is
a paracrine-acting growth factor which exert its several effects by binding tyrosine
kinase-linked receptors (flt-I & KDR) on vascular endothelial cells. It has been
suggested that VEGF expression may play an important role in regulation of tumour
angiogenesis and also to mediate the enhanced permeability of tumour vasculature
important for protein extravasation and stroma formatiun. Recently there have been
suggestions that VEGF may also play a role in metastasis. It has been shown
(Claffey et.al., 1996, Cancer Res.56: 172) that the human melanoma cell SK-MEL-2
stably transfected with full-length mouse VEGF-164 cDNA expressed and secreted
large amounts of mouse VEGF and formed well-vascularized tumours with approx.
50-fold higher experimental metastasis in SCID mice compared to parental cells.
In this study we have examined the possible link between VEGF expression
and metastasis in colorectal cancer. In preclinical studies we have characterised
VEGF expression in human colorectal cell lines HT29 & KM 12, comparing
parental cells and their metastatic variants in vitro and in vivo. These cells were
injected into nu/nu mice either orthotopically or ectopically (s.c.) and VEGF
expression was studied by RT-PCR and northern blotting in cell lines, in primary
tumours and spontaneous metastases. Our preliminary results suggest that VEGF
expression is higher (60-550%) in metastatic variants of cell lines under-study than
in corresponding parental cells. Furthermore, greater VEGF expression was
observed when cells were injected into the orthototopic site from which spontaneous
metastatic lesions are formed than into the ectopic site. In clinical studies we have
used ELISA to measure VEGF levels in pre-operative serum from patients with
varying stages of colorectal cancer. There was a significant increase in VEGF level
(pg/ml) in serum ofpatient with Duke stage D (905 ± 117) tumours compared with
stage A (282 ± 60) patients.and age-matched normals (233 ± 29). We aim to further
elucidate the role of VEGF in tumour biology and progression, and to establish
whether the simple and relatively non-invasive procedure of measuring serum levels
ofVEGF can have significance as a diagnostic test..
UTILISATION OF VARIOUS MODEL SYSTEMS TO
P96 EXAMINE TUMOUR CELL-DERIVED FACTOR
STIMULATION OF FIBROBLAST GLYCOSAMINOGLYCAN SYNTHESIS
M. Edward, J.L. Godden and R.M. MacKie, University Department of Dermatology, The
Robertson Building, Glasgow G12 8QQ.
We have previously shown that melanoma cell-conditioned medium (CM) contains
potent fibroblast glycosaminoglycan (GAG) stimulating activities, and now present
evidence that such tumour-derived factors are equally potent in stimulating GAG
synthesis by fibroblasts within contracted collagen lattices. Such interactions may be
important in facilitating tumour growth and invasion as hyaluronan is associated with
cell proliferation and migration, and found in enhanced amounts surrounding many
tumours. We have also examined the ability of melanoma cells to release GAG-
stimulating activities when grown as spheroids, and the effect of cocultures of fibroblasts
and melanoma cells on GAG synthesis.
Human breast skin fibroblasts were seeded into collagen gels which were allowed to
contract for 14 days before a 24 hr exposure to serum-free human melanoma cell CM
containing 3H-glucosamine. Radiolabelled, GAGs were isolated from both the medium
fraction and the contracted collagen lattices (pretreated with bacterial collagenase), by
cetylpyridinium chloride precipitation, the. precipitate dissolved in 2M NaCl, and
samples taken for scintillation counting. Spheroid cultures were prepared by incubating
melanoma cells on agar-coated plates, the spheroids washed with serum-free medium,
and CM prepared under serum-free conditions on an agar substrate. The spheroid CM
was then added to fibroblast monolayers and incubated in the presence of 3H-
glucosamine for 24hr. C8161, Hs294T and A375 melanoma cell CM from monolayer
cultures stimulated a 5.0, 5.1 and 3.7 fold increase respectively in incorporation of 3H-
glucosamine into medium GAG,, and a 4.1, 5.1 anid 4.9 fold increase respectively into
collagen lattice-associated GAGs. Conditioned medium from spheroid cultures appeared
to lack GAG-stimulating activity, however, preincubation of CM fro,m monolayer
cultures of tumour cells on agar coated dishes resulted in loss of activity suggesting that
the GAG-stimulating activity is binding to the agar substrate. Spheroid CM is currently
being utilised using non-agar substrates.
We have already shown that there are a number of factors produced by melanoma cells
that act synergistically in stimulating fibroblast GAG synthesis, and have now
demonstrated that such factors also stimulate GAG synthesis by fibroblasts in a
contracted collagen lattice model in which fibroblasts'are normally poorly responsive to
various growth factors. These preliminary results suggest the large increase in fibroblast
GAG stimulation brought about by melanoma cell-derived factors in monolayer cultures
is also applicable to more biologically relevant models substantiating the importance of
this paracrine relationship.Poster Presentations 43
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PROGNOSTIC EVALUATION OF STROMELYSIN 3
EXPRESSION IN HUMAN BREAST CANCER.
A.Ahmad', E.A.Dublin2, D.M.Barnes2, A.Hanby2, P.Basset3 and I.R. Hart'.
'Richard Dimbleby/ICRF Department of Cancer Research, St. Thomas
Hospital, London SEI 7EH, UK.2ICRF Clinical Oncology Unit, Guys
Hospital, London, SE9 7RT, UK.3IGBMC, CNRS/INSERM/ULP,
Strasbourg, France.
Stromelysin 3 (ST3) is a matrix metalloproteinase which is expressed
specifically in stromal fibroblasts surrounding invasive foci in hurnan
breast cancers (Basset et al, Nature 348:699-704,1990). In particular, ST3 RNA has been detected in most invasive breast carcinomas and in
situ carcinomas of the comedo type. Moreover, high levels ofST3 RNA
in primary tumours have been reported to predict greater likelihood of
recurrent disease (Engel et al, Int. J. Cancer,58, 1-7, 1994). In order to
study the possibility thatST3 expression serves as a prognostic marnker
in breast cancer patients we have used a monoclonal antibody (5ST-
4A9) raised against the C-terminal portion of the hemopexin-like
domain of the ST3 molecule. Using MAb 5ST-4A9, immunohistochemical analysis on formalin-fixed, paraffin-embedded
material was performed utilising heat-mediated antigen retrieval and a
peroxidase-conjugated streptavidin biotin system. 30 samples from each
of GradeI, II and III invasive breast carcinoma, 30 cases of lobular
carcinoma, 30 cases of ductal carcinoma-in-situ and 20 cases of benign
breast disease have been immunostained. Preliminary analysis of the
data indicates that: a) there is noST3 expression in benign breast tissue
(20 out of20 negative) b) increasingST3 expression is associated with
higher grade tumours (26/30 strongly positive grade III versus 5/30
grade I strongly positive) and c) it appears that high ST3 levels are
associated with increased risk of recurrence. These results support the
data of Engel et al and show that differences in mRNA are carried
through to the protein level in breast cancer progression.
p99 PHASE II STUDY OF MITOMYCIN C AND
ORAL ETOPOSIDE FOR ADVANCED GASTRO-
OESOPHAGEAL CARCINOMA. J.P. Braybrooke*, K.J. O'Byrne,
D.J. Propper, M.P.Saunders, A.J. Salisbury, P. Boardman, M.
Taylor, T. S. Ganesan, D. C. Talbot, A. L. Harris. ICRF Medical
Oncology Unit, Churchill Hospital, OxfordOX3 7LJ, U.K.
Etoposide is a topoisomerase II inhibitor with phase specific and
schedule dependent activity. Previous studies have shown that oral
etoposide is an effective treatment in small cell lung cancer and ovarian
cancer. This study evaluated protracted oral etoposide in combination
with mitomycin C for the treatment of inoperable gastro-oesophageal
carcinoma.
28 consecutive patients (22 male, 6 female; age range 36 - 86 years, median 59 years) with advanced histologically proven adenocarcinoma
of the upper gastrointestinal tract (12 gastric, 6 gastro-oesophageal, 9
oesophageal) were treated with intravenous bolus mitomycin C 6mg/rn2
every 21 days to a maximum of 4 courses. Oral etoposide capsules 50
mg b.i.d.(or 35mg b.i.d. liquid) were administered days 1 to 10,
extending to 14 days in subsequent courses if no haematological
toxicity, to a maximum of 6 courses.
A total of 107 courses of chemotherapy were administered. 26 patients
were evaluable for response (12 measurable, 14 evaluable). 4 patients
had a documented radiologicatl response(1 complete response, 3 partial
responses) with an objective response rate of 15% (95% confidence
interval 4 - 35%). 8 patients had stable disease and 14 progressive
disease. The median survival in all patients was 6 months extended to
9.5 months in those patients with stable disease or documented
response.. The schedule was well tolerated with no treatment related
deaths. 9 patients experienced leucopenia (7 grade II, 2 grade III).
Nausea and vomiting, alopecia and fatigue were the predominant
toxicities. This out-patient schedule is well tolerated and shows modest
activity in the treatment of advanced upper gastrointestinal
adenocarcinoma.
P98 iNFUSIONAL ETOI'OSI1)E PHOSPHATE IN RELAPSED OVARIAN CANCER. K.J. O'Byrne*, S. Joel', D. Propper,
J. Braybrooke, A. Sanders, M. Elliott, M.Slevin' and T.S. Ganesan. ICRF
Medical Oncology Unit, Churchill Hospital, Oxford, OX3 7LJ, U.K.; 'Dept.
of Medical Oncology, St Bartholomew's Hospital, London, EC1A 7BE, U.K.
Oral etoposide is effective in the treatment of relapsed, cisplatin resistant,
ovarian cancer (response rate 21-24%). The absorption of oral etoposide is
incomplete and variable, both between and within patients. We have shown
that therapeutic monitoring of infusional etoposide is feasible to maintain a
desired plasma concentration. Etoposide phosphate (EP), a more water soluble
pro-drug of etoposide permits easier continuous intravenous infusion (inf) in
outpatients. We have therefore conducted a study evaluating the
administration of EP as an inf over 120 hours every three weeks, maintaining
the plasma etoposide concentration ([E]) at 2pg/ml in patients with recurrent
or refractory ovarian cancer. A loading EP dose of 20mg/m2, given over 30
minutes, was immediately followed by the inf at a starting dose of
2mg/m2/hour. [El was monitored approximately 18 and 66 hours into the
infusion and the rate modified to ensure patients were treated at the planned
target level 2gag/ml [El. Evaluation of response was performed at the end of 3
cycles and patients received a further 3 if there was no progressive disease. 16
patients (age 42-79, median 64 years) with resistant (9) or recurrent (7)
disease, having been previously treated with platinum based chemotherapy
(16) and taxol (2) were entered into the trial. 66 cycles (median 4 cycles) of
EP were administered with 7/16 patients receiving six cycles. Mean [El in 15
evaluable patients at 18 hours into cycle I was 2.89_0.78 lg/ml, and was
within 20% of target in only 3 patients. At 66 hours of cycle 1, after dose
modification, mean [El was 2.16±0.331tg/ml, with1(1/14 patients within 20%
of target. Etoposide plasma clearance significantly correlated with EDTA
clearance (r=0.64, p=0.015) such that cycle I [El at 18 hours in patients with
EDTA clearance < 55mls/minute was 3.54 pg/ml, compared to 2.38 ig/ml in
patients with clearance >55mls/minute. Alopecia (100%) was the main
toxicity and 4/16 patients developed Hickman line related deep venous
thrombosis. 15/16 patients had neutropenia grade 2 or less. One patient died
during the first cycle of treatment from a disease related bowel perforation
with grade 4 neutropenia. 14/16 patients are evaluable for response; the
disease was stable in 4/16 and progressive in the remaining 10. These results
demonstrate the feasibility of pharmacokinetically guided EP infusions to
maintain [E] thereby reducing interpatient variability. A further fourteen
patients are being treated to maintain [El at 3 fg/ml.44 Poster Presentations
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TAMOXIFEN-TREATED BREAST CANCER PATIENTS AND
CORRELATIONS WITH RESPONSE. J.MacCallum, J.Cummings, J.M.Dixon* and
W.R.Miller, ICRF Medical Oncology Unit and *Edinburgh Breast Unit, Western
General Hospital, Edinburgh, EH4 2XU.
Patients treated with tamoxifen for primary breast cancer often
manifest de novo or acquired resistance, which may be the result of
tamoxifen metabolism. We have developed a solid-phase extraction method
and reversed-phase HPLC separation to determine levels of tamoxifen (TAM)
and metabolites 4-hydroxytamoxifen (40H) and desmethyltamoxifen (DMT).
Portions of tumour (50mg) were taken at surgery from 45 patients with
oestrogen-receptor positive tumours, after between 3-90 months of
treatment. During this time, response (both after 3 months treatment and at
definitive surgery) was nionitored by regular ultrasound and clinical
measurement of the tumour. Patients were classified as responding where
tumour volume decreased by at least 20%Y between initial biopsy and these
chosen timepoints; non-responders showed either no change or an increase in
tumour volume. Patients were then categonsed according to the response of
their tumour throughout treatment; tumours decreasing in size, with a
continued reduction or no change in tumour size thereafter (R-R, n=20);
tumours initially reducing in size on therapy, then increasing in size at some
point thereafter (R-NR, n=21); tumours remaining the same size or
increasing in size on treatment (NR-NR, n=4). Levels of TAM, DMT and 40H
for the three categories of patients are shown in the table below as ng/g of
tissue ± S.D..
R-R R-NR NR-NR
TAM 378.84±283.65 387.98±330.49 296.47±124.45
DMT 746.71±1123.93 599.6±579.3 393.42±232.12
40H 142.67±110.89 82.69±148.36 145.05±98.7
Although mean levels between tumours vary greatly, these results
provide no evidence that resistance to tamoxifen treatment is caused by
reduced levels or metabolism of TAM.
TUMOUR CONTAMINATION OF PERIPHERAL BLOOD PROGENITOR
P103 CELL (PBPC) HARVESTS IN PATIENTS WITH HIGH RISK STAGE 11 AND
IIIA BREAST CANCER.
A.C.Humphreys, K.MacRae, M.J.Lind, A.V.Boddy. Cancer Research Unit,
University of Newcastle, Newcastle upon Tyne, NE2 4HH.
High dose chemotherapy (HDC) with PBPC support is being used
increasingly in the treatment of solid tumours, particularly breast cancer.
There is concern that circulating tumour cells may also be collected during
PBPC harvest, reinfused into the patient and contribute to relapse.
Unfortunately there is no unique antigen which characterises breast tumour
cells, and therefore epithelial cell antigens have been used as targets for
identification of tumour cells. Cytokeratins (CK), which form part of the
cytoskeleton ofepithelial cells, are not present in haemopoietic cells. They
have therefore been used to detect breast tumour cells in bone marrow, PBPC
and peripheral blood. Using reverse transcriptase polymerase chain reaction
(Rt-PCR), CK19 has been the most promising target, although it is not
specific in all hands and has a false positive rate of 0 - 38%.
We have used the tumour cell line MDA-MB-231 to develop
immunocytochemistry (ICC) and Rt-PCR methods to apply to clinical
samples. Rt-PCR of CK19 can detect as low as 1 tumour cell in 106
mononuclear cells (MNC). ICC using a pancytokeratin antibody (EPIMET
kit) at the present time detects I tumour cell in 104 MNC consistently. Work
continues on this to improve sensitivity.
We have treated 14 patients with HDC and PBPC reinfusion as part of the
Anglo-Celtic trial, which compares conventional and HD chemotherapy in
patients with stage II and IIIa breast cancer with 4 or more positive axillary
lymph nodes. Aliquots of PBPC were cryopreserved and analysed by Rt-PCR
and ICC.
Mononuclear cells from 25 normal female volunteers without cancer and
PBPC from patients with chronic myeloid leukaemia were used as negative
controls for Rt-PCR.
The sensitivity and specificity of detection of tumour cells by the two
methods will be compared, and the prevalence of tumour cell contamination
in this group ofpatients presented.
P102 3-METHYLADENINE EXCRETION IN PATIENTS WITH
MALIGNANT MELANOMA RECEIVING DACARBAZINE,
2 2 D.E.G. Shukera', J. Braybrooke J.E. Crawley', E. Flanagan and A.L.
S21 Harris. MRC Toxicology Unit, University of Laicester, Leicester LEI 9HN,
2ICRF Medical Oncology Unit, The Churchill, Oxford Radcliffe Hospital,
Oxford OX3 7LJ.
Dacarbazine is converted to a methylating agent after oxidative N-
demethylation. A number of studies have shown that 06- and N7-
methylguanine are increased in peripheral lymphocyte DNA of patients
treatedwith dacarbazine and other methylating agents. We have recently
shown that urinary 3-methyladenine (3MA) is increased in patients treated
with methylating agents and that there is substantial interindividual variation
inthe response (Prevost et al., Biomarkers, 1996. 1, 244-251). As part of a
broader study of pharmacodynamic monitoring of dacarbazine therapy, 3MA
excretion has been measured in patientswith malignant melanoma who were
treated with dacarbazine1g/m2 iv infusion over 1 hour every 3 weeks for a
maximum of 6 cycles. Tamoxifen 20 mg o.d. was commenced 24 hours
after the first infusion and continued throughout the study. Timed urine
samples were collected from a series of patients (n=12) undergoing cycles 1
and 2 of treatment. A urine sample was collected immediately prior to drug
administration and at timed intervals (0-4, 4-10, 10-20 and 20-24 hours) over
the following 24 hours. Following collection the total urine volume was
recorded and aliquots were stored at -70°C until analyses were carried out
3MA was determined in 2 mL aliquots from each sample by immunoaffinity-
ELISA (Prevost et al., Carcinogenesis, 1990,11,1747-1751). The total
amount of 3MA excreted 24h. post administration varied about fivefold (249-
1637 nmol/24h, n=12). In most patients for whom complete sets of data are
available (n=9) the profiles of 3MA excretion showed either a broad peak of
excretion over 24h (n = 5) or a sharper peak of excretion between 4 and 1Oh
(n = 3). In one case a clear maximal excretion was not observed within 24h.
These preliminary results suggest that there are differences in not only the
extent of formation but also the kinetics of repair of 3MA between individuals
receiving the same dose of dacarbazine. The differences in repair may be
due to polymorphisms in 3MA glycosylase activity and this aspect is currently
under investigation.
p134 ISOLATION ANDCHARACTERIZATION OF A IIPIDMOBIlIZING
FACTOR FROM THE URINEOFCACHECI'IC CANCER PATIENTS,
K Hirai*l, 0 Ishikol, PT Todorov2, M JTisdale2, 1Dept of Ob&Gyn, Osaka City
University, Japan 545, 2Pharm Sci Inst, Aston University, Birmingham B47ET
Loss of body fat is common in many types of cancer and may be driven by
catabolic factors produced by certain tumours. A lipid mobilizing factor (LMF) has
been detected in the urine of patients with cancer cachexia by monitoring the ability
of stimulating lipolysis in freshly isolated murine epididymal adipocytes. The
material was found not to be present in the urine of patients without cachexia. The
LMF has now been isolated from urine using a combination of ion-exchange and
hydrophobic chromatography and shown to stimulate glycerol release in a dose-
dependent manner. Using plasma membranes from epididymal adipocytes the LMF
caused stimulation of adenylate cyclase in a GTP-dependent process with maximal
stimulation occurring at 0.1pM GTP. The material thus behaves like the natural
lipolytic hormones, but differs in both charge (acidic) and molecular weight (4OkDa).
In addition the capacity to induce lipolysis and to stimulate adenylate cyclase were
liihibited by the selective 33-adrenergic receptor antagonist (SR59230A) at a
concentration of 10-5M. The LMF was also capable of stimulation of adenylare
cyclase in murine hepatocyte plasma membranes suggesting that other effects of
cachexia (decrease in liver glycogen) may also be mediated by this factor. These
results suggest that the LMF may be responsible for the systemic effects of cancer
cachexiaPoster Presentations 45
P105 MR SPECTROSCOPY IN PATIENTS RECEIVING
CHEMOTHERAPY FOR BREAST CANCER.
M.W.Verrill*2, D.J.Collins', J.Glaholm', G.S.Paynel, M.O.Leach'.
Institute of Cancer Research'& Royal Marsden NHS TrusttSutton, UK.
Primary medical therapy is an increasingly popular treatment
option in patients with large operable breast cancers as it may
downsize the tumour enabling breast conserving surgery, preferred by
many patients to mastectomy. Although the response rates to pre-
operative chemotherapy are high', not every patient benefits, and it is
important to identify those with non responding tumours to enable early
referral for surgery. Difficulties in clinical evaluation of these patients
arise from inter-observer differences in tumour measurements and
changes in tumour consistency which may impair tumour edge
definition. To overcome these problems, it would be useful to have
objective methods of assessment which are independent of volume.
From a group of patients included in trials of primary medical
therapy23, 14 were entered into a study of sequential magnetic
resonance spectroscopy (MRS) tumour assessments. MRS was
performed before and during treatment and the MRS changes were
compared with volume response to chemotherapy, where possible
measured by MRI. Using the Spearman rank correlation test of
association, absolute phosphomonoester (PME) and total phosphate
(TP) levels at week 3 were statistically significantly associated with
volume response after 3 weeks (p=0.001, p=0.05 respectively) as were
early changes in PME and TP (p=0.008, p=0.03 respectively) In
addition, in a number of cases, marked changes in MRS parameters
occurred before corresponding changes in volume.
Although volume remains standard for response assessment in
these patients, MRS examinations early in treatment may provide an
objective measurement in those patients who are difficult to assess
clinically. In the future we hope to feed information back into the clinic
which may help to predict the eventual outcome of chemotherapy.
1. Smith IE, Walsh G, Jones A, et al. 1995: J Clin Oncol 13,424
2. Smith IE, Jones A, O'Brien M, etal. 1993: EurJ Cancer29A,1796
3. Powles TJ, Hickish T, Makris A, et al. 1995: J Clin Oncol 13, 547
PHASE I TRIAL OF ORAL VINORELBINE (VRL) IN
P107 PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC).
B.Chevallierlt, J.Bonneterre2, F. Le Bras3, C.Focan4, L.Mauriac5, M.Piccart6, P. Danel
E.Favreau3, I.Sdnac3. I.CAC H. Becquerel (Fr.); 2. CAC 0. Lambret (France); 3. I.R.P.F.(Fr.); 4.
H6p. StJ. Espdrance (Beig.); 5. Fond. Bergonid (Fr.); 6. Inst. J. Bordet (BeIg.).
A new formulation of oral VRL is being developed, which should offer several
advantages from the patients' perspective over the intravenous (I.V.)
administration, particularly in the setting of chronic or palliative treatment. The
aims ofthis Phase I were to determine the maximum tolerated dose (MTD) of oral
VRL administered weekly, defined as more than 50 % incidence of grade (G) 4
haematological or G 3/4 non haematological toxicity, to define a recommended
dose (RD) for further trials and to evaluate the activity profile of the drug.The
initial dose level was 60 mg/m2/week and the dose was increased by a 20 mg/m2
stepwise increment in subsequent cohorts of 6 pts each. Once the MTD was
reached, 6 more pts had to be included at the previous level in order to confirm
the RD. I.V. VRL having demonstrated to be highly effective in ABC, this Phase I
study was performed in this indication. Results are available on 27 pts (mean age:
55 y.o. ; range: 33-77): 7 at 60 mg/M2, 14 at 80 mg/M2 and 6 at 100 mg/M2. Pts
were pretreated by previous adjuvant chemotherapy for 6 of them and for
advanced/metastatic disease for 19 of them. About 50 % had predominantly
visceral disease (9 liver, 8 lung). 9 pts had bone metastasis and 16 presented
locally advanced/metastatic disease. 100 mg/m2/week was shown to be the MTD:
among the 6 pts included, 3 experienced G 4 neutropenia, 2 G 3/4 constipation
and 2 G 3 vomiting. Consequently, 80 mg/m2/week was defined as the RD: G 3-4
neutropenia occurred following 21.4 % of cycles, but without any clinical
consequences there were no G 3 nausea and G 3/4 vomiting occured following
1.4 % of cycles; G 3/4 neuroconstipation occurred following 1 % of cycles. No G
> 2 anemia or thrombocytopenia was observed at any dose level and only 1 pt
experienced G 3 alopecia. Efficacy results were very encouraging over 13
evaluable pts treated at 80 mg/m2/week and, for 2 of them, at 100 mg/M2 for 2
courses and then at 80 mg/m2/week, 6 partial responses were observed (ORR =
46 % IC95: 19.1-73.3), 3 of them on visceral disease (2 lung, 1 liver). The
median duration of response was 30+ weeks (20+-60+). It is concluded that oral
VRL administered at the weekly dose of 80mg/M2 is well tolerated by the patients
and presents a very interesting activity in the treatment of ABC.
ELEVATED BLOOD MONOCYTE TISSUE FACTOR
PL)6 LEVELS IN PATIENTS WITH CANCER. BA
Lwaleed1, M Chisholm' and JL Francis2. 'Dept. of Haematology, University,
Southampton, U.K. 2Hemostasis and Thrombosis Research Unit, FL 32701, U.S.A.
The association between cancer and thromboembolic disease has been known
since 18651. The phenomenon is poorly understood, but continuous
expression of tissue factor (TF), the principle initiator ofblood coagulation2
by endothelial cells, monocytes (mTF)/macrophages, may be implicated.
Measurements of mTF may provide a good index of intra-vascular clotting
activation and disease activi7. Using a two stage kinetic chromogenic assay
established in this laboratory , mTF levels were measured in controls [normal
(n=60) and patients undergoing hernia/cholecystectomy (n=60)] and patients
with benign and malignant disease of the bladder (n=73), prostate (n=81),
breast (n=83) and large bowel (n=62), under resting conditions and after
incubation for 6 hours with and without E. Coli endotoxin. Each benign
disease group was divided into inflammatory and non-inflammatory
categories. Cells were isolated in a one step procedure using leuko prep tubes
with negligible effect on the mTF expression3. The control groups and the
benign non-inflammatory groups gave similar results and have therefore been
unified for further analysis. There was a significant difference between the
malignant groups and the control groups for resting (P<0<001), un-stimulated
(P<0.05) and stimulated cells (P<0.001). Similarly, the benign inflammatory
groups differ from the control groups for resting (P<0.001), un-stimulated
(P<0.05) and stimulated (P<0.001). There was no difference between the
malignant groups and the benign inflammatory groups. Patients with
malignant diseases gave results above the upper quartile ofthe normal control
for resting (46%), un-stimulated (26%) and stimulated cells (62.4%). In
conclusion, mTF level israised in malignant conditions compared to controls
and patients with non-inflammatory conditions but not patients with
inflammatory conditions. Stimulated cells give better discrimination between
the groups and may be of value in identifying high risk individuals.
References:
1) Trousseau A. Balliere, 1865.
2) Nemerson Y. Semin Haemost. 1992; 29: 170.
3) Carvalho MG, Francis JL. Thromb Haemostas. 1993; 69: 601.
Pattem of expression of MIC antigens and
P108 epidermal growth factor receptor (EGFr) in oral
cancer:
A M E Nouri, H Cannell* and Oliver RTD. Depts. of Medical
Oncology and of Oral & Maxillofacial Surgery', London Hospital
Whilst the profiles of major histocompatibility complex (MHC)
antigen expression for malignancies of bladder, oesophagus, breast,
cervix and prostate have been published, less is known concerning
their expression in oral squamous cell carcinoma (OSCC). Using
monoclonal antibodies (Mabs) and immunocytochemical staining,
the pattern of expression of MHC class I (monomorphic and
polymorphic), class 11 antigens, pan-T cell marker, EGFr and
adhesion molecule (ICAM-1), was investigated on OSCC and the
results compared with those from ameloblastoma and from bladder
tumours.
Results showed:- compared with benign tumour and with normal
controls:-
a) 02-macroglobulin and Class I antigens were expressed in most
cases of oralSCC.
b) both Class 11 and ICAM-1 (cell adhesion molecule) were
expressed in most cases of oralOSCC.
c) T cell infiltration was also found to be at a higher density in oral
OSCC.
d) strong EGFr expression was present in most OSCC.
These findings are consistent with the notion that there were
abnormalities in the expressionl of MHC antigens in oral cancers. Our
working hypothesis to explain the unexpected higher frequency of
these abnormalities in the benign ameloblastoma is that although
both tumour types (more so in the case of ameloblastoma) have in
place an escape mechanism from the immune system, the over
expression of EGFr inOSCC may in part explain the more aggressive
behaviour of the malignancy.46 Poster Presentations
P109 THE UTILITY OF A CANCER INFORMATION SERVICE
ON THE INTERNET
GG Dark*. CancerWEB, Gray Laboratory Cancer Research
Trust, Northwood, Middlesex, HA6 2JR, UK.
CancerWEB was established as a cancer information resource site on the
World-Wide Web (WWW) in 1995. The aims were to provide up-to-date information
about cancer for patients, clinicians and scientific researchers. An agreement was made
with the National Cancer Institute to redistribute the Physicians Data Query (PDQ)
database of information and the CancerLIT abstracts. These plain text files were
processed into the formatting language HTML (HyperText Mark-up Language) for
availability on the WWW. Further functionality was provided by the addition of a
powerful search and indexing program which allows users to locate files or documents
that contain the specified search terms. The site has had over 2 million requests from
over 65 countries and has transferred in excess of 15 Gigabytes of information in the
first 12 months.
The provision of information on the Internet allows patients and clinicians to
access the documents at a time and setting to suit their needs. However, this flexibility
also extends to learning modules or multimedia teaching files, that allow users to learn
new topics at their own learning rates.
Random users were prompted for feedback on their views of the service,
regarding; the ease of access to information compared to traditional sources, the
relevance to their enquiry, the usefulness of the service and whether they would return
to use the service again.
Of the 1000 users questioned, 69% replied. The majority felt that the Internet
gave far greater ease of access to information than traditional sources, 93% of users had
their enquiries answered by the content of the documents, but many wanted additional
more detailed information. The organisation of resources into sections for groups of
users, such as clinicians and patients, was felt to be the most useful structuring of the
resources and 95% of responders indicated satisfaction with the service and would be
returnini,
The resources available on the Internet for patients with cancer and clinicians
working in oncology are increasing every day. This media certainly has an exciting
future with an increasing amount of information becoming available to a desktop
computer in the home, laboratory or outpatient clinic.
url: http://svvwvt.graylab.ac.uk/coancerweb.html
mail: cancerweb@www.graylab.ac.uk
P1.T. EVALUATION OF CANCERHELP UK INTERNET INFORMATION
PROVIDER. 'S.J.Tweddle', B. Wakel, D. Davies3, C. James', P.
Riding4, D. Coats5, N. James'. 1 CRC Institute for Cancer Studies, Clinical Research
Block, Edgbaston, Birmingham B15 2TT. 2 National Council for Educational
Technology, Milbum Hill Road, Science Park, Coventry CV7 2JJ, 3 Medical School,
University of Birmingham, Edgbaston, Birmingham B15 2TT, 4 Webserve, PO Box 56,
Saffron Walden, Essex CB1 1 4HT, 5 BACUP, 3 Bath Place, Rivington Street, Lonaon
EC2A 3JR
There is a proliferation of cancer information services on the World Wide Web
emanating from a vanety of sources and an increasing demand from British Internet
users for the information they provide. The evaluation of such services is essential
given that they will become more widely available in the future. We have developed a
Brtish-based cancer information service for the general public (CancerHelp UK) in
collaboration with BACUP which we have evaluated through 2 pilot studies as a
preliminary to a multi-site randomised cross-over study. The first study, of usage in
hospital waiting rooms by 60 patients and staff, evaluated the useability of a pilot
service. The second study evaluated the usefulness of a more fully developed
prototype service over a four month period on the Intemet through analysis of electronic
feedback and computer usage data. Of the patients and staff who used the service in
waiting rooms, 82% were women; all patients were over 40 and 94% of all users said
they would use the service again, although none had pnor Internet expenence and only
9% had 'a lot' of pror computer experience. 3.1% of Intemet users returned feedback
forms of whom 52% were male, 47% female and 1% unspecified. 36% were fnends
and relatives, 25% patients, 22% healthcare professionals and the remainder
'other'.Thematic analysis of coded responses indicated that infonrmation of most interest
was that about specific cancers, treatment and research into new treatments. Data
collected on the computer server showed that information on specific cancers and
treatment was most frequently accessed. 83% of users appeared to be serious users,
as opposed to 'surfers', accessingS5 or more pages of the service. The CancerHelp UK
service appears to be accessible and highly valued as a provider of information about
cancer and its treatment. A study currently in progress and funded by the Cancer
Research Campaign will indicate for which sectors of the population CancerHelp UK
proves most beneficial and how the service can be further improved.